Search for Reports in the web?

Reports (50)

Roots Analysis - Leaders in Pharmaceutical & Biotechnology Market Research

www.rootsanalysis.com
Submitted 16 day(s) ago by Alberto Brando

Roots Analysis offers market research reports highlighting insightful opinions within the pharma, biotech and medical devices industry. With over 500 clients spread across the small pharma, large pharma, VC firms and academic institutes, our intellectual capital encompasses very niche / emerging market segments.

Roots Analysis - Leaders in Pharmaceutical & Biotechnology Market Research

www.rootsanalysis.com
Submitted 17 day(s) ago by Alberto Brando

Roots Analysis offers market research reports highlighting insightful opinions within the pharma, biotech and medical devices industry. With over 500 clients spread across the small pharma, large pharma, VC firms and academic institutes, our intellectual capital encompasses very niche / emerging market segments.

Roots Analysis - Leaders in Pharmaceutical & Biotechnology Market Research

www.rootsanalysis.com
Submitted 18 day(s) ago by Alberto Brando

Roots Analysis offers market research reports highlighting insightful opinions within the pharma, biotech and medical devices industry. With over 500 clients spread across the small pharma, large pharma, VC firms and academic institutes, our intellectual capital encompasses very niche / emerging market segments.

Roots Analysis - Leaders in Pharmaceutical & Biotechnology Market Research

www.rootsanalysis.com
Submitted 19 day(s) ago by Alberto Brando

Roots Analysis offers market research reports highlighting insightful opinions within the pharma, biotech and medical devices industry. With over 500 clients spread across the small pharma, large pharma, VC firms and academic institutes, our intellectual capital encompasses very niche / emerging market segments.

Initial gaming benchmarks offer insights into the performance of one of NVIDIA's GeForce RTX 3060 laptop GPUs - NotebookCheck.net News

www.notebookcheck.net
Submitted 36 day(s) ago by system

The laptop versions of the NVIDIA GeForce RTX 3060 are yet to land, but the first gaming benchmarks are already online. The two videos compare the GeForce RTX 3060 against the GeForce RTX 2060 in nine games, including in CDPR's latest title, Cyberpunk 2077.

Liquid Biopsy and Other Non-Invasive Cancer Diagnostics Market (3rd Edition), 2019-2030


Submitted 38 day(s) ago by Harry sins

 

To order this 350+ page report, please visit this link

 

Key Inclusions

  • A detailed review of the overall landscape of the non-invasive cancer diagnostics market, featuring information on the developers of such products and analyses based on a number of relevant parameters, such as year of establishment, company size, geographical location, current development status of proprietary liquid biopsy test (under development, research use only, and available), type of product (assay kit, software / algorithm and device), type of tumor marker analyzed (CTCs, ctDNA, cfDNA, exosomes, and others), key applications (early diagnosis, treatment selection, patient monitoring and recurrence monitoring), type of analyte used (blood, urine and others) and target cancer indications.
  • An analysis of the various partnerships pertaining to non-invasive cancer diagnostics, which have been established between 2016 and 2019, based on various parameters, such as type of partnership, year of partnership, type of tumor marker, target cancer indications and the most active players.
  • An analysis of the investments made in companies engaged in the development of non-invasive cancer diagnostics, including details of seed financing, venture capital financing, debt financing, grants, and capital raised via IPOs and subsequent public offerings.
  • An analysis of the initiatives of big pharma players, highlighting the key focus areas of such companies and analysis based on various relevant parameters, such as stage of development of their proprietary non-invasive cancer diagnostic test(s), key applications, type of tumor marker and target disease indications.
  • A detailed acquisition target analysis, taking into consideration the historical trend of the activity of the companies that have acquired other firms since 2016, and offering a means for other industry stakeholders to identify potential acquisition targets.
  • Elaborate profiles of the key players engaged in this domain, featuring a brief overview of the company, its financial information (if available), a detailed description of its product portfolio, recent developments and an informed future outlook
  • Informed estimates of the existing market size and the future growth opportunities for non-invasive cancer diagnostics. Based on various parameters, such as number of available / under development products and estimated annual adoption rates, we have provided an informed estimate on the likely evolution of the market over the period 2019-2030.

 

The report features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:

  • Type of Tumor Marker
  • ctDNA
  • cfDNA
  • CTCs
  • Exosomes
  • Others

 

  • Application
  • Diagnosis / Early Diagnosis
  • Patient Monitoring
  • Recurrence Monitoring

 

  • Target Cancer Indication
  • Breast Cancer
  • Lung Cancer

Press Release: Variation 4 (Format 5)

 

  • Colorectal Cancer
  • Prostate Cancer
  • Bladder Cancer
  • Melanoma
  • Gastric Cancer
  • Pancreatic Cancer
  • Ovarian Cancer
  • Others

 

  • End Users
  • Hospitals
  • Research Institutes
  • Others

 

  • Key Geographical Regions 
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

 

The report also features inputs from eminent industry stakeholders, according to whom liquid biopsy has the potential to diagnose cancer at a very early stage by analyzing rare circulating tumour markers, thereby, facilitating appropriate / timely treatment decisions. The report includes detailed transcripts of discussions held with the following experts:

  • Joachim Fluhrer, Founder and Medical Director, Genostics
  • Shibichakravarthy Kannan, Founder and CEO, Theranosis Life Sciences
  • Abizar Lakdawalla, Founder, ProXeom
  • Philippe Nore, CEO and Co-founder, MiNDERA
  • Frank Szczepanski, President and CEO, IVDiagnostics
  • Mark Li, CEO, Resolution Bioscience
  • Brad Walsh, CEO, Minomic International
  • Anton Iliuk, President and Chief Technology Officer, Tymora Analytical Operations
  • Burkhard Jansen, Chief Medical Officer, DermTech
  • Christer Ericsson, Chief Scientific Officer, iCellate Medical
  • Jake Micallef, Chief Scientific Officer, VolitionRx
  • Nathalie Bernard, Marketing Director, OncoDNA
  • Riccardo Razzini, Sales and Marketing Manager, LCM Genect
  • Peter French, Strategic Technology Advisor, Sienna Cancer Diagnostics

 

To request sample pages, please visit this link             

                                                                                                               

Key Questions Answered

  • What are the prevalent trends within the liquid biopsy market?
  • What are the key applications of liquid biopsy?
  • Apart from liquid biopsy, what are the other novel non-invasive cancer diagnostics?
  • What is the role of big pharma players in the non-invasive cancer diagnostics domain?
  • What are the prevalent financing and investment trends within the liquid biopsy market?
  • What are the most popular cancer indications for which non-invasive diagnostics are being developed?
  • Who are the key service providers for liquid biopsy products?
  • How is the current and future market opportunity likely to be distributed across key market segments?

 

Press Release: Variation 4 (Format 5)

 

You may also be interested in the following titles:

  1. DNA-Encoded Libraries: Platforms and Services Market
  2. Antibody Discovery: Services and Platforms Market (2nd Edition), 2018-2028
  3. In Silico / Computer-Aided Drug Discovery Services Market: Focus on Large Molecules (Antibodies, Proteins, Peptides, Nucleic Acid, Gene Therapy and Vectors), 2020-2030 (Including Structure Based Drug Discovery, Fragment Based Drug Discovery, Ligand Based Drug Discovery, Target Based Drug Discovery, Interface Based Drug Discovery Approaches)

 

Contact Us:

Gaurav Chaudhary

+1 (415) 800 3415

+44 (122) 391 1091

Gaurav.Chaudhary@rootsanalysis.com

300 non-invasive diagnostic tests, designed for the detection of various types of cancers, are either already available in the market or under development across the world


Submitted 38 day(s) ago by Harry sins

 

Given the invasive and cost-intensive nature of tissue biopsies, there is a significant unmet need for safer and more patient-friendly cancer diagnostics that are capable of offering highly accurate, and actionable insights related to the disease.

 

To order this 350+ page report, which features 150+ figures and 200+ tables, please visit this link

 

The financial opportunity within the liquid biopsy and other non-invasive cancer diagnostics market has been analyzed across the following segments:

  • Type of Tumor Marker
  • ctDNA
  • cfDNA
  • CTCs
  • Exosomes
  • Others

 

  • Application
  • Diagnosis / Early Diagnosis
  • Patient Monitoring
  • Recurrence Monitoring

 

  • Target Cancer Indication
  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Bladder Cancer
  • Melanoma
  • Gastric Cancer
  • Pancreatic Cancer
  • Ovarian Cancer
  • Others

 

  • End Users
  • Hospitals
  • Research Institutes
  • Others

 

  • Key Geographical Regions 
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

 

The Liquid Biopsy and Other Non-Invasive Cancer Diagnostics Market (3rd Edition), 2019-2030: Focus on Circulating Tumor Markers such as CTCs, ctDNA, cfDNA, Exosomes and Other Biomarkers report features the following companies, which we identified to be key players in this domain:

  • Amoy Diagnostics
  • DiaCarta
  • HaploX Biotechnology
  • NeoGenomics
  • QIAGEN
  • Swift Biosciences
  • Sysmex Inostics
  • Thermo Fisher Scientific

Press Release: Variation 3 (Format 4)

 

Table of Contents

 

  1. Preface

    2. Executive Summary

  2. Introduction

 

  1. Non-Invasive Cancer Screening and Diagnosis

  2. Market Landscape

 

  1. Company Profiles

  2. Partnerships and Collaborations

 

  1. Funding and Investment Analysis

  2. Liquid Biopsy: Initiatives of Big Pharma Players

  3. Key Acquisition Targets

 

  1. Other Non-Invasive Cancer Diagnostics

  2. Market Sizing and Opportunity Analysis

  3. Survey Insights

 

  1. Conclusion

  2. Executive Insights

 

  1. Appendix 1: Tabulated Data

 

  1. Appendix 2: List of Companies and Organizations

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/liquid-biopsy-and-nicd-market/279.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

Gaurav.Chaudhary@rootsanalysis.com

The non-invasive cancer diagnostics market is projected to grow at an annualized rate of ~20%, till 2030


Submitted 38 day(s) ago by Harry sins

 

 

Roots Analysis has done a detailed study on Liquid Biopsy and Other Non-Invasive Cancer Diagnostics Market (3rd Edition), 2019-2030: Focus on Circulating Tumor Markers such as CTCs, ctDNA, cfDNA, Exosomes and Other Biomarkers, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

 

To order this 350+ page report, which features 150+ figures and 200+ tables, please visit this link

 

Key Market Insights

  • Presently, nearly 300 non-invasive diagnostic tests, designed for the detection of various types of cancers, are either already available in the market or under development across the world
  • Several modern diagnostic tests claim to be capable of offering results in relatively short time periods, thereby, facilitating early diagnosis that is particularly beneficial in the treatment of different types of cancers
  • Over time, big pharma players have initiated product development programs, having invested significant capital, time and effort, on non-invasive diagnostic solutions for use across different oncological indications
  • Investors, having realized the untapped opportunity within this emerging segment of the cancer diagnostics market, have invested over USD 3 billion across 120 instances in the period between 2015 and 2019
  • The growing interest in this field is also reflected in the partnership activity; deals inked in the recent past are focused on a diverse range of tumor markers, involving both international and indigenous stakeholders
  • The projected future opportunity is anticipated to be driven by increasing patient population and distributed across various disease indications and application areas across key geographies
  • These tests are capable of detecting diverse tumor markers that cater to the needs of different stakeholders; in fact, opinions of industry experts confirm the vast potential of liquid biopsies in disease diagnosis / monitoring

 

For more information, please visit https://www.rootsanalysis.com/reports/view_document/liquid-biopsy-and-nicd-market/279.html

                                                                                                               

Table of Contents

 

  1.   PREFACE

1.1.              Scope of the Report

1.2.              Research Methodology

1.3.              Chapter Outlines

 

  1.   EXECUTIVE SUMMARY

 

  1.   INTRODUCTION

3.1.              Chapter Overview

3.2.              Cancer Statistics and Burden of the Disease

3.3.              Importance of Early Cancer Detection

3.4.              Cancer Screening and Diagnosis

 

3.5.              Conventional Invasive Cancer Diagnostic Tests

3.5.1.           Biopsy

3.5.1.1.        Fine Needle Aspiration Biopsy

3.5.1.2.        Core Needle Biopsy

3.5.1.3.        Vacuum-Assisted Biopsy

3.5.1.4.        Image-Guided Biopsy

Press Release: Variation 2 (Format 3)

 

3.5.1.5.        Sentinel Node Biopsy

3.5.1.6.        Surgical Biopsy

3.5.1.7.        Endoscopic Biopsy

3.5.1.8.        Bone Marrow Biopsy

3.5.2.           Endoscopy

 

3.6.              Need for Non-Invasive Approaches

 

3.7.              Liquid Biopsy: Diagnosing Circulating Biomarkers

3.7.1.           Circulating Tumor Cells

3.7.2.           Circulating Tumor DNA

3.7.3.           Exosomes

           

3.8.              Costs and Benefits Associated with Liquid Biopsy and Non-Invasive Tests

3.9.              Emerging Trends in Intellectual Property Related to Non-Invasive Cancer Diagnostics

3.10.            Challenges Associated with Non-Invasive Cancer Diagnostics

3.11.            Future Perspectives

 

  1.   NON-INVASIVE CANCER SCREENING AND DIAGNOSIS

4.1.              Chapter Overview

4.2.              Diagnostic Imaging

4.2.1.           Magnetic Resonance Imaging (MRI)

4.2.2.           Mammography

4.2.3.           Bone Scan

4.2.4.           Computerized Tomography (CT) Scan

4.2.5.           Integrated Positron Emission Tomography (PET)-CT Scan

4.2.6.           Ultrasound

4.2.7.           X-ray Radiography (Barium Enema)

 

4.3.              Screening Assays

4.3.1.           Circulating Tumor Marker Test

4.3.2.           Digital Rectal Exam (DRE)

4.3.3.           Fecal Occult Blood Test (FOBT)

4.3.4.           Multigated Acquisition (MUGA) Scan

4.3.5.           Papanicolaou Test and Human Papilloma Virus Test

 

4.4.              Advanced Non-Invasive Approaches

4.4.1.           Cytogenetic / Gene Expression Studies

4.4.2.           Molecular Signature-based Non-Invasive Methods

4.4.3.           Saliva-based Oral Cancer Diagnostics

4.4.4.           Vital Staining

4.4.5.           Optical Biopsy

4.4.6.           Other Diagnostic Techniques

 

  1.   MARKET LANDSCAPE

5.1.              Chapter Overview

5.2.              Liquid Biopsy Products: List of Developers

5.2.1.           Analysis by Year of Establishment

5.2.2.           Analysis by Company Size and Geographical Location

5.2.3.           Leading Players

5.2.4.           Analysis by Geography

 

5.3.              Liquid Biopsy Products: List of Available / Under Development Products

5.3.1.           Analysis by Status of Development

5.3.2.           Analysis by Type of Product

5.3.3.           Analysis by Application Area 

Press Release: Variation 2 (Format 3)

 

5.3.4.           Analysis by Target Cancer Indication

5.3.5.           Analysis by Type of Tumor Marker

5.3.6.           Analysis by End User

5.3.7.           Analysis by Turnaround Time

 

5.4.              Liquid Biopsy Products: List of Other Products, Kits and Consumables

5.5.              Liquid Biopsy Products: List of Contract Service Providers

 

  1.   COMPANY PROFILES

6.1.              Chapter Overview

6.2.              Amoy Diagnostics

6.2.1.           Company Overview

6.2.2.           Financial Information

6.2.3.           Liquid Biopsy Product Portfolio

6.2.4.           Recent Developments and Future Outlook

Human Factors Engineering and Usability Testing Services Market for Medical Devices, 2020-2030


Submitted 38 day(s) ago by Harry sins

 

 

To order this detailed 200+ page report, please visit this link

 

Key Inclusions

  • A detailed assessment of the current market landscape of companies offering HFE and usability testing services based on several relevant parameters, including developer information (year of establishment, company size and location of headquarters), types of certifications obtained, types of HFE services offered in the concept phase (user research and use error risk analysis and management), design and development phase (prototype development and designing and interface development and designing), verification and validation phase (usability inspection, formative studies / usability verification, pre-validation testing / clinical trial, and summative studies / usability validation) and documentation / file compilation phase, types of other services offered (regulatory guidance, packaging and labeling, training and post market surveillance) and types of medical devices designed by the company (drug delivery devices, clinical use / care devices, diagnostic devices, therapeutic devices, home use medical devices and different laboratory and surgical equipment).
  • A detailed company competitiveness analysis of HFE and usability testing service providers, taking into consideration the supplier power (based on the year of establishment of developer) and other key specifications (such as core services offered, other services offered and types of medical devices designed) of players.
  • An elaborate discussion on the various guidelines established by major regulatory bodies, governing medical device HFE and usability testing services, across different regions.
  • A detailed discussion on the cost implications across various steps of the HFE and usability testing process.
  • Profiles of HFE and usability testing service providers (shortlisted on the basis of the number of services offered), featuring an overview of the company, details related to their HFE and usability testing service portfolio and an informed future outlook.
  • A discussion on important industry-specific trends, key market drivers and challenges, under a SWOT framework, featuring a qualitative Harvey ball analysis that highlights the relative impact of each SWOT parameter on the overall HFE and usability testing services market.

 

The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:

 

  • Type of tools used
  • Generative tools
  • Evaluative tools

 

  • Type of steps involved
  • Contextual analysis
  • Task analysis
  • Design analysis
  • Formative studies
  • Use risk analysis
  • Known use error analysis
  • Summative studies
  • Regulatory document preparation’

 

  • Device class
  • Class I medical devices
  • Class II medical devices
  • Class III medical devices

 

  • Key geographical regions
  • North America
  • Europe
  • Asia Pacific

 

To request sample pages, please visit this link

 

Key Questions Answered

  • Who are the leading players providing human factors engineering and usability testing services to medical device developers?
  • What is the cost associated with different steps of the human factors engineering and usability testing process for medical devices?
  • What kind of cost savings can be achieved through the adoption of the human factors engineering and usability testing approach for medical device development?
  • In the past, how has the adoption of human factors engineering and usability testing approaches impacted medical device recall rates?
  • How do the guidelines for human factors engineering and usability testing for medical devices, differ across key global regions?
  • What are the prevalent and emerging trends within the human factors engineering and usability testing service providers market?
  • How is the recent COVID-19 pandemic likely to impact human factors engineering and usability testing services market?
  • How is the current and future opportunity likely to be distributed across key market segments?

 

You may also be interested in the following titles:

  1. Global Handheld Ultrasound Imaging Devices Market, 2020-2030
  2. Non-Invasive Neurostimulation Market, 2020-2030
  3. Medical Devices CROs Market (2nd Edition), 2020-2030

 

Contact Us

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com

 

More than 90 companies claim to offer human factors engineering and usability testing services, catering to needs across different stages of the medical device development process, for medical devices, claims Roots Analysis


Submitted 38 day(s) ago by Harry sins

 

Human factors engineering and usability testing have now become an essential part of product design across almost all industries, offering developers the chance to optimize proprietary products in alignment to the preferences of consumers

 

To order this 200+ page report, which features 120+ figures and 100+ tables, please visit this link

 

The USD 1 Billion (by 2030) financial opportunity within the human factors engineering and usability testing market has been analysed across the following segments:

  • Type of tools used
  • Generative tools
  • Evaluative tools

 

  • Type of steps involved
  • Contextual analysis
  • Task analysis
  • Design analysis
  • Formative studies
  • Use risk analysis
  • Known use error analysis
  • Summative studies
  • Regulatory document preparation’

 

  • Device class
  • Class I medical devices
  • Class II medical devices
  • Class III medical devices

 

  • Key geographical regions
  • North America
  • Europe
  • Asia Pacific

 

The Human Factors Engineering and Usability Testing Services Market for Medical Devices, 2020-2030 report features the following companies, which we identified to be key players in this domain:

  • Agilis
  • Human Factors Consulting Service
  • Human Factors MD
  • User wise
  • Ximedica
  • Austrian Center for Medical Innovation and Technology (ACIMT)
  • Auxergo
  • THAY Medical
  • Ergotech
  • Jonathan Bar-Or Industrial Design

 

 

 

Table of Contents

 

  1. Preface

    2. Executive Summary

  2. Introduction

  3. Regulatory Landscape

  4. Service Provider Landscape

 

  1. Company Competitive Analysis

  2. Company Profiles

  3. Cost Implications Related to Human Factors Engineering and Usability Testing Process

  4. Case Study: Medical Devices Recalls and Role of Human Factors Engineering

  5. Market Forecast and Opportunity Analysis

 

  1. Case Study: Impact of COVID-19 Pandemic on Human Factors Engineering and Usability Testing Services Market

  2. SWOT Analysis

 

  1. Conclusion

 

  1. Executive Insights

 

  1. Appendix 1: Tabulated Data

 

  1. Appendix 2: List of Companies and Organizations

 

 

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/human-factors-engineering-and-usability-testing-services.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com 

 

The human factors engineering and usability testing service market is projected to grow at an annualized rate of ~14%, till 2030


Submitted 38 day(s) ago by Harry sins

 

Roots Analysis has done a detailed study on Human Factors Engineering and Usability Testing Services Market for Medical Devices, 2020-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

 

To order this 200+ page report, which features 120+ figures and 100+ tables, please visit this link

 

 

Key Market Insights

  • Over time, a number of medical devices have been recalled due to various reasons; therefore, presently, HFE and usability testing is being perceived as a fundamental necessity in order to drive product development efforts
  • Currently, more than 90 companies claim to offer human factors engineering and usability testing services, catering to needs across different stages of the medical device development process
  • The market landscape is highly fragmented, featuring the presence of several well-established players and new entrants, many of which have varied service portfolios, focused on different types of medical devices
  • Players involved in this domain are steadily expanding their capabilities in order to enhance their respective service portfolios and gain an advantage over competitor firms
  • As device developers continue to rely on specialty service providers for critical inputs on device design, the HFE and usability testing services market is anticipated to register double digit growth in the long term

 

For more information, please visit https://www.rootsanalysis.com/reports/human-factors-engineering-and-usability-testing-services.html

 

Table of Contents

 

  1. 1. PREFACE

1.1.       Scope of the Report

1.2.       Research Methodology

1.3.       Chapter Outlines

 

  1. EXECUTIVE SUMMARY

 

  1. INTRODUCTION

3.1.       Context and Background

3.2.       Overview of Human Factors Engineering and Usability Testing

3.2.1.    Human Factors Engineering (HFE)

3.2.2.    Usability Testing

3.2.3.    Ergonomics and Hedonomics

3.3.       Human Factors Considerations for Medical Device Design

3.3.1.    Users

3.3.2.    Use Environment

3.3.3.    Device-User Interface

 

3.4.       Human Factors and Usability Testing Process

3.5.       Advantages of Outsourcing HFE Testing Operations

3.6.       Risks and Challenges Associated with Outsourcing HFE Testing Services

3.7.       Key Considerations for Selecting an HFE and Usability Testing Partner

 

  1. REGULATORY LANDSCAPE

4.1.       Chapter Overview

4.2.       Key Regulatory Authorities on Human Factors and Usability Testing Services

4.3.       Regulatory Landscape in North America

4.3.1.    FDA Recognized Standards on Human Factors

4.3.2.    FDA Guidance Documents related to Human Factors

4.3.3.    FDA Human Factors Engineering Process

 

4.4.       Regulatory Landscape in Europe

4.4.1.    EU-Recognized Standards on Human Factors

4.4.2.    EU Human Factors Engineering Process

 

4.5.       Human Factors Engineering Pathway: Comparison of Guidelines in the US and EU

4.5.1.    Alignment between Regulations in the US and EU

4.5.2.    Abbreviated Human Factors Engineering and Usability Testing

 

4.6.       Concluding Remarks

 

  1. SERVICE PROVIDER LANDSCAPE

5.1.       Chapter Overview

5.2.       Human Factors Engineering and Usability Testing Service Providers for Medical Devices: Overall Market Landscape

5.2.1.    Analysis by Year of Establishment

5.2.2.    Analysis by Company Size

5.2.3.    Analysis by Location of Headquarters

5.2.4.    Analysis by Types of Certifications Obtained

5.2.5.    Analysis by Types of Medical Device Designed

5.2.6.    Analysis by Types of Human Factors Engineering and Usability Testing Services Offered

5.2.6.1. Analysis by Types of Services Offered in the Concept Phase

5.2.6.2. Analysis by Types of Services Offered in the Design and Development Phase

5.2.6.3. Analysis by Types Services Offered in the Verification and Validation Phase

5.2.7.    Analysis by Other Services Offered

 

5.3.       Human Factors Engineering and Usability Testing Service Providers for Medical Devices Software: Overall Market Landscape

5.3.1.    Analysis by Year of Establishment

5.3.2.    Analysis by Company Size

5.3.3.    Analysis by Location of Headquarters

 

  1. COMPANY COMPETITIVENESS ANALYSIS

6.1.       Chapter Overview

6.2.       Assumptions and Key Parameters

6.3.       Methodology

 

6.4.       Company Competitiveness Analysis

6.4.1.    Human Factors Engineering and Usability Testing Service Providers based in North America

6.4.2.    Human Factors Engineering and Usability Testing Service Providers based in Europe

6.4.3.    Human Factors Engineering and Usability Testing Service Providers based in Asia

            Pacific / RoW

 

  1. COMPANY PROFILES

7.1.       Chapter Overview

7.2.       Service Providers in North America

7.2.1.    Agilis

7.2.1.1. Company Overview

7.2.1.2. Service Portfolio

7.2.1.3. Future Outlook

 

7.2.2.    Human Factors Consulting Service

7.2.2.1. Company Overview

7.2.2.2. Service Portfolio

7.2.2.3. Future Outlook

 

7.2.3.    Human Factors MD

7.2.3.1. Company Overview

7.2.3.2. Service Portfolio

7.2.3.3. Future Outlook

 

7.2.4.    User wise

7.2.4.1. Company Overview

7.2.4.2. Service Portfolio

7.2.4.3. Future Outlook

 

7.2.5.    Ximedica

7.2.5.1. Company Overview

7.2.5.2. Service Portfolio

7.2.5.3. Future Outlook

 

7.3.       Service Providers in Europe

7.3.1.    Austrian Center for Medical Innovation and Technology (ACMIT)

7.3.1.1. Company Overview

7.3.1.2. Service Portfolio

7.3.1.3. Future Outlook

 

7.3.2.    Auxergo

7.3.2.1. Company Overview

7.3.2.2. Service Portfolio

7.3.2.3. Future Outlook

 

7.3.3.    THAY Medical

7.3.3.1. Company Overview

7.3.3.2. Service Portfolio

7.3.3.3. Future Outlook

 

7.4.       Service Providers in Asia Pacific

7.4.1.    Ergotech

7.4.1.1. Company Overview

7.4.1.2. Service Portfolio

7.4.1.3. Future Outlook

 

7.4.2.    Jonathan Bar-Or Industrial Design

7.4.2.1. Company Overview

7.4.2.2. Service Portfolio

7.4.2.3. Future Outlook

                       

  1. COST IMPLICATIONS RELATED TO HUMAN FACTORS ENGINEERING AND USABILITY TESTING PROCESS

8.1.       Chapter Overview

8.2.       Steps involved in Human Factors Engineering and Usability Testing Process

8.3.       Cost Distribution across the Different Steps of Human Factors Engineering and Usability Testing Process

8.3.1.    Costs Associated with Contextual Inquiry

8.3.2.    Costs Associated with Task Analysis

8.3.3.    Costs Associated with Human Factors Assessment for Device Design

8.3.4.    Costs Associated with Formative Studies

8.3.5.    Costs Associated with Risk Analysis

8.3.6.    Costs Associated with Use Error Analysis

8.3.7.    Costs Associated with Summative Studies

8.3.8     Costs Associated with Regulatory Document Preparation

 

China Biopharmaceutical Contract Manufacturing Market, 2020-2030


Submitted 39 day(s) ago by Harry sins

 

 

To order this detailed 250+ page report, please visit this link

 

Key Inclusions

  • A detailed review of the overall landscape of companies offering contract manufacturing services for biopharmaceuticals in China, along with information on year of establishment, company size, scale of operation (preclinical, clinical and commercial), location of headquarters, number of manufacturing facilities, as well as location of these facilities, type of business segment, type of manufacturing service(s) offered (process development and characterization, method validation and testing, analytical development, stability studies, quality assurance and control, scale-up, downstream processing, regulatory support, data analytics and reporting, and others), type of biologic(s) manufactured (peptides / proteins, antibodies, vaccines, cell therapies, gene therapies, antibody drug conjugates, vectors, biosimilars, nucleic acids and others), type of expression system(s) used (mammalian, microbial and others), type of bioreactor(s) used (single-use bioreactors and stainless steel bioreactors) and its mode of operation (batch, fed-batch and perfusion), type of packaging, and affiliations to regulatory accreditations and certifications (if any).
  • An analysis of the various partnerships pertaining to biopharmaceutical manufacturing in China, which have been established since 2016, based on several parameters, such as the year of partnership, type of partnership model adopted, scale of operation, type of biologic, focus area of the deal, target indication, most active players (in terms of number of partnerships signed), and geography.
  • An analysis of the various expansion initiatives undertaken by contract manufacturers in China, in order to augment their capabilities, over the period 2016-2020 (till February), taking into consideration several relevant parameters, such as year of expansion, type of expansion (capability expansion, capacity expansion, facility expansion and new facility), scale of operation of manufacturing facility, type of biologic and location of manufacturing facility.
  • A clinical trial analysis of completed and active studies related to biopharmaceuticals that have been / are being / are likely to be conducted in China, based on trial registration year, trial phase, trial recruitment status, type of sponsor / collaborator, geography and number of patients enrolled.
  • An estimate of the overall, installed capacity for manufacturing biopharmaceuticals, based on data reported by industry stakeholders in the public domain; it highlights the distribution of available biopharmaceutical production capacity on the basis of company size (small, mid-sized, large and very large firms), scale of operation (preclinical, clinical and commercial), key geographical regions (China, Hong-Kong, Taiwan) and expression system used.
  • A review of recent initiatives undertaken by big pharma players in China for the manufacturing of biopharmaceuticals, highlighting trends across various parameters, such as number of initiatives, year of initiative, and benchmark analysis of big pharma players.
  • A qualitative analysis, highlighting the various factors that need to be taken into consideration by drug / therapy developers while deciding whether to manufacture their respective products in-house or engage the services of a CMO.
  • Elaborate profiles of key players that have a diverse range of capabilities for the development, manufacturing and packaging of biopharmaceutical products. Each profile features an overview of the company, its financial performance (if available), information on its service portfolio, details related to manufacturing capabilities and facilities, recent developments (partnerships and expansions), and an informed future outlook.
  • A case study comparing the key characteristics of large molecule and small molecule drugs, along with details on the various steps involved in their respective manufacturing processes.
  • A discussion on industry affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact the evolution of this field. It also includes a Harvey ball analysis, highlighting the relative impact of each SWOT parameter on industry dynamics.

 

The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:

  • Type of Product
  • API
  • FDF

 

  • Type of Expression System Used
  • Mammalian
  • Microbial
  • Others

 

  • Scale of Operation
  • Preclinical / Clinical
  • Commercial

 

  • Size of Manufacturers
  • Small
  • Mid-sized
  • Large / Very Large

 

  • Type of Biologic
  • Antibody 
  • Vaccine
  • Others

 

To request sample pages, please visit this link

 

Key Questions Answered

  • Who are the leading biopharmaceutical contract manufacturers in China?
  • What is the annual clinical demand for biopharmaceuticals in China?
  • What is the current installed capacity for manufacturing biopharmaceuticals in China?
  • What kind of partnership models are commonly adopted by stakeholders engaged in this domain?
  • What were the various expansion initiatives carried out by Chinese biopharmaceutical CMOs?
  • What were the different biopharmaceutical focused initiatives undertaken by big pharma players in the recent past, in China?
  • How is the current and future market opportunity likely to be distributed across key market segments?

 

You may also be interested in the following titles:

  1. China Pharmaceutical Contract Manufacturing Services Market, 2020-2030
  2. Live Biotherapeutics Products and Microbiome Contract Manufacturing Market: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms, 2020-2030
  3. Oligonucleotide Synthesis, Modification and Purification Services Market: Focus on Research, Diagnostic and Therapeutic Applications, 2020-2030

 

Contact Us

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com

Over 35 CMOs / CDMOs in China claim to offer a variety of services related to development and manufacturing of a wide range of biotherapeutic products, claims Roots Analysis


Submitted 39 day(s) ago by Harry sins

 

Owing to benefits, such as reduced manufacturing costs, availability of cheap and skilled labor, and a supportive regulatory landscape, biopharmaceutical developers from across the globe, are increasingly outsourcing their manufacturing operations to China based CMOs. Further, in order to meet the growing demand for their services, Chinese CMOs are actively consolidating / expanding their capabilities through partnerships and / or dedicated expansion initiatives.  

 

To order this 250+ page report, which features 100+ figures and 120+ tables, please visit this link

 

The USD 2.6 billion (by 2030) financial opportunity within the China biopharmaceutical contract manufacturing market has been analyzed across the following segments:

  • Type of Product 
  • API
  • FDF

 

  • Type of Expression System Used
  • Mammalian
  • Microbial
  • Others

 

  • Scale of Operation
  • Preclinical / Clinical
  • Commercial

 

  • Size of Manufacturer
  • Small
  • Mid-sized
  • Large / Very Large

 

  • Type of Biologic 
  • Antibody 
  • Vaccine
  • Others

 

The China Biopharmaceutical Contract Manufacturing Market, 2020-2030 report features the following companies, which we identified to be key players in this domain:

  • ChemPartner Biologics
  • JHL Biotech
  • JOINN Biologics
  • MabPlex
  • Mycenax Biotech
  • WuXi AppTec

 

Table of Contents

 

  1. Preface

    2. Executive Summary

  2. Introduction

  3. Case Study: Comparison of Small Molecules and Large Molecules

  4. Competitive Landscape

  5. Company Profiles

  6. Partnerships

  7. Recent Expansions

  8. Clinical Trial Analysis

  9. Regional Capability Analysis

  10. Capacity Analysis

  11. Big Pharma Biopharmaceutical Manufacturing Initiatives in China

  12. Make Versus Buy Decision Making Framework

  13. Market Sizing and Opportunity Analysis

 

  1. COVID-19 Impact on China Biopharmaceutical CMO Market

 

  1. SWOT Analysis

 

  1. Future of the China Biopharmaceutical CMO Market

 

  1. Interview Transcripts

 

  1. APPENDIX 1: TABULATED DATA

 

  1. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/china-biopharmaceutical-contract-manufacturing/313.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com  

 

Chines biopharmaceutical contract manufacturing market is projected to grow at an annualized rate of ~13%, till 2030


Submitted 39 day(s) ago by Harry sins

 

Roots Analysis has done a detailed study on China Biopharmaceutical Contract Manufacturing Market, 2020-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

 

To order this 250+ page report, which features 100+ figures and 120+ tables, please visit this link

 

Key Market Insights

  • Over 35 CMOs / CDMOs in China claim to offer a variety of services related to development and manufacturing of a wide range of biotherapeutic products
  • Several players provide one-stop solutions and are capable of operating at various scales; the landscape includes a mix of both established players and new entrants
  • In order to cater to the evolving needs of clients / sponsors, CMOs have established facilities across different regions of China; Eastern China, with the maximum number of sites, has emerged as a manufacturing hub
  • With over 80 deals inked in past five years, there has been a surge in the partnership activity within this domain; majority of these collaborations were signed for the development and manufacturing of antibody-based products
  • Big pharma players have also made significant investments in this region, including establishing new facilities, expanding existing R&D centers and growing manufacturing facilities, focused on biotherapeutics
  • We expect global biopharmaceutical developers to continue to outsource their manufacturing operations to China in the long term; we anticipate the CMO industry in the region to grow at an annualized rate of ~13%, till 2030

For more information, please visit https://www.rootsanalysis.com/reports/view_document/china-biopharmaceutical-contract-manufacturing/313.html

 

Table of Contents

 

  1. PREFACE
    1.1. Scope of the Report
    1.2.       Research Methodology
    1.3.       Chapter Outlines

    2.         EXECUTIVE SUMMARY

  2. INTRODUCTION
    3.1. Chapter Overview

 

  • Overview of Biopharmaceuticals

 

3.3.       Manufacturing of Biopharmaceuticals

3.3.1.    Types of Expression Systems Used

3.3.1.1. Bacterial Expression Systems

3.3.1.2. Yeast Expression Systems

3.3.1.3. Insect Expression Systems

3.3.1.4. Plant Expression Systems

3.3.1.5. Mammalian Expression Systems

3.3.1.6. Fungal Expression Systems

 

3.3.2.    Processing Steps

3.3.2.1. Upstream Processing

3.3.2.2. Downstream Processing

 

3.4.       Overview of Contract Manufacturing

3.4.1.    Contract Manufacturing Scenario in China

3.5.       Need for Outsourcing in the Biopharmaceutical Industry

3.5.1.    Biopharmaceutical Outsourcing in China: Regulatory Scenario

 

3.6.       Commonly Outsourced Operations in the Biopharmaceutical Industry

 

3.7.       Basic Guidelines for Selecting a CMO Partner

3.8.       Advantages of Outsourcing Manufacturing Services

3.8.1.    Benefits of Engaging Chinese Contract Service Providers

 

3.9.       Risks and Challenges Associated with Biopharmaceutical Contract Manufacturing

3.9.1.    Challenges Associated with Engaging Chinese Contract Service Providers

3.10.     Future Perspective

 

  1. CASE STUDY: COMPARISON OF SMALL MOLECULES AND LARGE MOLECULES

4.1.       Chapter Overview

 

4.2.       Small Molecule and Large Molecule Drugs / Therapies

4.2.1.    Comparison of Key Characteristics

4.2.2.    Comparison of Manufacturing Processes

4.2.3.    Comparison of Key Manufacturing-Related Challenges

           

  1. COMPETITIVE LANDSCAPE

5.1.       Chapter Overview

 

5.2.       Chinese Biopharmaceutical Contract Manufacturers: Overall Market Landscape

5.2.1.    Analysis by Year of Establishment

5.2.2.    Analysis by Company Size

5.2.3.    Analysis by Scale of Operation

5.2.4.    Analysis by Location of Headquarters

5.2.5.    Analysis by Location of Manufacturing Facilities

5.2.6.    Analysis by Type of Product

5.2.7.    Analysis by Types of Services Offered

5.2.8.    Analysis by Type of Biologic

5.2.9.    Analysis by Expression System Used

5.2.10.  Analysis by Type of Bioreactor Used

5.2.11.  Analysis by Mode of Operation of Bioreactor

5.2.12.  Analysis by Packaging Form Used

5.2.13.  Analysis by Regulatory Accreditations / Certifications

           

  1. COMPANY PROFILES

6.1        Chapter Overview

 

6.2        ChemPartner Biologics

6.2.1.    Company Overview

6.2.2.    Service Portfolio

6.2.3.    Manufacturing Facilities and Capabilities

6.2.4.    Recent Developments and Future Outlook

 

6.3.       JHL Biotech

6.3.1.    Company Overview

6.3.2.    Service Portfolio

6.3.3.    Manufacturing Facilities and Capabilities

6.3.4.    Recent Developments and Future Outlook

 

6.4.       JOINN Biologics

6.4.1.    Company Overview

6.4.2.    Service Portfolio

6.4.3.    Manufacturing Facilities and Capabilities

6.4.4.    Recent Developments and Future Outlook

 

6.5        MabPlex

6.5.1.    Company Overview

6.5.2.    Service Portfolio

6.5.3.    Manufacturing Facilities and Capabilities

6.5.4.    Recent Developments and Future Outlook

 

6.6.       Mycenax Biotech

6.6.1.    Company Overview

6.6.2.    Service Portfolio

6.6.3.    Manufacturing Facilities and Capabilities

6.6.4.    Recent Developments and Future Outlook

 

6.7.       WuXi AppTec

6.7.1.    Company Overview

6.7.2.    Financial Information

6.7.3.    Service Portfolio

6.7.4.    Manufacturing Facilities and Capabilities

6.7.5.    Recent Developments and Future Outlook

 

  1. PARTNERSHIPS

7.1        Chapter Overview

 

7.2.       Partnership Models

 

7.3.       Chinese Biopharmaceutical Contract Manufacturers: Recent Partnerships

7.3.1.    Analysis by Year of Partnership

7.3.2.    Analysis by Type of Partnership

7.3.3.    Analysis by Scale of Operation

7.3.4.    Analysis by Type of Biologic

7.3.5.    Analysis by Focus Area

7.3.6.    Analysis by Therapeutic Area

7.3.7.    Most Active Players: Analysis by Number of Partnerships

7.3.8.    Geographical Analysis

7.3.9.    Geographical Distribution by Number of Partnerships

7.3.10.  Intercontinental and Intracontinental Agreements

 

  1. RECENT EXPANSIONS

8.1.       Chapter Overview

 

8.2.       Chinese Biopharmaceutical Contract Manufacturers: Recent Expansions

8.2.1.    Analysis by Year of Expansion

8.2.2.    Analysis by Type of Expansion

8.2.3.    Analysis by Scale of Operation

8.2.4.    Analysis by Type of Biologic

Presently, close to 50 companies are offering a variety of analytical testing solutions for the assessment of novel cancer biomarkers; majority of these tests are intended to facilitate important therapy-related decisions, claims Roots Analysis


Submitted 39 day(s) ago by Harry sins

 

Over time, pharmaceutical players have demonstrated significant interest in this domain and have launched clinical research initiatives to investigate the relevance and applications of these novel biomarkers. Several companies have already developed / are developing analytical tests for novel cancer biomarkers (TMB, MSI / MMR and TILs), intended to assist physicians in making personalized treatment decisions.

 

To order this 370+ page report, which features 190+ figures and 180+ tables, please visit this link

 

The USD  860 million (by 2030) financial opportunity within the cancer biomarkers market has been analyzed across the following segments:

  • Type of test
  • Laboratory Developed Tests (LDTs)
  • Companion Diagnostic Tests (CDx)

 

  • Type of disease indication
  • Breast cancer
  • Blood cancer
  • Colon / Colorectal cancer
  • Lung Cancer
  • Melanoma
  • Prostate Cancer

 

  • Type of cancer biomarker
  • TMB
  • MSI / MMR
  • TILs

 

  • Type of analytical technique
  • Next Generation Sequencing (NGS)
  • Polymerase Chain Reaction (PCR)
  • Immunohistochemistry (IHC)
  • Others

 

  • Key geographical regions
  • North America
  • Europe
  • Japan
  • China
  • Australia

 

The Cancer Biomarkers Market: Focus on TMB, MSI / MMR and TILs Testing, 2019-2030 report features the following companies, which we identified to be key players in this domain:

  • Foundation Medicine
  • NeoGenomics Laboratories
  • Novogene
  • Q2 Solutions
  • Personal Genome Diagnostics
  • Dr Lal PathLabs
  • Shenzhen Yuce Biotechnology

 

Table of Contents

 

  1. Preface

    2. Executive Summary

  2. Introduction

  3. Current Market Landscape

  4. Product Competitiveness Analysis

  5. Company Profiles

  6. Publication Analysis

  7. Innovative Designs for Biomarker-Based Clinical Trials

  8. Clinical Trial Analysis

  9. Market Forecast

  10. Future Growth Opportunities

  11. Case Study: Analysis of Needs of Stakeholders in The Companion Diagnostics Industry

  12. Case Study: Analysis of Value Chain in the Companion Diagnostics Industry

  13. Clinical Research on Cancer Biomarkers: A Big Pharma Perspective

 

  1. Executive Insights

 

  1. Appendix 1: Tabulated Data

 

  1. Appendix 2: List of Companies and Organizations

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/cancer-biomarkers-market-focus-on-tmb-msi--mmr-and-tils-testing-2019--2030/253.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com 

 

 

Cancer biomarkers market for TMB, MSI / MMR and TILs is projected to grow at an annualized rate of ~18%, till 2030


Submitted 39 day(s) ago by Harry sins

 

Roots Analysis has done a detailed study on Cancer Biomarkers Market: Focus on TMB, MSI / MMR and TILs Testing, 2019-2030, covering key aspects of the industry and identifying key future growth opportunities.

 

To order this 370+ page report, which features 190+ figures and 180+ tables, please visit this link

 

Key Market Insights

  • Several novel biomarkers are presently under investigation for a variety of cancer indications; the initiatives of big pharmaceutical companies are indicative of the growing interest in this domain
  • Presently, close to 50 companies are offering a variety of analytical testing solutions for the assessment of novel cancer biomarkers; majority of these tests are intended to facilitate important therapy-related decisions
  • Multiple tests are currently available for specific diseases indications; next generation sequencing has emerged as a key driver, enabling high throughput results and faster turnaround times
  • Companies involved in this domain are putting in significant efforts to develop efficient tests and differentiate their offerings, from those of other stakeholders, to maintain a competitive edge
  • Till date, close to 200 trials, evaluating the expression of novel biomarkers have been registered across different cancer indications, phases of development and geographical locations
  • The growing research activity in this domain is also evident across published scientific literature; several biomarker-focused studies are evaluating different types of immunotherapies
  • The growing interest in this field is also reflected by the 120+ partnerships have been signed in the last two years, involving both international and indigenous stakeholders
  • The opportunity is likely to be driven by the applicability of these tests across multiple cancer indications; the market is anticipated to grow as more biomarker based drugs get approved in the coming decade
  • The projected future opportunity is expected to be distributed across different application areas, types of analytical techniques used and various global regions

 

For more information, please visit https://www.rootsanalysis.com/reports/view_document/cancer-biomarkers-market-focus-on-tmb-msi--mmr-and-tils-testing-2019--2030/253.html

 

Table of Contents

 

  1. PREFACE

1.1.       Scope of the Report

1.2.       Research Methodology

1.3.       Chapter Outlines

 

  1. EXECUTIVE SUMMARY

 

  1. INTRODUCTION

3.1.       Chapter Overview

3.2.       Cancer Immunotherapy

3.2.1.    Cancer Immunotherapy Biomarkers

3.2.2.    Identification of a Candidate Biomarker

3.2.3.    Need for Novel Cancer Biomarkers

 

3.3.       Tumor Mutation Burden (TMB)

3.3.1.    Overview

3.3.2.    Variation of TMB across Multiple Indications

3.3.3.    Methods for Measurement of TMB

3.3.4.    Factors Affecting Measurement of TMB

3.3.5.    Initiatives for Assessment of TMB as a Potential Biomarker

 

3.4.       Microsatellite Instability / Mismatch Repair Deficiency (MSI / MMR)

3.4.1.    Overview

3.4.2.    Variation of MSI across Multiple Indications

3.4.3.    Methods of Measurement of MSI

 

3.5.       Tumor Infiltrating Lymphocytes and Other Novel Biomarkers

 

4          CURRENT MARKET LANDSCAPE

4.1.       Chapter Overview

4.2.       Cancer Biomarkers Testing Services: Overall Market Landscape

4.2.1.    Analysis by Year of Establishment

4.2.2.    Analysis by Company Size

4.2.3.    Analysis by Geographical Location

4.2.4.    Analysis by Test Availability

4.2.5.    Analysis by Type of Biomarker

4.2.6.    Analysis by Application Area

4.2.7.    Analysis by Disease Indication

4.2.8.    Analysis by Analytical Technique Used

4.2.9.    Analysis by Turnaround Time

4.2.10.  Analysis by Sample Input

4.2.11.  Analysis by Nucleic Acid Tested

4.2.12.  Key Players: Analysis by Type of Biomarker

 

4.3.       TMB Tests

4.3.1.    Analysis by Application Area

4.3.2.    Analysis by Disease Indication

4.3.3.    Analysis by Analytical Technique Used

4.3.4.    Analysis by Turnaround Time

 

4.4.       MSI / MMR Tests

4.4.1.    Analysis by Application Area

4.4.2.    Analysis by Disease Indication

4.4.3.    Analysis by Analytical Technique Used

4.4.4.    Analysis by Turnaround Time

 

4.5.       TIL-based Tests

4.5.1.    Analysis by Application Area

4.5.2.    Analysis by Disease Indication

4.5.3.    Analysis by Analytical Technique Used

4.5.4.    Analysis by Turnaround Time

 

5          PRODUCT COMPETITIVENESS ANALYSIS

5.1.       Chapter Overview

5.2.       Product Competitiveness Analysis: Key Assumptions and Methodology

5.2.1.    Tests for the Assessment of TMB

5.2.2.    Tests for the Assessment of MSI / MMR

5.2.3.    Tests for the Assessment of TILs

 

6          COMPANY PROFILES 

6.1.       Chapter Overview

6.2.       Dr Lal PathLabs

6.2.1.    Company Overview      

6.2.2.    Financial Information    

6.2.3.    Product / Service Portfolio        

6.2.3.1. Biomarkers Testing Portfolio     

6.2.3.1.1. Microsatellite Instability (MSI) by PCR 

6.2.3.1.2. OncoPro NCCN Lung Cancer Panel (*9 Genes *MSI)  

6.2.3.1.3. OncoPro Liquid Biopsy 73 Gene Panel with MSI          

6.2.4.    Recent Developments and Future Outlook         

 

6.3.       Foundation Medicine    

6.3.1.    Company Overview      

6.3.2.    Financial Information    

6.3.3.    Product / Service Portfolio        

6.3.3.1. Biomarkers Testing Portfolio     

6.3.3.1.1. FoundationOne CDx  

6.3.3.1.2. FoundationOne Liquid

6.3.3.1.3. FoundationOne Heme

6.3.4.    Recent Developments and Future Outlook         

           

6.4.       NeoGenomics Laboratories       

6.4.1.    Company Overview      

6.4.2.    Financial Information    

6.4.3.    Product / Service Portfolio        

6.4.3.1. Biomarkers Testing Portfolio     

6.4.3.1.1. NeoTYPE Discovery Profile for Solid Tumors  

6.4.3.1.2. MSI Analysis / MMR Panel by IHC      

6.4.3.1.3. MultiOmyx Tumor Infiltrating Lymphocyte Panel          

6.4.4.    Recent Developments and Future Outlook         

 

6.5.       Novogene        

6.5.1.    Company Overview      

6.5.2.    Product / Service Portfolio        

6.5.2.1. Biomarkers Testing Portfolio     

6.5.2.1.1. NovoPM Cancer Panel           

6.5.2.1.2. NovoPM TMB

6.5.2.1.3. NovoPM bTMB

6.5.2.1.4. NovoPM MSI

6.5.3.    Recent Developments and Future Outlook

 

6.6.       Q2 Solutions    

6.6.1.    Company Overview      

6.6.2.    Product / Service Portfolio        

6.6.2.1. Biomarkers Testing Portfolio     

6.6.2.1.1. TMB Assay   

6.6.2.1.2. MSI Assay    

6.6.2.1.3. TILs Testing  

6.6.3.    Recent Developments and Future Outlook

Asian shares rise as U.S. stimulus plans offset virus woes | Reuters

www.reuters.com
Submitted 41 day(s) ago by system

Asian shares rose on Monday as concerns over rising COVID-19 cases and delays in vaccine supplies were eclipsed by expectations of a $1.9 trillion fiscal stimulus plan to help revive the U.S. economy.

Excellent Information For Your Cost Haggling Requirements For Cars

carsimulcast.com
Submitted 46 day(s) ago by Flood64Devine

Car or truck browsing is a horror to a lot of drivers. The new vehicle will be enjoyment, but only after a lengthy learning procedure. Using this information can support make car or truck buying pleasurable rather of miserable.

In no way succumb to the salesperson's practices by agreeing to obtain a motor vehicle priced outside of your price range. Some salesmen can discuss you into an costly vehicle you are not able to pay for. Recall, the extra pricey the automobile, the much more fee he or she will make.

Get your financial loan lined up prior to going to the dealership. Getting a car from a dealership will take a lengthy time for the reason that your dealer demands to discover you a bank loan. It will be a lot quicker if you have a personal loan all set.

Organize the financing for your automobile right before you car store. You must do this by your financial institution. This will often present you with a decrease interest amount, and when you get to the dealership, you will know the amount of money you can pay for toMarvelous Guidance For Your Price Haggling Desires For Vehicles

Automobile obtaining is a horror to several drivers. The new auto or truck will be interesting, but only shortly soon after a extended mastering system. Performing with this specifics can help make motor vehicle procuring pleasurable in its spot of depressing.

Never succumb to the salesperson's procedures by agreeing to purchase a auto priced outside of your cash. Some salesmen can explore you into an higher priced car or truck you are not equipped to handle. Continue to keep in head, the much extra high priced the automobile, the extra commission he or she will make.

Get your house loan lined up prior to traveling to the dealership. Obtaining a motor vehicle from a dealership can just take a extended time mainly because your vendor demands to appear throughout you a loan. It will be a great offer a lot quicker if you have a economical personal loan all established.

Arrange the funding for your vehicle proper ahead of you auto shop. You must do this by way of your financial establishment. This will routinely offer you with a lessen fascination rate, and when you get to the dealership, you will know the amount of revenue you can pay out for to devote.

When you shop for automobiles, set apart ample time to get the process completed. You in no way want to genuinely truly feel rushed so that you dedicate you to a provide that you are not severely comfy with. You should seriously founded aside the entire afternoon for that. You can generally get there once again some other time if you are pressed for time.

Test with for advice and tips from some other people. How do they like the vehicles they individual? Would they order the exact very same vehicle or truck again? Are they hearing good products about other cars on the recent market? When you materialize to be making a motor motor vehicle purchase, this can be a good way to get some details to assistance you get began.

When you are all set to buy a new motor vehicle, know your funds prior to likely to the seller. When motor car paying for, by no means at any time go in excess of your utmost money no issue of what phrases arrive out of the sellers mouth. The salesman is not the guy or girl that make six yrs worthy of of motor car or truck payments.

Glance at a vehicle's gas efficiency and how it will operate with your spending plan when getting a vehicle. For instance, you may perhaps feel a major V-eight motor, paired with a towing supply, is a fantastic concept. That mentioned, if you only tow a boat when a yr, you can hope to be shelling out by way of the nose for gasoline unnecessarily the other 364 moments.

Manufacturing an auto acquire can be tiring, but also very pleasant. Do not neglect that you can retail outlet for a auto on the world-wide-web from residence, conserving you a very good offer of time and earning it significantly additional pleasant. There are a selection of net websites that record motor vehicle selling charges. This is a great way to learn your suitable car or truck and come across out extra about the excellent places to shop for a new motor motor vehicle.

Know your having to pay for marketing selling price just right before you thrust to the dealership. Determine this amount mainly centered on what you can pay for to spend for, as properly as existing automobile values.

Use the Net to find out employed motor automobiles. It is just not expected to go to a terrific offer anymore. Analyze Craigslist, eBay and labeled world wide web web pages. This will aid you assist preserve some income and keep away from pushy salespeople.

Under no circumstances indicator any design of auto settlement till sooner or later you go by it. You actually need to not just indicator the offer with out reading through. Assure you analyze it from main to base. If you sign, you are positive to the arrangement. If you do not realize one thing or want to consider your time finding out it, issue to pick a copy home to look through above prior to you indicator it. If they won't enable you take into consideration it with you, request them for a duplicate.

Only phone the entire ton to see if they have the style and design you need to have in inventory. In any other scenario, the salesman will check out to get you to get 1 factor you may well possibly not want. If you definitely want a four doorway sedan and they really you should not have any, which is a squander of your time. Give them a ring and see what is essentially quickly offered.

Remember that a salesman desires practically nothing at all considerably more than to get commission and meet up with a quota. When this is a introduced, you might nicely neglect this simple actuality when confronted with a strong salesperson. Beware the extras and raise-ons that can get tacked on at the finish of a sale. Even discount automobiles can boost by hundreds or hundreds.

When it arrives to motor car buying, guys and girls are faced with tough possibilities. The a good deal additional educated you are on the challenge, the enhanced the selection is that you will inevitably make. Use the tips you just go through and get ready your self by performing some investigation on diverse tends to make and products and solutions until eventually you identify the ideal automobile. shell out.

When you store for automobiles, established aside ample time to get the process concluded. You never ever want to experience rushed so that you dedicate yourself to a deal that you are not actually relaxed with. You should really established apart the full afternoon for that. You can usually occur back again some other time if you are pressed for time.

Request for guidance and recommendations from other individuals. How do they like the cars and trucks they own? Would they purchase the identical motor vehicle all over again? Are they hearing great issues about other cars on the market? When you are producing a auto order, this can be a terrific way to gain some details to aid you get started.

When you are completely ready to purchase a new automobile, know your spending plan prior to going to the supplier. When vehicle procuring, never go about your utmost finances regardless of what phrases appear out of the dealers mouth. The salesman is not the man or woman that make six years truly worth of automobile payments.

Glance at a vehicle's fuel efficiency and how it will function with your spending plan when acquiring a auto. For occasion, you may assume a major V-eight motor, paired with a towing package, is a terrific concept. That explained, if you only tow a boat when a calendar year, you are going to be shelling out by the nose for gas unnecessarily the other 364 times.

Generating an car acquire can be tiring, but also incredibly enjoyable. Do not forget about that you can store for a car on-line from dwelling, preserving you a great deal of time and earning it far more pleasant. There are a variety of web sites that checklist auto prices. This is a great way to discover your great car and uncover out additional about the greatest places to store for a new motor vehicle.

Know carfax purchasing value ahead of you drive to the dealership. Estimate this number dependent on what you can manage, as effectively as present automobile values.

Use the World-wide-web to come across employed automobiles. It is not necessary to go to a whole lot any more. Check Craigslist, eBay and labeled sites. This will aid you help you save some income and keep away from pushy salespeople.

Under no circumstances signal any variety of automobile deal until finally you study it. You should really not just indicator the contract with no reading through. Assure you go through it from top to bottom. If you signal, you're certain to the settlement. If you do not realize a little something or want to get your time reading through it, check with to get a duplicate residence to read above before you signal it. If they will never allow you just take it with you, ask them for a copy.

Contact the large amount to see if they have the product you drive in stock. Normally, the salesman will consider to get you to acquire one thing you might not want. If you definitely want a four doorway sedan and they never have any, that's a waste of your time. Give them a ring and see what is actually accessible.

Bear in mind that a salesman wishes nothing extra than to gain commission and meet a quota. Although this is a presented, you may well forget about this reality when confronted with a robust salesperson. Beware the extras and incorporate-ons that can get tacked on at the end of a sale. Even discount automobiles can maximize by hundreds or countless numbers.

When it will come to car getting, persons are confronted with tricky conclusions. The more educated you are on the issue, the improved the final decision is that you will in the long run make. Use the guidelines you just examine and get ready by yourself by performing some investigate on different tends to make and designs until you come across the best car.

How To Find A Terrific Offer On A New Vehicle

carsimulcast.com
Submitted 46 day(s) ago by Flood64Devine

Most folks you should not delight in procuring for cars and trucks, but obtaining a new motor vehicle is a quite enjoyable experience. If you want to just take the thriller out of acquiring a new car, it can be critical to do all the exploration you can. The pursuing post will educate you what you need to have to know about this procedure.

If it is really not negotiated down from its sticker cost when automobile procuring, you will be shedding cash. You shouldn't ever have to get a car at its advertised price. Sticker selling prices are intentionally superior as a way to facilitate negotiation.

Look for your car or truck on the Online ahead of going to the whole lot. You have to know the actual car or truck you want, or have a brief listing, ahead of you go to the dealer. Some on-line exploration can be good for narrowing your checklist of feasible tends to make and types and for studying points that the salespeople may well not convey to you.

If you're searching for a utilised auto, attempt to have it inspected by a mechanic not from the dealership. If they refuse, go somewhere else. You require a mechanic to give you an goal opinion about the car's situation and check for damages, submersion in drinking water or other difficulties some dealers consider to cover.
How To Attain A Excellent Offer On A New Auto

Most persons currently you should not enjoy obtaining for automobiles, but acquiring a new car is a unbelievably satisfying realistic practical experience. If you want to acquire the thriller out of obtaining a new auto, it can be important to do all the review you can. The pursuing posting will educate you what you will need to know about this treatment.

If it truly is not negotiated down from its sticker marketing value when motor auto searching, you will be shedding profits. You really should not at any time have to get a car at its advertised expense. Sticker costs are intentionally superior as a way to support negotiation.

Look for your vehicle on the Web prior to possible to the big amount. You have to know the correct car or truck you want, or have a brief listing, forward of you go to the seller. Some on the web investigation can be great for narrowing your list of doable can make and types and for getting out troubles that the salespeople may possibly not tell you.

If you are acquiring for a employed vehicle, contemplate to have it inspected by a mechanic not from the dealership. If they refuse, go in other places. You need a mechanic to give you an intention impression about the car's difficulty and verify out for damages, submersion in consuming h2o or other complications some dealers exam to conceal.

Concern your close good friends about what they listen to. Are they astonished with the autos that they have? How effectively would they say the automobile has held its worth? What have they listened to about other types? This is a excellent way to get a lay of the land just just before you get started out your automobile or truck browsing.

Do not chat about trade-ins, down payments or incentives ideal right up until before long immediately after you have a organization rate on the motor vehicle or truck you want. These remedies should be subtracted from the cheapest negotiated value. You are unquestionably absolutely sure to do much superior if you negotiate the rate really very first, then toss in the other elements.

In purchase to verify out a motor vehicle, lease it. Renting a motor vehicle or truck from a area rental agency is a wonderful way to get a private truly feel for a unique automobile about a exam generate of a doing work day or additional. Deliver the overall family members users along with for a exam travel. This will permit you to be snug with it in progress of having to pay out the dollars on it.

Getting a new automobile is both of those similarly scary and fascinating. You can do significantly of your procuring on the internet. Many internet websites offer side by aspect comparisons of a wide range of autos. This can support you in making a option quicker.

Express yet another person with you. An purpose bash will make it considerably much easier for you to keep absent from basing your obtain decision on thoughts. They are neutral and will explain to you any downsides they see.

When you have determined a car or truck that passions you, be certain that you wholly examine it. Glimpse above the process of the vehicle for any imperfections. When it arrives to the inside of, test for carpet stains or upholstery tears. You are caught with this motor vehicle or truck when you devote in it. Ownership extends to any hurt, stains or blemishes in or on the car or truck or truck.

Do not maintain if you occur to come to feel as nevertheless you are remaining bullied. You should actually go, even if they consider to preserve you there. If you should to holiday resort to it, lie to them. Get absent from there as fast as possible. There are also very a couple obtainable selections to continue to be someplace that would make you really come to feel hassled and uncomfortable.

You want to seem sharp but not loaded when getting a automobile. You are not going to score a wonderful offer you from a dealership if you are wearing luxurious-sum jewellery and a fur coat.

You truly really should usually do a examination drive ideal before you get a little something. The car or truck might have concerns they you you should really not see proper up until finally you make a particular transform or get to a certain tempo. You will not want any surprises as before long as you signal on the dotted line, so examination as a lot of maneuvers in the motor motor vehicle as you can.

Think about employing your monetary institution to order your vehicle or truck. It can protect you very little bit of money in want rates. Banks normally have a lower curiosity rate.

It truly is difficult to argue with the stage that automobile getting can be challenging. The truth of the matter of the make a difference is, if you get ready proper ahead of ecosystem out on to vehicle or truck a lot, you can have an enjoyable know-how. The better than piece is amazing starting phase for the approach.

Talk to your close friends about what they hear. Are they impressed with the automobiles that they have? How properly would they say the auto has held its value? What have they heard about other designs? carfax is a good way to get a lay of the land just before you commence your car or truck browsing.

Do not discuss about trade-ins, down payments or incentives right until just after you have a organization rate on the vehicle you want. These options should be subtracted from the most affordable negotiated cost. You are certain to do better if you negotiate the price 1st, then throw in the other factors.

In purchase to exam out a car or truck, rent it. Renting a vehicle from a regional rental company is a great way to get a personalized feel for a certain motor vehicle in excess of a take a look at travel of a day or much more. Provide the total household together for a test generate. This will permit you to be snug with it just before shelling out the cash on it.

Getting a new car is the two frightening and enjoyable. You can do a great deal of your procuring on-line. A lot of web sites offer you facet by facet comparisons of various automobiles. This can help you in creating a selection faster.

Convey a person with you. An goal social gathering will make it simpler for you to avoid basing your purchase decision on thoughts. They are impartial and will tell you any downsides they see.

Whenever you have discovered a motor vehicle that interests you, make sure that you thoroughly examine it. Search in excess of the physique of the motor vehicle for any imperfections. When it comes to the interior, examine for carpet stains or upholstery tears. You are caught with this car as soon as you buy it. Possession extends to any destruction, stains or blemishes in or on the automobile.

Do not keep if you really feel as though you are currently being bullied. You need to go, even if they try to maintain you there. If you must vacation resort to it, lie to them. Get absent from there as rapidly as doable. There are much too a lot of obtainable choices to stay someplace that tends to make you sense hassled and awkward.

You want to glimpse sharp but not prosperous when acquiring a car or truck. You are not going to rating a good offer from a dealership if you are carrying luxurious-stage jewelry and a fur coat.

You really should usually do a examination travel just before you obtain just about anything. The auto could have concerns they you do not see until finally you make a selected convert or get to a specified velocity. You do not want any surprises after you sign on the dotted line, so exam as several maneuvers in the car as you can.

Think about utilizing your lender to purchase your vehicle. It can conserve you little bit of cash in fascination premiums. Banking companies typically have a reduce fascination charge.

It is really hard to argue with the actuality that auto browsing can be overwhelming. The truth is, if you put together ahead of environment out onto motor vehicle loads, you can have an satisfying practical experience. The higher than piece is superb starting action for the process.

The ‘Contract Regulatory Affairs Management Market for Medical Devices, 2019-2030’ report features a detailed study on the current landscape of contract service providers focused on regulatory affairs management for medical devices.


Submitted 90 day(s) ago by Harry sins

 

To order this detailed 550+ page report, please visit this link

 

Key Inclusions

 

  • A detailed review of the current market landscape of the medical devices regulatory affairs outsourcing market, featuring a list of over 400 CROs engaged in this domain, and detailed analysis based on a number of relevant parameters, such as year of establishment, size of employee base, geographical location, device class (class I, class II, and class III), type and size of clientele (medical device developers, medical device manufacturers, medical device research organizations, and others), types of services offered, ([A] regulatory management services (such as legal representation, notified body selection, project registration and clinical trial application, regulatory writing and publishing, regulatory document submission, product labelling related service, gap-analysis, technical dossier set-up, vigilance & medical device report, risk management-related services), [B] additional services (such as biostatistics, consulting, clinical operations, post-marketing activities, quality assurance, reimbursement, training)), region(s) of operation wherein the company is offering regulatory management services.
  • A detailed discussion on the need for regulatory review / oversight across different stages of the medical devices supply chain, with emphasis on the optimization of the supply chain using upcoming tools / technologies (such as artificial intelligence, big data analytical, blockchain, internet of things and others).
  • An elaborate discussion on the various guidelines established by major regulatory bodies for medical device approval across North America (the US, Canada and Mexico), Europe (France, Germany, Italy, Spain, the UK and rest of Europe), Asia-Pacific and rest of the world (Australia, Brazil, China, India, Israel, Japan, New Zealand, Singapore, South Africa, South Korea, Taiwan, and Thailand). The report also features an insightful multi-dimensional, heat map analysis, featuring a comparison of the contemporary regulatory and reimbursement scenarios in key geographies across the globe.
  • Elaborate profiles of popular players that specialize in offering end-to-end regulatory services for medical devices across key geographies (North America, Europe and Asia-Pacific). Each profile features a brief overview of the company, including information on company headquarters, year of establishment, number of employees, and therapeutic area expertise, financial information (if available), detailed description of service portfolio, and an informed future outlook.
  • A benchmark analysis, highlighting the key focus areas of very small-sized, small-sized, mid-sized and large companies, comparing their existing capabilities within and beyond their respective peer groups, providing a means for stakeholders to identify ways to gain a competitive edge in the industry.
  • An elaborate discussion on the various outsourcing business models adopted for regulatory affairs management, along with an insightful Harvey ball analysis of key considerations that need to be assessed by industry stakeholders while selecting a CRO partner.
  • An analysis highlighting the key performance indicators used by sponsor companies to evaluate service providers that are active in the domain, based on information gathered via secondary research (for top-ten medical device players) and primary research.
  • A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in providing regulatory affairs management services to medical device developers.

 

The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:

  • Medical Device Class
  • Class I
  • Class II
  • Class III

 

  • Therapeutic Area
  • Cardiovascular Disorders
  • CNS Disorders
  • Metabolic Disorders
  • Oncological Disorders
  • Ophthalmological Disease
  • Orthopedic Disorders
  • Pain Disorders
  • Respiratory Disorders
  • Others

 

  • Type of Regulatory Affairs Service
  • Pharmacies GAP-Analysis
  • Pharmacies Legal Representation
  • Pharmacies Notified Body Selection
  • Product Labelling-related Services
  • Product Registration and Clinical Trial Applications
  • Regulatory Document Submissions
  • Regulatory Writing and Publishing
  • Risk Management-related Services
  • Technical Dossier Set-up
  • Vigilance & Medical Device Report

 

  • Key Geographical Regions
  • North America
  • Europe
  • Asia-Pacific and Rest of the World

 

To request sample pages, please visit this link

 

Key Questions Answered

  • Who are the leading CROs offering regulatory affairs-management services for medical devices?
  • What are differences in regulatory guidelines for medical device approval, across various geographies?
  • What are the key performance indicators used by sponsors to evaluate potential service providers?
  • What are the popular outsourcing models used by medical device companies for regulatory affairs-management purposes?
  • What are the key challenges faced by medical device developers / manufacturers in terms of regulations related to medical device approvals?
  • How is the current and future market opportunity likely to be distributed across key market segments?

 

You may also be interested in the following titles:

  1. Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market (3rd Edition), 2019-2030
  2. Medical Device Labels Manufacturing Market, 2019-2030
  3. Medical Device Contract Manufacturing Market, 2019-2030

 

Contact Us

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com

 

 

Over 400 companies claim to possess the required expertise to offer regulatory affairs management-related services to medical device-focused business entities, claims Roots Analysis


Submitted 90 day(s) ago by Harry sins

 

 

More than 130 medical devices were approved by the FDA since January 2018, while several are currently being evaluated across more than 9,500 (active) clinical trials, worldwide. Even though technical innovation has enabled the development of a variety of versatile medical devices, product approval, given stringent regulatory standards, is still a concern.

 

To order this 550+ page report, which features 245+ figures and 250+ tables, please visit this link

 

The USD 820 million (by 2030) financial opportunity within the contract regulatory affairs-management services market for medical devices has been analyzed across the following segments:

  • Medical Device Class
  • Class I
  • Class II
  • Class III

 

  • Therapeutic Area
  • Cardiovascular Disorders
  • CNS Disorders
  • Metabolic Disorders
  • Oncological Disorders
  • Ophthalmological Disease
  • Orthopedic Disorders
  • Pain Disorders
  • Respiratory Disorders
  • Others

 

  • Type of Regulatory Affairs Service
  • Pharmacies GAP-Analysis
  • Pharmacies Legal Representation
  • Pharmacies Notified Body Selection
  • Product Labelling-related Services
  • Product Registration and Clinical Trial Applications
  • Regulatory Document Submissions
  • Regulatory Writing and Publishing
  • Risk Management-related Services
  • Technical Dossier Set-up
  • Vigilance & Medical Device Report

 

  • Key Geographical Regions
  • North America
  • Europe
  • Asia-Pacific and Rest of the World

 

The Contract Regulatory Affairs-Management Market for Medical Devices, 2019-2030 report features the following companies, which we identified to be key players in this domain:

  • CTI Clinical Trial and Consulting Services
  • CROMSOURCE
  • ICON
  • Intertek
  • Medpace
  • MIC Medical
  • North American Science Associates (NAMSA)
  • Parexel
  • PharmaLex
  • Premier Research 
  • Société Générale de Surveillance (SGS)
  • Underwriters Laboratory (UL)

 

Table of Contents

 

  1. Preface

    2. Executive Summary

  2. Introduction

  3. Role of Regulatory Affairs in Medical Device Supply Chain

  4. Regulatory and Reimbursement Landscape for Medical Devices

  5. Competitive Landscape

  6. Company Profiles

  7. Competitive Benchmarking

  8. Guide to Regulatory Outsourcing Models

  9. Medical Device Regulatory Affairs: Key Performance Indicators

  10. Market Forecast

  11. Conclusion

  12. Survey Insights

  13. Executive Insights

 

  1. Appendix 1: Tabulated Data

 

  1. Appendix 2: List of Companies and Organizations

 

To purchase a copy, please visit  https://www.rootsanalysis.com/reports/view_document/med-dev-regulatory/282.html  

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com

 

 

The contract regulatory affairs-management services market for medical devices is estimated to be worth USD 820 million by 2030, growing at a CAGR of 6.9%,


Submitted 90 day(s) ago by Harry sins

 

Roots Analysis has done a detailed study on Medical Device CROs for Regulatory Affairs Management Market, 2019-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

 

To order this 550+ page report, which features 245+ figures and 250+ tables, please visit this link

 

Key Market Insights

  • Over 400 companies claim to possess the required expertise to offer regulatory affairs management-related services to medical device-focused business entities
  • The market landscape is highly fragmented, featuring the presence of both established players and new entrants; majority of such firms are located in the developed geographies
  • Service providers are catering to a diverse clientele, enabling sponsors to compliance to the standards of both regional and international regulators
  • Owing to the high competition, companies involved in this domain are steadily expanding their capabilities in order to augment their respective service portfolios and comply to evolving industry benchmarks
  • CROs are actively engaged in expanding their global footprint in order to enable their clients to navigate the technical and regulatory complexities across various geographies
  • The medical device regulatory affairs outsourcing market is anticipated to grow at an annualized rate of 6.8%; the opportunity is likely to be distributed across different therapeutic areas and geographies
  • Based on prevalent and anticipated trends, the revenue share will vary across important market segments, such as different types of services, size of service provider and device class

 

For more information, please visit https://www.rootsanalysis.com/reports/view_document/med-dev-regulatory/282.html

 

Table of Contents

 

  1. PREFACE
    1.1. Scope of the Report
    1.2. Research Methodology
    1.3. Chapter Outlines

    2. EXECUTIVE SUMMARY

  2. INTRODUCTION
    3.1. Chapter Overview

3.2. Contract Research Organizations (CROs)

3.2.1. Evolution of CROs

3.3. Role of CROs in the Medical Device Industry

3.4. Types of Medical Device CROs

3.5. Types of Services Offered by CROs

3.5.1. Types of Regulatory Affairs-Related Services Offered by CROs

3.6. Need for Outsourcing Regulatory Affairs-Related Operations for Medical Devices

3.7. Key Considerations for Selecting a Suitable CRO Partner

3.8. Advantages of Working with CROs

3.9. Risks and Challenges Related to Working with CROs

3.10. Concluding Remarks

 

  1. ROLE OF REGULATORY AFFAIRS IN MEDICAL DEVICE SUPPLY CHAIN

4.1. Chapter Overview

4.2. Overview of Medical Device Supply Chain

4.2.1. Importance of Regulatory Affairs in Medical Device Supply Chain

4.2.1.1. Concept and Feasibility Assessment Stage

4.2.1.2. Preclinical Stage

4.2.1.3. Manufacturing / Production Stage

4.2.1.4. Marketing Stage

4.2.1.5. Post-Marketing Stage

4.3. Factors Affecting the Medical Device Supply Chain

4.4. Key Performance Indicators for Medical Device Supply Chain Management

4.5. Optimization of Regulatory Affairs in the Medical Device Supply Chain

4.5.1. Digitalization of the Medical Device Supply Chain

 

  1. REGULATORY AND REIMBURSEMENT LANDSCAPE FOR MEDICAL DEVICES

5.1. Chapter Overview

5.2. General Regulatory and Reimbursement Guidelines for Medical Devices

5.3. Regulatory and Reimbursement Landscape in North America

5.3.1. The US Scenario

5.3.1.1. Regulatory Authority

5.3.1.2. Review / Approval Process

5.3.1.3. Reimbursement Landscape

5.3.1.3.1. Payer Mix

5.3.1.3.2. Reimbursement Process

5.3.2.    The Canadian Scenario

5.3.2.1. Regulatory Authority

5.3.2.2. Review / Approval Process

5.3.2.3. Reimbursement Landscape

5.3.2.3.1. Payer Mix

5.3.2.3.2. Reimbursement Process

5.3.3.    The Mexican Scenario

5.3.3.1. Regulatory Authority

5.3.3.2. Review / Approval Process

5.3.3.3. Reimbursement Landscape

5.3.3.3.1. Payer Mix

 

5.4.       Regulatory and Reimbursement Landscape in Europe

5.4.1.    Overall Scenario

5.4.1.1. Overall Regulatory Authority

5.4.1.2. Overall Review / Approval Process

5.4.2.    The UK Scenario

5.4.2.1. Regulatory Authority

5.4.2.2. Review / Approval Process

5.4.2.3. Reimbursement Landscape

5.4.2.3.1. Payer Mix

5.4.2.3.2. Reimbursement Process

5.4.3.    The French Scenario

5.4.3.1. Regulatory Authority

5.4.3.2. Review / Approval Process

5.4.3.3. Reimbursement Landscape

5.4.3.3.1. Payer Mix

5.4.3.3.2. Reimbursement Process

5.4.4.    The German Scenario

5.4.4.1. Regulatory Authority

5.4.4.2. Review / Approval Process

5.4.4.3. Reimbursement Landscape

5.4.4.3.1. Payer Mix

5.4.4.3.2. Reimbursement Process

5.4.5.    The Italian Scenario

5.4.5.1. Regulatory Authority

5.4.5.2. Review / Approval Process

5.4.5.3. Reimbursement Landscape

5.4.5.3.1. Payer Mix

5.4.5.3.2. Reimbursement Process

5.4.6.    The Spanish Scenario

5.4.6.1. Regulatory Authority

5.4.6.2. Review / Approval Process

5.4.6.3. Reimbursement Landscape

5.4.6.3.1. Payer Mix

5.4.6.3.2. Reimbursement Process

 

5.5.       Regulatory and Reimbursement Landscape in Asia-Pacific and Rest of the World

5.5.1.    The Australian Scenario

5.5.1.1. Regulatory Authority

5.5.1.2. Review / Approval Process

5.5.1.3. Reimbursement Landscape

5.5.1.3.1. Payer Mix

5.5.1.3.2. Reimbursement Process

5.5.2.    The Brazilian Scenario

5.5.2.1. Regulatory Authority

5.5.2.2. Review / Approval Process

5.5.2.3. Reimbursement Landscape

5.5.2.3.1. Payer Mix

5.5.2.3.2. Reimbursement Process

5.5.3.    The Chinese Scenario

5.5.3.1. Regulatory Authority

5.5.3.2. Review / Approval Process

5.5.3.3. Reimbursement Landscape

5.5.3.3.1. Payer Mix

5.5.3.3.2. Reimbursement Process

5.5.4.    The Indian Scenario

5.5.4.1. Regulatory Authority

5.5.4.2. Review / Approval Process

5.5.4.3. Reimbursement Landscape

5.5.4.3.1. Payer Mix

5.5.5.    The Israeli Scenario

5.5.5.1. Regulatory Authority

5.5.5.2. Review / Approval Process

5.5.5.3. Reimbursement Landscape

5.5.5.3.1. Payer Mix

5.5.6.    The Japanese Scenario

5.5.6.1. Regulatory Authority

5.5.6.2. Review / Approval Process

5.5.6.3. Reimbursement Landscape

5.5.6.3.1. Payer Mix

5.5.6.3.2. Reimbursement Process

5.5.7.    The New Zealand Scenario

5.5.7.1. Regulatory Authority

5.5.7.2. Review / Approval Process

5.5.7.3. Reimbursement Landscape

5.5.7.3.1. Payer Mix

5.5.7.3.2. Reimbursement Process

5.5.8.    The Singaporean Scenario

5.5.8.1. Regulatory Authority

5.5.8.2. Review / Approval Process

5.5.8.3. Reimbursement Landscape

5.5.8.3.1. Payer Mix

5.5.8.3.2. Reimbursement Process

5.5.9.    The South Korea Scenario

5.5.9.1. Regulatory Authority

5.5.9.2. Review / Approval Process

5.5.9.3. Reimbursement Landscape

5.5.9.3.1. Payer Mix

5.5.9.3.2. Reimbursement Process

5.5.10. The South African Scenario

5.5.10.1. Regulatory Authority

5.5.10.2. Review / Approval Process

5.5.10.3. Reimbursement Landscape

5.5.11. The Taiwanese Scenario

5.5.11.1. Regulatory Authority

5.5.11.2. Review / Approval Process

5.5.11.3. Reimbursement Landscape

5.5.11.3.1. Payer Mix

5.5.11.3.2. Reimbursement Process

5.5.12. The Thailand Scenario

5.5.12.1. Regulatory Authority

5.5.12.2. Review / Approval Process

5.5.12.3. Reimbursement Landscape

5.6.       Comparison of Regional Regulatory Environment

5.7.       Concluding Remarks

 

  1. COMPETITIVE LANDSCAPE

6.1.       Chapter Overview

6.2.       CROs Offering Regulatory Affairs-Related Services for Medical Devices: List of Companies

6.2.1.    Analysis by Year of Establishment

6.2.2.    Analysis by Size of Employee Base

6.2.3.    Analysis by Location of Headquarters

6.2.4.    Analysis by Company Size and Geography

6.3.       CROs Offering Regulatory Affairs-Related Services for Medical Devices: Information on Area of Specialization

6.3.1.    Analysis by Area of Specialization

6.4.       CROs Offering Medical Device Regulatory Services: Information on Type of Regulatory Affairs-Related Services Offered

6.4.1.    Analysis by Type of Regulatory Affairs-Related Service Offered

6.4.2.    Analysis by Year of Establishment, Geography and Type of Regulatory Affairs-Related Services           Offered

6.5.       CROs Offering Regulatory Affairs-Related Services for Medical Devices: Information on Type of  Additional Services Offered

6.5.1.    Analysis by Type of Additional Services Offered

6.6.       CROs Offering Regulatory Affairs-Related Services for Medical Devices: Information on Device Class

6.6.1.    Analysis by Device Class

6.7.       CROs Offering Regulatory Affairs-Related Services for Medical Devices: Information on Type and Size of Clientele

6.7.1.    Analysis by Type and Size of Clientele

6.8.       CROs Offering Regulatory Affairs-Related Services for Medical Devices: Information on Medical Device Regulatory Compliance Authorities

6.8.1.    Analysis by Medical Device Regulatory Compliance Authorities

 

6.9.       CROs Offering Regulatory Affairs-Related Services for Medical Devices: Information on Geographical Reach (Region-wise)

6.9.1.    Analysis by Geographical Reach (Region-Wise)

 

6.10.     CROs Offering Regulatory Affairs-Related Services for Medical Devices: Information on Geographical Reach (Country-wise)

6.10.1.  Analysis by Geographical Reach (Country-Wise)

 

  1. COMPANY PROFILES

7.1. Chapter Overview

 

7.2. CROs Headquartered in North America

7.2.1. CTI Clinical Trial and Consulting (CTI)

7.2.1.1. Company Overview

7.2.1.2. Service Portfolio

7.2.1.3. Future Outlook

 

7.2.2. Medpace

7.2.2.1. Company Overview

7.2.2.2 Financial Information

7.2.2.3. Service Portfolio

7.2.2.4. Future Outlook

 

7.2.3. NAMSA

7.2.3.1. Company Overview

7.2.3.2. Service Portfolio

7.2.3.3. Future Outlook

 

7.2.4. PAREXEL

7.2.4.1. Company Overview

7.2.4.2 Financial Information

7.2.4.3. Service Portfolio

7.2.4.4. Future Outlook

 

7.2.5. Premier Research

7.2.5.1. Company Overview

7.2.5.2. Service Portfolio

7.2.5.3. Future Outlook

 

7.2.6. Underwriters Laboratory (UL)

7.2.6.1. Company Overview

7.2.6.2. Service Portfolio

7.2.6.3. Future Outlook

 

7.3. CROs Headquartered in Europe

7.3.1. CROMSOURCE

7.3.1.1. Company Overview

7.3.1.2. Service Portfolio

7.3.1.3 Future Outlook

 

7.3.2. ICON

7.3.2.1. Company Overview

7.3.2.2 Financial Information

7.3.2.3. Service Portfolio

7.3.2.4. Future Outlook

 

7.3.3. Intertek

7.3.3.1. Company Overview

7.3.3.2 Financial Information

7.3.3.3. Service Portfolio

7.3.3.4. Future Outlook

 

7.3.4. PharmaLex

7.3.4.1. Company Overview

7.3.4.2. Service Portfolio

7.3.4.3 Future Outlook

7.3.5. Société Générale de Surveillance (SGS)

7.3.5.1. Company Overview

7.3.5.2. Service Portfolio

7.3.5.3 Future Outlook

 

7.3.4. SteriPack

7.3.4.1. Company Overview

7.3.4.2. Service Portfolio

7.3.4.3 Future Outlook

 

7.4. CROs Headquartered in Asia-Pacific and Rest of the World

7.4.1. MIC Medical

7.4.1.1. Company Overview

7.4.1.2. Service Portfolio

7.4.1.3 Recent Developments

 

  1. COMPETITIVE BENCHMARKING

8.1. Chapter Overview

8.2. Benchmark Analysis: Methodology

8.3. Region-wise Benchmark Analysis

8.3.1. North America, Peer Group I

8.3.2. North America, Peer Group II

8.3.3. North America, Peer Group III

8.3.4. North America, Peer Group IV

8.3.5. Europe, Peer Group V

8.3.6. Europe, Peer Group VI

8.3.7. Europe, Peer Group VII

8.3.8. Europe, Peer Group VIII

8.3.9. Asia Pacific and Rest of the World, Peer Group IX

8.3.10. Asia Pacific and Rest of the World, Peer Group X

8.3.11. Asia Pacific and Rest of the World, Peer Group XI

8.3.12. Asia Pacific and Rest of the World, Peer Group XII

8.4. Concluding Remarks

 

  1. GUIDE TO REGULATORY OUTSOURCING MODELS

9.1. Chapter Overview

9.2. Guiding Models for Regulatory Outsourcing

 

9.2.1. Functional Service Providers (FSP) Model: Large Medical Device Developers

9.2.1.1. Vendor Evaluation

 

9.2.2. End-to-End Model: Small-Sized Medical Device Developers

9.2.2.1. Vendor Evaluation

 

9.2.3. Hybrid Model: Mid-Sized Medical Device Developers

9.2.3.1. Vendor Evaluation

 

9.3. Concluding Remarks

 

  1. MEDICAL DEVICE REGULATORY AFFAIRS: KEY PERFORMANCE INDICATORS

10.1. Chapter Overview

10.2. Definition and Importance of Key Performance Indicators

10.3. Key Considerations for Selection of Key Performance Indicators

10.4. Types of Key Performance Indicators

10.4.1. Financial Indicators

10.4.1.1. Most Important KPIs

10.4.1.1.1. Financial Stability

10.4.1.1.2. Cost of Services Offered

10.4.1.1.3. Comparative Analysis of Financial Indicators

 

10.4.1.2. Industry Perspective

10.4.1.2.1. Sponsor (Big Pharma) Perspective

10.4.1.2.2. Contract Service Providers’ Perspective

 

10.4.2. Process / Capability Indicators

10.4.2.1. Most Important KPIs

10.4.2.1.1. Proximity to Sponsor

10.4.2.1.2. Capability to Innovate / Mitigate Risk

10.4.2.1.3. Strength of Service Portfolio

10.4.2.1.4. Comparative Analysis of Process / Capability Indicators

10.4.2.2. Industry Perspective

10.4.2.2.1. Sponsor (Big Pharma) Perspective

10.4.2.2.2. Contract Service Providers’ Perspective

 

10.4.3. Market Reputation Indicators

10.4.3.1. Most Important KPIs

10.4.3.1.1. Flexibility / Adaptability

10.4.3.1.2. Time Management

10.4.3.1.3. Quality / Reliability

10.4.3.1.4. Regulatory Compliance / Track Record

10.4.3.1.5. Comparative Analysis of Market Reputation Indicators

 

10.4.3.2. Industry Perspective

10.4.3.2.1. Sponsor (Big Pharma) Perspective

10.4.3.2.2. Contract Service Providers’ Perspective

 

10.5. Comparison of Key Performance Indicators

10.6. Concluding Remarks

 

  1. MARKET FORECAST

11.1 Chapter Overview

11.2. Forecast Methodology and Key Assumptions

11.3. Overall Medical Device Regulatory Affairs Outsourcing Market, 2019-2030

 

11.4. Medical Device Regulatory Affairs Outsourcing Market: Distribution by Geography, 2019 and 2030

11.4.1. Medical Device Regulatory Affairs Outsourcing Market in North America, 2019-2030

11.4.1.1. Medical Device Regulatory Affairs Outsourcing Market in the US, 2019-2030

11.4.1.2. Medical Device Regulatory Affairs Outsourcing Market in Rest of North America, 2019-2030

 

11.4.2. Medical Device Regulatory Affairs Outsourcing Market in Europe, 2019-2030

11.4.2.1. Medical Device Regulatory Affairs Outsourcing Market in Italy, 2019-2030

11.4.2.2. Medical Device Regulatory Affairs Outsourcing Market in Germany, 2019-2030

11.4.2.3. Medical Device Regulatory Affairs Outsourcing Market in France, 2019-2030

11.4.2.4. Medical Device Regulatory Affairs Outsourcing Market in Spain, 2019-2030

11.4.2.5. Medical Device Regulatory Affairs Outsourcing Market in the UK, 2019-2030

11.4.2.6. Medical Device Regulatory Affairs Outsourcing Market in Rest of Europe, 2019-2030

 

11.4.3. Medical Device Regulatory Affairs Outsourcing Market in Asia-Pacific, 2019-2030

11.4.3.1. Medical Device Regulatory Affairs Outsourcing Market in China, 2019-2030

11.4.3.2. Medical Device Regulatory Affairs Outsourcing Market in Japan, 2019-2030

11.4.3.3. Medical Device Regulatory Affairs Outsourcing Market in India, 2019-2030

11.4.3.4. Medical Device Regulatory Affairs Outsourcing Market in Rest of the Asia-Pacific, 2019-2030

 

11.4.4. Medical Device Regulatory Affairs Outsourcing Market in Rest of the World, 2019-2030

 

11.5. Medical Device Regulatory Affairs Outsourcing Market: Distribution by Type of Regulatory Affairs-Related Service, 2019 and 2030

11.5.1. Medical Device Regulatory Affairs Outsourcing Market for GAP-Analysis, 2019-2030

11.5.2. Medical Device Regulatory Affairs Outsourcing Market for Legal Representation, 2019-2030

11.5.3. Medical Device Regulatory Affairs Outsourcing Market for Notified Body Selection, 2019-2030

11.5.4. Medical Device Regulatory Affairs Outsourcing Market for Product Labeling-Related Services, 2019-2030

11.5.5. Medical Device Regulatory Affairs Outsourcing Market for Product Registration and Clinical Trial Applications, 2019-2030

11.5.6. Medical Device Regulatory Affairs Outsourcing Market for Regulatory Writing and Publishing, 2019-2030

11.5.7. Medical Device Regulatory Affairs Outsourcing Market for Regulatory Document Submissions, 2019-2030

11.5.8. Medical Device Regulatory Affairs Outsourcing Market for Risk Management Service, 2019-2030

11.5.9. Medical Device Regulatory Affairs Outsourcing Market for Technical Dossier Set-Up, 2019-2030

11.5.10. Medical Device Regulatory Affairs Outsourcing Market for Vigilance & Medical Device Report, 2019-2030

11.6. Medical Device Regulatory Affairs Outsourcing Market: Distribution by Device Class, 2019 and 2030

11.6.1. Medical Device Regulatory Affairs Outsourcing Market for Class I Devices, 2019-2030

11.6.2. Medical Device Regulatory Affairs Outsourcing Market for Class II Devices, 2019-2030

11.6.3. Medical Device Regulatory Affairs Outsourcing Market for Class III Devices, 2019-2030

 

11.7. Medical Device Regulatory Affairs Outsourcing Market: Distribution by Therapeutic Area, 2019 and 2030

11.7.1. Medical Device Regulatory Affairs Outsourcing Market for Cardiovascular Disorders, 2019-2030

11.7.2. Medical Device Regulatory Affairs Outsourcing Market for Central Nervous System (CNS) Disorders, 2019-2030

11.7.3. Medical Device Regulatory Affairs Outsourcing Market for Metabolic Disorders, 2019-2030

11.7.4. Medical Device Regulatory Affairs Outsourcing Market for Oncological Disorders, 2019-2030

11.7.5. Medical Device Regulatory Affairs Outsourcing Market for Orthopedic Disorders, 2019-2030

11.7.6. Medical Device Regulatory Affairs Outsourcing Market for Ophthalmic Disorders, 2019-2030

11.7.7. Medical Device Regulatory Affairs Outsourcing Market for Pain Disorders, 2019-2030

11.7.8. Medical Device Regulatory Affairs Outsourcing Market for Respiratory Disorders, 2019-2030

11.7.9. Medical Device Regulatory Affairs Outsourcing Market for Other Therapeutic Areas, 2019-2030

 

11.8. Medical Device Regulatory Affairs Outsourcing Market: Distribution by Type of Regulatory Affairs-Related Service and Geography

11.8.1. Medical Device Regulatory Affairs Outsourcing Market for GAP-Analysis in North America, 2019-2030

11.8.2. Medical Device Regulatory Affairs Outsourcing Market for GAP-Analysis in Europe, 2019-2030

11.8.3. Medical Device Regulatory Affairs Outsourcing Market for GAP-Analysis in Asia-Pacific, 2019-2030

11.8.4. Medical Device Regulatory Affairs Outsourcing Market for GAP-Analysis in Rest of the World, 2019-2030

11.8.5. Medical Device Regulatory Affairs Outsourcing Market for Legal Representation in North America, 2019-2030

11.8.6. Medical Device Regulatory Affairs Outsourcing Market for Legal Representation in Europe, 2019-2030

11.8.7. Medical Device Regulatory Affairs Outsourcing Market for Legal Representation in Asia-Pacific, 2019-2030

11.8.8. Medical Device Regulatory Affairs Outsourcing Market for Legal Representation in Rest of the World, 2019-2030

11.8.9. Medical Device Regulatory Affairs Outsourcing Market for Notified Body Selection in North America, 2019-2030

11.8.10. Medical Device Regulatory Affairs Outsourcing Market for Notified Body Selection in Europe, 2019-2030

11.8.11. Medical Device Regulatory Affairs Outsourcing Market for Notified Body Selection in Asia-Pacific, 2019-2030

11.8.12. Medical Device Regulatory Affairs Outsourcing Market for Notified Body Selection in Rest of the World, 2019-2030

11.8.13. Medical Device Regulatory Affairs Outsourcing Market for Product Labeling-Related Services in North America, 2019-2030

11.8.14. Medical Device Regulatory Affairs Outsourcing Market for Product Labeling-Related Services in Europe, 2019-2030

11.8.15. Medical Device Regulatory Affairs Outsourcing Market for Product Labeling-Related Services in Asia-Pacific, 2019-2030

11.8.16. Medical Device Regulatory Affairs Outsourcing Market for Product Labeling-Related Services in Rest of the World, 2019-2030

11.8.17. Medical Device Regulatory Affairs Outsourcing Market for Product Registration and Clinical Trial Applications in North America, 2019-2030

11.8.18. Medical Device Regulatory Affairs Outsourcing Market for Product Registration and Clinical Trial Applications in Europe, 2019-2030

11.8.19. Medical Device Regulatory Affairs Outsourcing Market for Product Registration and Clinical Trial Applications in Asia-Pacific, 2019-2030

11.8.20. Medical Device Regulatory Affairs Outsourcing Market for Product Registration and Clinical Trial Applications in Rest of the World, 2019-2030

11.8.21. Medical Device Regulatory Affairs Outsourcing Market for Regulatory Writing and Publishing in North America, 2019-2030

11.8.22. Medical Device Regulatory Affairs Outsourcing Market for Regulatory Writing and Publishing in Europe, 2019-2030

11.8.23. Medical Device Regulatory Affairs Outsourcing Market for Regulatory Writing and Publishing in Asia-Pacific, 2019-2030

11.8.24. Medical Device Regulatory Affairs Outsourcing Market for Regulatory Writing and Publishing in Rest of the World, 2019-2030

11.8.25. Medical Device Regulatory Affairs Outsourcing Market for Regulatory Document Submissions in North America, 2019-2030

11.8.26. Medical Device Regulatory Affairs Outsourcing Market for Regulatory Document Submissions in Europe, 2019-2030

11.8.27. Medical Device Regulatory Affairs Outsourcing Market for Regulatory Document Submissions in Asia-Pacific, 2019-2030

11.8.28. Medical Device Regulatory Affairs Outsourcing Market for Regulatory Document Submissions in Rest of the World, 2019-2030

11.8.29. Medical Device Regulatory Affairs Outsourcing Market for Risk Management Service in North America, 2019-2030

11.8.30. Medical Device Regulatory Affairs Outsourcing Market for Risk Management Service in Europe, 2019-2030

11.8.311. Medical Device Regulatory Affairs Outsourcing Market for Risk Management Service in Asia-Pacific, 2019-2030

11.8.32. Medical Device Regulatory Affairs Outsourcing Market for Risk Management Service in Rest of the World, 2019-2030

11.8.33. Medical Device Regulatory Affairs Outsourcing Market for Technical Dossier Set-Up in North America, 2019-2030

11.8.34. Medical Device Regulatory Affairs Outsourcing Market for Technical Dossier Set-Up in Europe, 2019-2030

11.8.35. Medical Device Regulatory Affairs Outsourcing Market for Technical Dossier Set-Up in Asia-Pacific, 2019-2030

11.8.36. Medical Device Regulatory Affairs Outsourcing Market for Technical Dossier Set-Up in Rest of the World, 2019-2030

11.8.37. Medical Device Regulatory Affairs Outsourcing Market for Vigilance & Medical Device Report in North America, 2019-2030

11.8.38. Medical Device Regulatory Affairs Outsourcing Market for Vigilance & Medical Device Report in Europe, 2019-2030

11.8.39. Medical Device Regulatory Affairs Outsourcing Market for Vigilance & Medical Device Report in Asia-Pacific, 2019-2030

11.8.40. Medical Device Regulatory Affairs Outsourcing Market for Vigilance & Medical Device Report in Rest of the World, 2019-2030

 

11.9. Medical Device Regulatory Affairs Outsourcing Market: Distribution by Device Class and Geography

11.9.1. Medical Device Regulatory Affairs Outsourcing Market for Class I Devices in North America, 2019-2030

11.9.2. Medical Device Regulatory Affairs Outsourcing Market for Class I Devices in Europe, 2019-2030

11.9.3. Medical Device Regulatory Affairs Outsourcing Market for Class I Devices in Asia-Pacific, 2019-2030

11.9.4. Medical Device Regulatory Affairs Outsourcing Market for Class I Devices in Rest of the World, 2019-2030

11.9.5. Medical Device Regulatory Affairs Outsourcing Market for Class II Devices in North America, 2019-2030

11.9.6. Medical Device Regulatory Affairs Outsourcing Market for Class II Devices in Europe, 2019-2030

11.9.7. Medical Device Regulatory Affairs Outsourcing Market for Class II Devices in Asia-Pacific, 2019-2030

11.9.8. Medical Device Regulatory Affairs Outsourcing Market for Class II Devices in Rest of the World, 2019-2030

11.9.9. Medical Device Regulatory Affairs Outsourcing Market for Class III Devices in North America, 2019-2030

11.9.10. Medical Device Regulatory Affairs Outsourcing Market for Class III Devices in Europe, 2019-2030

11.9.11. Medical Device Regulatory Affairs Outsourcing Market for Class III Devices in Asia-Pacific, 2019-2030

11.9.12. Medical Device Regulatory Affairs Outsourcing Market for Class III Devices in Rest of the World, 2019-2030

11.10. Medical Device Regulatory Affairs Outsourcing Market: Distribution by Therapeutic Area and Geography

11.10.1. Medical Device Regulatory Affairs Outsourcing Market for Cardiovascular Disorders in North America, 2019-2030

11.10.2. Medical Device Regulatory Affairs Outsourcing Market for Cardiovascular Disorders in Europe, 2019-2030

11.10.3. Medical Device Regulatory Affairs Outsourcing Market for Cardiovascular Disorders in Asia-Pacific, 2019-2030

11.10.4. Medical Device Regulatory Affairs Outsourcing Market for Cardiovascular Disorders in Rest of the World, 2019-2030

11.10.5. Medical Device Regulatory Affairs Outsourcing Market for Central Nervous System Disorders in North America, 2019-2030

11.10.6. Medical Device Regulatory Affairs Outsourcing Market for Central Nervous System Disorders in Europe, 2019-2030

11.10.7. Medical Device Regulatory Affairs Outsourcing Market for Central Nervous System Disorders in Asia-Pacific, 2019-2030

11.10.8. Medical Device Regulatory Affairs Outsourcing Market for Central Nervous System Disorders in Rest of the World, 2019-2030

11.10.9. Medical Device Regulatory Affairs Outsourcing Market for Metabolic Disorders in North America, 2019-2030

11.10.10. Medical Device Regulatory Affairs Outsourcing Market for Metabolic Disorders in Europe, 2019-2030

11.10.11. Medical Device Regulatory Affairs Outsourcing Market for Metabolic Disorders in Asia-Pacific, 2019-2030

11.10.12. Medical Device Regulatory Affairs Outsourcing Market for Metabolic Disorders in Rest of the World, 2019-2030

11.10.13. Medical Device Regulatory Affairs Outsourcing Market for Oncological Disorders in North America, 2019-2030

11.10.14. Medical Device Regulatory Affairs Outsourcing Market for Oncological Disorders in Europe, 2019-2030

11.10.15. Medical Device Regulatory Affairs Outsourcing Market for Oncological Disorders in Asia-Pacific, 2019-2030

11.10.16. Medical Device Regulatory Affairs Outsourcing Market for Oncological Disorders in Rest of the World, 2019-2030

11.10.17. Medical Device Regulatory Affairs Outsourcing Market for Ophthalmological Disorders in North America, 2019-2030

11.10.18. Medical Device Regulatory Affairs Outsourcing Market for Ophthalmological Disorders in Europe, 2019-2030

11.10.19. Medical Device Regulatory Affairs Outsourcing Market for Ophthalmological Disorders in Asia-Pacific, 2019-2030

11.10.20. Medical Device Regulatory Affairs Outsourcing Market for Ophthalmological Disorders in Rest of the World, 2019-2030

11.10.21. Medical Device Regulatory Affairs Outsourcing Market for Orthopedic Disorders in North America, 2019-2030

11.10.22. Medical Device Regulatory Affairs Outsourcing Market for Orthopedic Disorders in Europe, 2019-2030

11.10.23. Medical Device Regulatory Affairs Outsourcing Market for Orthopedic Disorders in Asia-Pacific, 2019-2030

11.10.24. Medical Device Regulatory Affairs Outsourcing Market for Orthopedic Disorders in Rest of the World, 2019-2030

11.10.25. Medical Device Regulatory Affairs Outsourcing Market for Pain Disorders in North America, 2019-2030

11.10.26. Medical Device Regulatory Affairs Outsourcing Market for Pain Disorders in Europe, 2019-2030

11.10.27. Medical Device Regulatory Affairs Outsourcing Market for Pain Disorders in Asia-Pacific, 2019-2030

11.10.28. Medical Device Regulatory Affairs Outsourcing Market for Pain Disorders in Rest of the World, 2019-2030

11.10.29. Medical Device Regulatory Affairs Outsourcing Market for Respiratory Disorders in North America, 2019-2030

11.10.30. Medical Device Regulatory Affairs Outsourcing Market for Respiratory Disorders in Europe, 2019-2030

11.10.31. Medical Device Regulatory Affairs Outsourcing Market for Respiratory Disorders in Asia-Pacific, 2019-2030

11.10.32. Medical Device Regulatory Affairs Outsourcing Market for Respiratory Disorders in Rest of the World, 2019-2030

11.10.33. Medical Device Regulatory Affairs Outsourcing Market for Other Disorders in North America, 2019-2030

11.10.34. Medical Device Regulatory Affairs Outsourcing Market for Other Disorders in Europe, 2019-2030

11.10.35. Medical Device Regulatory Affairs Outsourcing Market for Other Disorders in Asia-Pacific, 2019-2030

11.10.36. Medical Device Regulatory Affairs Outsourcing Market for Other Disorders in Rest of the World, 2019-2030

 

11.11. Medical Device Regulatory Affairs Outsourcing Market: Distribution by Company Size, 2019-2030

11.11.1. Medical Device Regulatory Affairs Outsourcing Market for Small-Sized Companies, 2019-2030

11.11.2. Medical Device Regulatory Affairs Outsourcing Market for Mid-Sized Companies, 2019-2030

11.11.3. Medical Device Regulatory Affairs Outsourcing Market for Large Companies, 2019-2030

 

11.12. Concluding Remarks

 

  1. CONCLUSION

12.1. Chapter Overview

12.2. Key Takeaways

 

  1. SURVEY INSIGHTS

13.1. Chapter Overview

13.2. Company Specifics of Respondents

13.3. Designation of Respondents

13.4. Types of Regulatory Affairs-Related Services

13.5. Analysis by Geographical Reach

13.6. Type and Size of Clientele

13.7. Average Number of Projects

13.8. Proportion of Clients Outsourcing Regulatory Affairs-Related Services

13.9. Cost of Outsourcing Regulatory Affairs-Related Services

13.10. Current and Future Market Opportunity

 

  1. EXECUTIVE INSIGHTS

14.1. Chapter Overview

14.2. A+ Science

14.2.1. Company Snapshot

14.2.2. Interview Transcript: Tania Persson, Business Development Manager

 

14.3. AtoZ-CRO

14.3.1. Company Snapshot

14.3.2. Interview Transcript: Alexa Foltin-Mertgen, Business Development Manager

 

14.4. CROMSOURCE

14.4.1. Company Snapshot

14.4.2. Interview Transcript: Troy Mccall, Chief Operating Officer

 

14.5. CW Research & Management

14.5.1. Company Snapshot

14.5.2. Interview Transcript: Christian Wolflehner, Managing Director, Clinical Trial Specialist

 

14.6. HungaroTrial

14.6.1 Company Snapshot

14.6.2. Interview Transcript: Antal Solyom, Director of Medical Device Unit

14.7. Metrics Research

 

14.7.1 Company Snapshot

14.7.2. Interview Transcript: Dr. Nazish Urooj, Senior Manager, Medical & Clinical Operations

 

14.8. Vyomus Consulting

14.8.1 Company Snapshot

14.8.2. Interview Transcript: Dr. C Omprakash, Technical Director and Partner

 

  1. APPENDIX I: TABULATED DATA

 

  1. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS


Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com

The “China Pharmaceutical Contract Manufacturing Services Market, 2020-2030” report features an extensive study of the current market landscape and future opportunities associated with the pharmaceutical contract manufacturing market in China.


Submitted 90 day(s) ago by Harry sins

 

Key Inclusions

  • A review of the current market landscape of companies offering pharmaceutical contract manufacturing services in China, along with information on year of establishment, company size, location of headquarters, type of product (active pharmaceutical ingredients (APIs), intermediates and finished dosage formulations (FDFs)), type of FDFs, type of packaging and number of manufacturing facilities.
  • A detailed landscape of the pharmaceutical manufacturing facilities in China, including an analysis based on location of these facilities, highlighting key manufacturing hubs.
  • A brief discussion of various guidelines laid down by regulatory authorities in China for the manufacturing of pharmaceuticals. It also provides information on various challenges, related to regulatory scrutiny, faced by pharmaceutical manufacturers in China.
  • Elaborate profiles of key players that offer a diverse range of capabilities for the manufacturing of pharmaceutical products in China. Each profile includes an overview of the company, information related to its pharmaceutical manufacturing service portfolio, details related to its manufacturing facilities, recent developments, and an informed future outlook.
  • A review of the pharmaceutical manufacturing related initiatives of the top 10 big pharma players (shortlisted from the top companies of 2019 by revenues), featuring a [A] analysis by investments made, with detailed information on investments related to R&D centers and manufacturing facilities in established and emerging regions of China, [B] Harvey ball framework, presenting a summary of all initiatives
  • A case study of the key recent developments (including partnerships and acquisitions) pertaining to the manufacturing of pharmaceutical drugs, during 2014-2020 (till February), based on several parameters, such as year of partnership, type of partnership and geography.
  • A detailed capacity analysis based on the individual reactor capacities of various industry stakeholders, taking into consideration parameters, such as company size (small-sized, mid-sized, large and very large), and location of the manufacturing facility (Eastern China, Southern China and Northern China).
  • A discussion on industry affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact the evolution of this field. It also includes a Harvey ball analysis, highlighting the relative impact of each SWOT parameter on industry dynamics.
  • A case study comparing the key characteristics of large molecule and small molecule drugs, along with details on the various steps involved in their respective manufacturing processes.

 

The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:

 

  • Key Geographical Regions
  • Eastern China
  • Southern China
  • Northern China 

 

  • Type of Product
  • Active Pharmaceutical Ingredients (APIs)
  • Drug Products

 

  • Type of Drug Product
  • Solid
  • Liquid / Semi-Solid
  • Injectable
  • Others

 

  • Scale of Operation
  • Clinical
  • Commercial

 

  • Company Size
  • Small
  • Mid-Sized
  • Large / Very Large

 

 

To request sample pages, please visit this link

 

Key Questions Answered

  • Who are the leading China-based pharmaceutical CMOs engaged in the production of APIs, intermediates and FDFs?
  • What are the key manufacturing hubs within China (in terms of number of manufacturing facilities)?
  • What is the current installed capacity for manufacturing of pharmaceuticals, in China?
  • What are the major market trends and driving factors that are likely to impact the growth of the pharmaceutical manufacturing market in China?
  • What is the likely short-term and long-term impact of the COVID-19 pandemic on the pharmaceutical contract manufacturing industry in China?
  • What kind of initiatives are being undertaken by big pharmaceutical players for pharmaceutical manufacturing in China?
  • How is the current and future market opportunity likely to be distributed across key market segments?

 

You may also be interested in the following titles:

  1. China Biopharmaceutical Contract Manufacturing Market, 2020 – 2030
  2. HPAPI and Cytotoxic Drugs Manufacturing Market (3rd Edition), 2020-2030
  3. Novel coronavirus (COVID-19): Preventive Vaccines, Therapeutics and Diagnostics in Development

 

Contact Us

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com

Presently, over 100 CMOs across the globe claim to have manufacturing facilities in China, offering services for pharmaceutical API, intermediates and FDF manufacturing, claims Roots Analysis


Submitted 90 day(s) ago by Harry sins

 

A growing economy, large population base, and innovation-friendly environment are other key parameters that are anticipated to drive the growth of the pharmaceutical contract manufacturing market in China. Further, in order to meet the growing demand for their services, CMOs having manufacturing facilities in China are actively expanding their existing capacities and capabilities in the region.

 

To order this 200+ page report, which features 85+ figures and 100+ tables, please visit this link

 

The USD 13 billion (by 2030) financial opportunity within the pharmaceuticals contract manufacturing market in China has been analyzed across the following segments:

  • Key Geographical Regions
  • Eastern China
  • Southern China
  • Northern China 

 

  • Type of Product
  • Active Pharmaceutical Ingredients (APIs)
  • Drug Products

 

  • Type of Drug Product
  • Solid
  • Liquid / Semi-Solid
  • Injectable
  • Others

 

  • Scale of Operation
  • Clinical
  • Commercial

 

  • Company Size
  • Small
  • Mid-Sized
  • Large / Very Large

 

 

The China Pharmaceutical Contract Manufacturing Services Market, 2020-2030 report features the following companies, which we identified to be key players in this domain:

  • 2Y-Chem
  • Aurisco Pharmaceutical
  • ChemPartner
  • Dorrapharma
  • Hubei Biocause Pharmaceutical
  • Infoark
  • Ningbo Menovo Pharmaceutical
  • Shandong Xinhua Pharmaceutical
  • Shanghai Acebright Pharmaceuticals
  • STA Pharmaceutical
  • Zhejiang Huahai Pharmaceutical

 

Table of Contents

 

  1. Preface

    2. Executive Summary

  2. Introduction

  3. Case Study: Comparison of Small Molecules and Large Molecules

  4. Market Overview

  5. Manufacturing Facilities of Pharmaceutical CMOs in China

  6. Pharmaceutical Manufacturing Regulations in China

  7. Company Profiles

  8. Big Pharma Initiatives in China

  9. Recent Trends

  10. Capacity Analysis

  11. SWOT Analysis

  12. Market Forecast

 

  1. Case Study: Impact of Coronavirus Outbreak

  2. Conclusion

 

  1. Executive Insights

 

  1. Appendix 1: Tabulated Data

 

  1. Appendix 2: List of Companies and Organizations

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/china-pharmaceutical-contract-manufacturing/312.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com 

 

The contract manufacturing market for Pharmaceuticals in China is projected to grow at an annualized rate of ~8.9%, till 2030


Submitted 90 day(s) ago by Harry sins

 

Roots Analysis has done a detailed study on China Pharmaceutical Contract Manufacturing Services Market, 2020-2030, covering key aspects of the industry and identifying key future growth opportunities.

 

To order this 200+ page report, which features 85+ figures and 100+ tables, please visit this link

 

Key Market Insights

  • Presently, over 100 CMOs across the globe claim to have manufacturing facilities in China, offering services for pharmaceutical API, intermediates and FDF manufacturing
  • CMOs have established manufacturing facilities across different regions of China; Eastern China has emerged as a popular hub, serving as a base of operations for many contract service providers
  • The current, installed manufacturing capacity of pharmaceutical CMOs in China is estimated to be over 46 million liters; interestingly, capacity utilization has been observed to be ~75% over the last few years
  • Big pharma players have also invested significantly in this region for initiatives related to the establishment or expansion of R&D centers and manufacturing facilities focused on pharmaceutical products
  • Innovator companies are expected to continue outsourcing clinical and commercial manufacturing operations to China-based CMOs; the contract services industry in the region is likely to grow at a CAGR of ~8.9%
  • In the long-term, the projected future opportunity is anticipated to be well distributed across various market segments, such as different types of products (APIs and FDFs), region (eastern china, southern china, western china) and others

 

For more information, please visit https://www.rootsanalysis.com/reports/view_document/china-pharmaceutical-contract-manufacturing/312.html

 

Table of Contents

 

  1. PREFACE
    1.1. Scope of the Report
    1.2.                  Research Methodology
    1.3.                  Chapter Outlines

    2.                     EXECUTIVE SUMMARY

  2. INTRODUCTION
    3.1. Chapter Overview
    3.2.                  Need for Outsourcing in the Pharmaceutical Industry
    3.3.                  Overview of the Pharmaceutical Contract Manufacturing
    3.4.                  Evolution of the Pharmaceutical Contract Manufacturing Industry
    3.4.1.                Traditional Contract Manufacturing Organizations (CMOs)

3.4.2.                Modern CMOs
3.5.                  Services Offered by CMOs
3.6.                  Pharmaceutical Contract Manufacturing Scenario in China

3.7.                  Advantages and Challenges associated with Outsourcing Pharmaceutical Manufacturing to China-based CMOs

 

  1. CASE STUDY: COMPARISON OF SMALL MOLECULES AND LARGE MOLECULES
    4.1.                  Chapter Overview
    4.2.                  Small Molecule and Large Molecule Drugs / Therapies

4.2.1.                Comparison of General Characteristics
4.2.2.                Comparison of Manufacturing Processes
4.2.3.                Comparison of Key Manufacturing-related Challenges

 

  1. MARKET OVERVIEW
    5.1.                   Chapter Overview
    5.2.                   Chinese Pharmaceutical CMOs with Manufacturing Facilities in China: List of Companies

5.2.1.                Analysis by Year of Establishment
5.2.2.                Analysis by Company Size
5.2.3.                Analysis by Location of Headquarters

5.2.4.                Analysis by Type of Product (API and FDF)
5.2.5.                Analysis by Type of FDF
5.2.6.                Analysis by Type of Packaging

5.2.7.                Analysis by Manufacturing Facilities

 

5.3.                   Non-Chinese Pharmaceutical CMOs with Manufacturing Facilities in China: List of Companies

5.3.1.                Analysis by Year of Establishment

5.3.2.                Analysis by Company Size

5.3.3.                Analysis by Location of Headquarters

5.3.4.                Analysis by Type of Product (API and FDF)

5.3.5.                Analysis by Type of FDF

5.3.6.                Analysis by Type of Packaging

5.3.7                 Analysis by Manufacturing Facilities

 

  1. MANUFACTURING FACILITIES OF PHARMACEUTICAL CMOs IN CHINA
    6.1.                   Chapter Overview
    6.2.                   Chinese Pharmaceutical CMOs: List of Manufacturing Facilities

    6.2.1.                Analysis by CMO Manufacturing Facilities in Eastern China
    6.2.2.                Analysis by CMO Manufacturing Facilities in Southern China
    6.2.3.                Analysis by CMO Manufacturing Facilities in Northern China

  2. PHARMACEUTICAL MANUFACTURING REGULATIONS IN CHINA

7.1.                   Chapter Overview

7.1.1.                Health Authorities in China

7.1.2.                Overview of Regulatory Guidelines in China

 

  1. COMPANY PROFILES

8.1.                   Chapter Overview

8.2.                   2Y-Chem

8.2.1.                Company Overview

8.2.2.                Service Portfolio

8.2.3.                China-based Manufacturing Facilities and Capabilities

8.2.4.                Recent Developments and Future Outlook

 

8.3.                   Aurisco Pharmaceutical

8.3.1.                Company Overview

8.3.2.                Service Portfolio

8.3.3.                China-based Manufacturing Facilities and Capabilities

8.3.4.                Recent Developments and Future Outlook

 

8.4.                   ChemPartner

8.4.1.                Company Overview

8.4.2.                Service Portfolio

8.4.3.                China-based Manufacturing Facilities and Capabilities

8.4.4.                Recent Developments and Future Outlook

 

8.5.                   Dorrapharma

8.5.1.                Company Overview

8.5.2.                Service Portfolio

8.5.3.                China-based Manufacturing Facilities and Capabilities

8.5.4.                Recent Developments and Future Outlook

 

8.6.                   Hubei Biocause Pharmaceutical

8.6.1.                Company Overview

8.6.2.                Service Portfolio

8.6.3.                China-based Manufacturing Facilities and Capabilities

8.6.4.                Recent Developments and Future Outlook

 

8.7.                   Infoark

8.7.1.                Company Overview

8.7.2.                Service Portfolio

8.7.3.                China-based Manufacturing Facilities and Capabilities

8.7.4.                Recent Developments and Future Outlook

 

8.8.                   Ningbo Menovo Pharmaceutical

8.8.1.                Company Overview

8.8.2.                Service Portfolio

8.8.3.                China-based Manufacturing Facilities and Capabilities

8.8.4.                Recent Developments and Future Outlook

 

8.9.                   Shandong Xinhua Pharmaceutical

8.9.1.                Company Overview

8.9.2.                Service Portfolio

8.9.3.                China-based Manufacturing Facilities and Capabilities

8.9.4.                Recent Developments and Future Outlook

 

8.10.                 Shanghai Acebright Pharmaceuticals 

8.10.1.             Company Overview

8.10.2.             Service Portfolio

8.10.3.             China-based Manufacturing Facilities and Capabilities

8.10.4.             Recent Developments and Future Outlook

           

8.11.                 STA Pharmaceutical

8.11.1.             Company Overview

8.11.2.             Service Portfolio

8.11.3.             China-based Manufacturing Facilities and Capabilities

8.11.4.             Recent Developments and Future Outlook

 

8.12.                 Zhejiang Huahai Pharmaceutical

8.12.1.             Company Overview

8.12.2.             Service Portfolio

8.12.3.             China-based Manufacturing Facilities and Capabilities

8.12.4.             Recent Developments and Future Outlook

 

  1. BIG PHARMA INITIATIVES IN CHINA

9.1.                   Chapter Overview

9.2.                   Big Pharma Players: List of Initiatives

9.2.1.                Analysis by Number of Initiatives

9.2.2.                Analysis by Year of Initiative

9.2.3.                Analysis by Company and Year of Initiative

9.2.4.                Analysis by Type of Initiative

 

9.3.                   Benchmark Analysis of Big Pharma Players

9.3.1.                Harvey Ball Analysis: Summary of Investments Made

9.3.2.                Geographical Analysis by Investments Made (Facility Specific)

 

  1. RECENT TRENDS

10.1.                 Chapter Overview

10.2.                 CMOs with Manufacturing Facilities in China: List of Partnerships

10.3.                 Analysis by Year and Type of Partnership

10.4.                 Logo Landscape of Key Partners

10.5.                 Geographical Analysis

           

  1. CAPACITY ANALYSIS

11.1.                 Chapter Overview

11.2.                 Key Assumptions and Methodology

11.3.                 CMOs with Manufacturing Facilities in China: Installed Capacity

11.3.1.              Analysis by Company Size

11.3.2.             Analysis by Location of Chinese Manufacturing Facilities

11.3.2.1.           Capacity Analysis: Eastern China

11.3.2.2.           Capacity Analysis: Southcentral China

11.3.2.3.           Capacity Analysis: Northern China

 

  1. SWOT ANALYSIS

12.1.                 Chapter Overview

12.2.                 Comparison of SWOT Factors

12.3.                 Concluding Remarks

 

  1. MARKET FORECAST

13.1.                 Chapter Overview

13.2.                 Forecast Methodology and Key Assumptions

13.3.                 Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030

13.4.                 Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Distribution by Geography

13.4.1.              Pharmaceutical Contract Manufacturing Services Market in Eastern China, 2020-2030

13.4.2.              Pharmaceutical Contract Manufacturing Services Market in Southern China, 2020-2030

13.4.3.              Pharmaceutical Contract Manufacturing Services Market in Northern China, 2020-2030

13.5.                 Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Distribution by Type of Product

13.5.1.              API Contract Manufacturing Services Market in China, 2020-2030

13.5.1.1.           API Contract Manufacturing Services Market in China, 2020-2030: Distribution by Geography

13.5.1.1.1.         API Contract Manufacturing Services Market in Eastern China, 2020-2030

13.5.1.1.2.         API Contract Manufacturing Services Market in Southern China, 2020-2030

13.5.1.1.3.         API Contract Manufacturing Services Market in Northern China, 2020-2030

13.5.2.              Drug Product Contract Manufacturing Services Market in China, 2020-2030

13.5.2.1.           Drug Product Contract Manufacturing Services Market in China, 2020-2030: Distribution by Geography

13.5.2.1.1.         Drug Product Contract Manufacturing Services Market in Eastern China, 2020-2030

13.5.2.1.2.         Drug Product Contract Manufacturing Services Market in Southern China, 2020-2030

13.5.2.1.3.         Drug Product Contract Manufacturing Services Market in Northern China, 2020-2030

           

13.5.2.2.           Drug Product Contract Manufacturing Services Market in China, 2020-2030: Distribution by Type of Drug Product

13.5.2.2.1.         Drug Product Contract Manufacturing Services Market in China, 2020-2030: Share of Solid Drug Product

13.5.2.2.2.         Drug Product Contract Manufacturing Services Market in China, 2020-2030: Share of Liquid and Semi Solid Drug Product

13.5.2.2.3.         Drug Product Contract Manufacturing Services Market in China, 2020-2030: Share of Injectable Drug Product

13.5.2.2.4.         Drug product Contract Manufacturing Services Market in China, 2020-2030: Share of Other Drug Products

13.6.                 Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Distribution by Scale of Operation

13.6.1.              Clinical Scale Contract Manufacturing Services Market in China, 2020-2030

13.6.2.              Commercial Scale Contract Manufacturing Services Market in China, 2020-2030  

13.7.                 Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Distribution by Size of Manufacturers

13.7.1.              Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Share of Small Companies

13.7.2.              Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Share of Mid-sized Companies

13.7.3.              Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Share of Large / Very Large Companies

 

 

 

  1. CASE STUDY: IMPACT OF CORONAVIRUS OUTBREAK

14.1.                 Chapter Overview

 

14.2.                 Current Opinions and Recuperative Initiatives of Key Players

14.2.1.              Wuxi AppTec

14.2.2.              Porton Pharma Solutions

14.2.3.              Lonza

14.3.                 Impact on Future Market Opportunity for Pharmaceutical CMOs in China

 

 

  1. CONCLUSION

 

  1. APPENDIX 1: TABULATED DATA

 

  1. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com

 

Continuous Manufacturing Market (Small Molecules and Biologics), 2020 – 2030” report features an extensive study of the current market landscape and future opportunities for companies with capabilities in continuous manufacturing (both innovator companies


Submitted 100 day(s) ago by Harry sins

 

To order this 310+ page report, which features 110+ figures and 200+ tables, please visit this link

 

Key Inclusions

  • A detailed assessment of the overall landscape of companies with capabilities for continuous manufacturing, along with information on a number of relevant parameters, such as year of establishment, company size, purpose of manufacturing (in-house and contract services), scale of operation (preclinical, clinical and commercial), location of headquarters, location of manufacturing facilities, type of drug molecule (biologic and small molecule), type of continuous manufacturing related service(s) offered (process development, API manufacturing, intermediate manufacturing, drug product manufacturing, and packaging and fill / finish), type of dosage form (solid and liquid), and installed capacity and batch size (if available).
  • Elaborate profiles of some of the key contract manufacturers active in the pharmaceutical and biopharmaceutical continuous manufacturing market in North America, Europe and Asia-Pacific. Each profile features an overview of the company, along with information related to its service portfolio, continuous manufacturing capabilities and facilities, recent developments and an informed future outlook.
  • An analysis of the various partnerships related to continuous manufacturing, which have been established since 2013, based on several parameters, such as year of an agreement, the type of partnership (research agreements, facility development / establishment agreements, technology enhancement agreements, service alliances, process development agreements, manufacturing agreements and other relevant agreements), scale of operation (preclinical, clinical and commercial), type of drug molecule (biologic and small molecule), type of continuous manufacturing related service (API manufacturing, intermediate manufacturing and end product manufacturing) and type of dosage form (solid and liquid). It also provides the regional distribution of the collaborations.
  • An analysis of the expansions related to continuous manufacturing, which have been established since 2013, based on several parameters, such as year of an expansion and the type of expansion (facility / plant expansion, technology installation, technology enhancement and service expansion), geographical location of the facility, scale of operation (preclinical, clinical and commercial), type of drug molecule (biologic and small molecule), type of continuous manufacturing related service (API manufacturing, intermediate manufacturing and end product manufacturing) and type of dosage form (solid and liquid).
  • An estimate of the global, continuous manufacturing capacity, based on the capacities of various industry stakeholders (as available on their respective company websites). The study examines the distribution of capacity, based on the type of drug molecule (biologic and small molecule), company size (small-sized, mid-sized and large), scale of operation (preclinical, clinical and commercial), location of headquarters (North America, Europe and Asia-Pacific) and location of manufacturing facilities (North America, Europe and Asia-Pacific).
  • A study of the various grants that have been awarded to research institutes engaged in projects related to continuous manufacturing, between 2014 and 2019, highlighting multiple parameters, such as year of award, type of grant, grant amount, focus area, support period, popular recipient organizations, type of recipient organization, funding institute center, funding mechanism and prominent program officers.
  • An in-depth analysis of the various patents that have been filed / granted related to continuous manufacturing till 2019. It includes information on key parameters, such as patent type, publication year, geographical location, CPC symbol, emerging focus areas, type of applicant and leading industry / non-industry players (in terms of the size of intellectual property portfolio). It also features a three-dimensional bubble analysis (based on patent citation count, publication year, extended geographical reach), as well as a patent benchmarking and a detailed valuation analysis.
  • Initiatives taken by the leading pharmaceutical companies (in terms of revenues), covering both partnered as well as in-house projects.
  • A review of the companies offering modular facilities / modular cleanrooms, with information on their geographical location (North America, Europe, Asia-Pacific and rest of the world), year of establishment, company size (small-sized, mid-sized or large) and type of industries served (pharmaceutical, biotechnology or others). It also includes information on the recent projects undertaken / executed by the companies providing modular facilities.
  • A case study of the companies offering technologies / equipment (continuous blenders and mixers, continuous granulators, continuous dryers, continuous compressors, continuous coaters, flow reactors, continuous filtration, distillation and centrifugation equipment, continuous chromatography, PAT technology and other technologies) that can potentially be used in a continuous manufacturing process, providing information on the geographical location of potential stakeholders and the type of technology / equipment provided.
  • A case study on the roadmap for the adoption of continuous manufacturing technique, discussing different strategies that can be followed by the company in order to adopt this technology or transition from batch manufacturing to continuous manufacturing.

 

The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:

  • Purpose of Manufacturing
  • In-House
  • Contract service
  • Scale of Operation
  • Commercial
  • Preclinical / Clinical
  • Type of Continuous Manufacturing related Service
  • API Manufacturing
  • End Product manufacturing
  • Type of Drug Molecule
  • Biologic
  • Small Molecule
  • Type of dosage form
  • Solid
  • Liquid
  • Key Geographical Regions
  • North America
  • Europe
  • Asia Pacific
  • Transcripts of interviews held with the following senior level representatives of stakeholder companies
  • Andrea Adamo, Founder and Chief Executive Officer, Zaiput Flow technologies
  • Bayan Takizawa, Co-Founder and Chief Business Officer, CONTINUUS Pharmaceuticals
  • Nick Thomson, Senior Director Chemical Research and Development, Pfizer
  • Himanshu Gadgil, Director and Chief Scientific Officer, Enzene Biosciences
  • Eric Fang, Chief Scientific Officer, Snapdragon Chemistry)
  • Ian Houson, Technical Project Manager, Continuous Manufacturing and Crystallization, University of Strathclyde

 

 

To request sample pages, please visit this link

 

Key Questions Answered

  • Who are the key players engaged in continuous manufacturing of small molecules and biologics?
  • What is the installed, global capacity for continuous manufacturing?
  • What are the key growth drivers within this domain?
  • What are the various paths to evolution within this industry?
  • Who are the other key stakeholders (modular facility providers and technology / equipment developers) in this domain?
  • How is the current and future market opportunity likely to be distributed across key market segments?

 

You may also be interested in the following titles:

  1. Pharmaceutical Contract Manufacturing Market (2nd Edition), 2018-2028
  2. Biopharma Contract Manufacturing Market (3rd Edition), 2019 - 2030
  3. China Pharmaceutical Contract Manufacturing Services Market, 2020-2030
  4. China Biopharmaceutical Contract Manufacturing Market, 2020 - 2030

 

Contact Us

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com

Over 60 companies across the globe claim to manufacture drug products / drug substances using the continuous manufacturing technique, either for in-house requirements or for contract service engagements, claims Roots Analysis


Submitted 100 day(s) ago by Harry sins

 

The COVID-19 pandemic has severely impaired the overall pharmaceutical supply chain, mostly owing to the absence of workers at manufacturing sites and restrictions imposed on distribution networks. In this context, continuous manufacturing offers a viable solution given the fact that continuous processes are largely automated. In fact, the FDA (and other regulatory bodies) have also expressed interest in advocating a shift to the use of advanced manufacturing technologies, such as continuous manufacturing.

 

To order this 310+ page report, which features 110+ figures and 200+ tables, please visit this link

 

The USD 1.9 billion (by 2030) financial opportunity within the continuous manufacturing market has been analyzed across the following segments:

  • Purpose of Manufacturing
  • In-House
  • Contract service

 

  • Scale of Operation
  • Commercial
  • Preclinical / Clinical

 

  • Type of Continuous Manufacturing related Service
  • API Manufacturing
  • End Product manufacturing

 

  • Type of Drug Molecule
  • Biologic
  • Small Molecule

 

  • Type of dosage form
  • Solid
  • Liquid

 

  • Key Geographical Regions
  • North America
  • Europe
  • Asia Pacific

 

The Continuous Manufacturing Market (Small Molecules and Biologics), 2020 – 2030 report features the following companies, which we identified to be key players in this domain:

  • AbbVie Contract Manufacturing
  • Ajinomoto Bio-Pharma Services
  • Almac
  • Boehringer Ingelheim BioXcellence
  • Cambrex
  • CordonPharma
  • Hovione
  • Kaneka
  • Lonza
  • Patheon
  • SK biotek

 

Table of Contents

 

  1. Preface

    2. Executive Summary

  2. Introduction

  3. Market Landscape

  4. Companies with Expertise in Continuous Manufacturing in North America: Profiles

  5. Companies with Expertise in Continuous Manufacturing in Europe: Profiles

  6. Companies with Expertise in Continuous Manufacturing in Asia-Pacific: Profiles

  7. Recent Partnerships and Collaborations

  8. Recent Expansions

  9. Capacity Analysis

  10. Academic Grant Analysis

  11. Patent Analysis

  12. Initiatives of Companies with In-House Continuous Manufacturing Capabilities

  13. Case Study: Modular Facilities in pharmaceutical / Biotechnological Industry

 

  1. Case Study: Technology and Equipment Providers

 

  1. Case Study: Roadmap for the Adoption of Continuous Manufacturing Processes

 

  1. Market Forecast and Opportunity Analysis

 

  1. Conclusion

 

  1. Executive Insights

 

  1. Appendix 1: Tabulated Data

 

  1. Appendix 2: List of Companies and Organizations

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/continuous-manufacturing/308.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com 

The continuous manufacturing market is projected to grow at an annualized rate of over 15%, till 2030


Submitted 100 day(s) ago by Harry sins

 

 

Roots Analysis has done a detailed study on Continuous Manufacturing Market (Small Molecules and Biologics), 2020 – 2030, covering key aspects of the industry and identifying future growth opportunities.

 

To order this 310+ page report, which features 110+ figures and 200+ tables, please visit this link

 

Key Market Insights

  • Eminent representatives from prominent contract service provider companies / organizations are both optimistic and cautious regarding the rising interest in continuous flow technologies, and its adoption
  • Over 60 companies across the globe claim to manufacture drug products / drug substances using the continuous manufacturing technique, either for in-house requirements or for contract service engagements
  • The market landscape features the presence of several well-established players, most of which claim to manufacture small molecules via the continuous technique, and are based in the developed geographies
  • Companies have established continuous drug manufacturing facilities for diverse types of dosage forms in various geographies; Europe and North America have emerged as the key hubs for these facilities
  • Several patents have been filed / granted specifically related to continuous manufacturing of pharmaceutical substances, both industry and non-industry players are actively involved in such efforts
  • Organizations have also extended financial support to aid the research efforts being put by various stakeholders in this domain; the current focus is on investigation of continuous manufacturing technologies
  • Over time, there has been a lot of activity in this arena, including the establishment of several partnerships and investments in capability and capacity expansions and new facilities worldwide
  • Most of the continuous manufacturing capacity belongs to established companies (in-house manufacturers and CMOs), accounting for over 70% of the available capacity across various geographies
  • Involvement of various other stakeholders including continuous equipment providers and modular facility providers is likely to revolutionize the overall manufacturing domain
  • As the adoption of continuous manufacturing technologies increases, the market is likely to witness significant growth; in the short term, majority of service-based revenues is likely to come from drug product related projects

 

For more information, please visit https://www.rootsanalysis.com/reports/view_document/continuous-manufacturing/308.html

 

Table of Contents

 

TABLE OF CONTENTS

 

  1. PREFACE

1.1.       Scope of the Report

1.2.       Research Methodology

1.3.       Chapter Outlines

 

  1. EXECUTIVE SUMMARY

 

  1. INTRODUCTION

3.1.       Chapter Overview

3.2.       Historical Evolution of Continuous Manufacturing

3.3.       Continuous Manufacturing in the Pharmaceutical Industry

3.3.1.    Regulatory Landscape

3.3.2.    Early Adopters of Continuous Manufacturing

3.3.3.    Anticipated Shift to Continuous Manufacturing

3.3.4.    Advantages of Continuous Manufacturing

3.3.5.    Key Challenges Associated with Continuous Manufacturing

3.3.6.    Future Perspectives

 

  1. MARKET LANDSCAPE

4.1.       Chapter Overview

4.2.       Companies with Expertise in Continuous Manufacturing: Overall Market Landscape

4.2.1.    Analysis by Year of Establishment

4.2.2.    Analysis by Company Size

4.2.3.    Analysis by Purpose of Manufacturing

4.2.4.    Analysis by Scale of Operation

4.2.5.    Analysis by Location of Headquarters

4.2.6.    Analysis by Location of Continuous Manufacturing Facilities

4.2.7.    Analysis by Type of Drug Molecule

4.2.8.    Analysis by Type of Continuous Manufacturing Related Service

4.2.9.    Analysis by Type of Dosage Form

4.2.10.  Heat Map: Analysis by Company Size and Location of Headquarters

4.2.11.  Information on Production Capacity

4.2.12.  Logo Landscape: Analysis by Year of Establishment and Company Size 

4.2.13.  Grid Representation: Analysis by Scale of Operation, Type of Continuous Manufacturing Related Service and Type of Dosage Form

4.2.14.  Geographical Map: Analysis by Location of Continuous Manufacturing Facilities and Type of Drug Molecule

 

  1. COMPANIES WITH EXPERTISE IN CONTINUOUS MANUFACTURING IN NORTH AMERICA: PROFILES

5.1.       Chapter Overview

5.2.       AbbVie Contract Manufacturing

5.2.1.    Company Overview

5.2.2.    Service Portfolio

5.2.3.    Continuous Manufacturing Capabilities and Facilities

5.2.4.    Recent Developments and Future Outlook

 

5.3.       Cambrex

5.3.1.    Company Overview

5.3.2.    Service Portfolio

5.3.3.    Continuous Manufacturing Capabilities and Facilities

5.3.4.    Recent Developments and Future Outlook

 

5.4.       Patheon

5.4.1.    Company Overview

5.4.2.    Service Portfolio

5.4.3.    Continuous Manufacturing Capabilities and Facilities

5.4.4.    Recent Developments and Future Outlook

 

5.5.       SK biotek

5.5.1.    Company Overview

5.5.2.    Service Portfolio

5.5.3.    Continuous Manufacturing Capabilities and Facilities

5.5.4.    Recent Developments and Future Outlook

 

  1. COMPANIES WITH EXPERTISE IN CONTINUOUS MANUFACTURING IN EUROPE: PROFILES

6.1.       Chapter Overview

6.2.       Ajinomoto Bio-Pharma Services

6.2.1.    Company Overview

6.2.2.    Service Portfolio

6.2.3.    Continuous Manufacturing Capabilities and Facilities

6.2.4.    Recent Developments and Future Outlook

 

6.3.       Almac

6.3.1.    Company Overview

6.3.2.    Service Portfolio

6.3.3.    Continuous Manufacturing Capabilities and Facilities

6.3.4.    Recent Developments and Future Outlook

 

6.4.       Boehringer Ingelheim BioXcellence™

6.4.1.    Company Overview

6.4.2.    Service Portfolio

6.4.3.    Continuous Manufacturing Capabilities and Facilities

6.4.4.    Recent Developments and Future Outlook

 

6.5.       CordonPharma

6.5.1.    Company Overview

6.5.2.    Service Portfolio

6.5.3.    Continuous Manufacturing Capabilities and Facilities

6.5.4.    Recent Developments and Future Outlook

 

6.6.       Hovione

6.6.1.    Company Overview

6.6.2.    Service Portfolio

6.6.3.    Continuous Manufacturing Capabilities and Facilities

6.6.4.    Recent Developments and Future Outlook

 

6.7.       Lonza

6.7.1.    Company Overview

6.7.2.    Service Portfolio

6.7.3.    Continuous Manufacturing Capabilities and Facilities

6.7.4.    Recent Developments and Future Outlook

 

  1. COMPANIES WITH EXPERTISE IN CONTINUOUS MANUFACTURING IN ASIA-PACIFIC: PROFILES

7.1.       Chapter Overview

7.2.       Kaneka

7.2.1.    Company Overview

7.2.2.    Service Portfolio

7.2.3.    Continuous Manufacturing Capabilities and Facilities

7.2.4.    Recent Developments and Future Outlook     

 

7.3.       WuXi AppTec

7.3.1.    Company Overview

7.3.2.    Service Portfolio

7.3.3.    Continuous Manufacturing Capabilities and Facilities

7.3.4.    Recent Developments and Future Outlook                 

 

  1. RECENT PARTNERSHIPS AND COLLABORATIONS

8.1.       Chapter Overview

8.2.       Partnership Models

8.3.       List of Partnerships and Collaborations

8.3.1.    Analysis by Year of Partnership

8.3.2.    Analysis by Type of Partnership

8.3.3.    Analysis by Scale of Operation

8.3.4.    Analysis by Type of Drug Molecule

8.3.5.    Analysis by Type of Continuous Manufacturing Related Service

8.3.6.    Analysis by Type of Dosage Form

8.3.7.    Most Active Players: Analysis by Number of Partnerships

 

8.3.8.    Regional Analysis

8.3.8.1. Intercontinental and Intracontinental Agreements

 

  1. RECENT EXPANSIONS

9.1.       Chapter Overview

9.2.       Recent Expansions

9.2.1.    Analysis by Year of Expansion

9.2.2.    Analysis by Type of Expansion

9.2.3.    Analysis by Expanded Scale of Expansion

9.2.4.    Analysis by Type of Drug Molecule

9.2.5.    Analysis by Type of Continuous Manufacturing Related Service

9.2.6.    Analysis by Type of Dosage Form

9.2.7.    Most Active Players: Analysis by Number of Expansions

 

9.2.8.    Regional Analysis

9.2.8.1. Analysis by Location of Expansion Project

 

  1. CAPACITY ANALYSIS

10.1.     Chapter Overview

10.2.     Assumptions and Methodology

10.3.     Global, Continuous Manufacturing Capacity for Small Molecule APIs

10.3.1.  Analysis by Company Size

10.3.2. Analysis by Purpose of Manufacturing

10.3.3.  Analysis by Scale of Operation

10.3.4.  Analysis by Location of Headquarters

10.3.4.  Analysis by Location of Continuous Manufacturing Facilities

 

10.4.     Global, Continuous Manufacturing Capacity for Small Molecule End Products

10.4.1.  Analysis by Company Size

10.4.2. Analysis by Purpose of Manufacturing

10.4.3.  Analysis by Scale of Operation

10.4.4.  Analysis by Location of Headquarters

10.4.5.  Analysis by Location of Continuous Manufacturing Facilities

 

10.5.     Global, Continuous Manufacturing Capacity for Biologic

10.5.1.  Analysis by Company Size

10.5.2. Analysis by Purpose of Manufacturing

10.5.3.  Analysis by Scale of Operation

10.5.4.  Analysis by Location of Headquarters

10.5.5.  Analysis by Location of Continuous Manufacturing Facilities

 

  1. ACADEMIC GRANT ANALYSIS

11.1.     Chapter Overview

11.2.     Scope and Methodology

11.3.     Continuous Manufacturing: List of Academic Grants

11.3.1.  Analysis by Number of Grants

11.3.2.  Analysis by Activity Code

11.3.3.  Analysis by Grant Amount

11.3.4.  Analysis by Focus Area

11.3.5.  Analysis by Support Period

11.3.6   Popular Recipient Organizations: Analysis by Number of Grants

11.3.7   Analysis by Type of Recipient Organization

11.3.8.  Analysis by Funding Institute Centre

11.3.9.  Analysis by Funding Mechanism

11.3.10. Prominent Program Officers: Analysis by Number of Grants

 

  1. PATENT ANALYSIS

12.1.     Chapter Overview

12.2.     Scope and Methodology

12.3.     Continuous Manufacturing: Patent Analysis

12.3.1.  Analysis by Publication Year

12.3.2.  Analysis by Geography

12.3.3.  Analysis by CPC Symbols

12.3.4.  Emerging Focus Areas

12.3.5.  Analysis by Type of Applicant

12.3.6.  Leading Players: Analysis by Number of Patents

12.3.7.  Continuous Manufacturing: Three-Dimensional Bubble Analysis

12.3.8.  Continuous Manufacturing: Patent Valuation Analysis

12.3.8.1. Leading Patents: Information by Number of Citations

 

  1. INITIATIVES OF COMPANIES WITH IN-HOUSE CONTINUOUS MANUFACTURING CAPABILITIES

13.1.     Chapter Overview

13.2.     Continuous Manufacturing Initiatives of Leading Companies

13.2.1.  AbbVie

13.2.1.1. Partnered Initiatives

13.2.1.2 In-House Initiatives

 

13.2.2.  Amgen

13.2.2.1. Partnered Initiatives

13.2.2.2. In-House Initiatives

 

13.2.3.  Bristol-Myers Squibb

13.2.3.1. Partnered Initiatives

13.2.3.2. In-House Initiatives

 

13.2.4.  GlaxoSmithKline

13.2.4.1. Partnered Initiatives

13.2.4.2. In-House Initiatives

 

13.2.5.  Merck

13.2.5.1. Partnered Initiatives

13.2.5.2. In-House Initiatives

 

13.2.6.  Novartis

13.2.6.1. Partnered Initiatives

13.2.6.2. In-House Initiatives

 

13.2.7.  Pfizer

13.2.7.1. Partnered Initiatives

13.2.7.2. In-House Initiatives

 

13.2.8.  Roche

13.2.8.1. Partnered Initiatives

13.2.8.2. In-House Initiatives

13.2.9.  Sanofi

13.2.9.1. Partnered Initiatives

13.2.9.2. In-House Initiatives

 

  1. CASE STUDY: MODULAR FACILITIES IN PHARMACEUTICAL / BIOTECHNOLOGY INDUSTRY

14.1.     Chapter Overview

14.2.     Historical Background

14.3.     Concept of Modularization

14.3.1.  Types of Modules

14.3.2.  Modular Construction Process

 

14.4.     Modular Construction in the Pharmaceutical Industry

14.4.1.  Advantages of Modular Construction in the Pharmaceutical Industry

 

14.5.     Modular Facility Manufacturers

14.5.1.  Distribution by Industry Served

14.5.2.  Distribution by Geography

14.5.3.  Modular Projects Executed / Undertaken

 

14.6.     Modular Pharmaceutical Cleanrooms

14.6.1.  Cleanroom Classification and Current Standards

14.6.2.  Advantages of Modular Cleanrooms

14.6.3.  Regulations and Standards Concerning Modular Cleanroom Construction

 

14.7.     Modular Cleanroom Providers

14.7.1.  Distribution by Industry Served

14.7.2.  Distribution by Geography

14.7.3.  Type of Modular Cleanrooms Offered

 

  1. CASE STUDY: TECHNOLOGY AND EQUIPMENT PROVIDERS

15.1.     Chapter Overview

15.2.     Types of Continuous Manufacturing Technologies

15.3.     Equipment and Technologies for Continuous Manufacturing Small Molecules and Biologics

15.3.1.  Continuous Blending and Mixing Equipment

15.3.2.  Continuous Granulating Equipment

15.3.3.  Continuous Drying Equipment

15.3.4.  Continuous Compression Equipment

15.3.5.  Continuous Coating Equipment

15.3.6.  Continuous Filtration, Continuous Distillation and Continuous Centrifugation Equipment

15.3.7.  Continuous Chromatography Equipment

15.3.8.  Continuous Reactors / Bioreactors

15.3.9.  Full Line Continuous Platforms

15.3.10. Process Analytical Technologies

15.3.11. Other Technologies

15.4.     Logo Landscape: Analysis of Technology Providers by Number and Type of Equipment

 

  1. CASE STUDY: ROADMAP FOR THE ADOPTION OF CONTINUOUS MANUFACTURING PROCESSES

16.1.     Chapter Overview

16.2.     Key Strategies for the Adoption of Continuous Manufacturing Processes

16.2. 1. Phase I: Process Development and Implementation

16.2. 2. Phase II: Equipment / Technology Development and Installation

16.2. 3. Phase III: Facility / Plant Development and Establishment

16.2. 4. Phase IV: Product Development and Manufacturing

 

  1. MARKET FORECAST AND OPPORTUNITY ANALYSIS

17.1.     Chapter Overview

17.2.     Forecast Methodology and Key Assumptions

17.3.     Overall, Continuous Manufacturing Market, 2020-2030

17.3.1.  Continuous Manufacturing Market: Distribution by Purpose of Manufacturing, 2020-2030

17.3.2.  Continuous Manufacturing Market: Distribution by Scale of Operation, 2020-2030

17.3.3.  Continuous Manufacturing Market: Distribution by Type of Drug Molecule, 2020-2030

17.3.4.  Continuous Manufacturing Market: Distribution by Type of Continuous Manufacturing Related Service, 2020-2030

17.3.5.  Continuous Manufacturing Market: Distribution by Type of Dosage Form, 2020-2030

17.3.6.  Continuous Manufacturing Market: Distribution by Key Geographical Regions, 2020-2030

 

17.4.     Continuous Manufacturing Market for Small Molecule, 2020-2030

17.4.1.  Distribution by Purpose of Manufacturing, 2020-2030

17.4.2.  Distribution by Scale of Operation, 2020-2030

17.4.3.  Distribution by Type of Continuous Manufacturing Related Service, 2020-2030

17.4.4.  Distribution by Key Geographical Regions, 2020-2030

 

17.5.     Continuous Manufacturing Market for Biologic, 2020-2030

17.5.1.  Distribution by Purpose of Manufacturing, 2020-2030

17.5.2.  Distribution by Scale of Operation, 2020-2030

17.5.3.  Distribution by Type of Continuous Manufacturing Related Service, 2020-2030

17.5.4.  Distribution by Key Geographical Regions, 2020-2030

 

  1. CONCLUSION

18.1.     Chapter Overview

18.2.     Key Takeaways

 

  1. EXECUTIVE INSIGHTS

19.1.     Chapter Overview

19.2.     Zaiput Flow Technologies

19.2.1.  Company Snapshot

19.2.2.  Interview Transcript: Andrea Adamo, Founder and Chief Executive Officer

 

19.3.     CONTINUUS Pharmaceuticals

19.3.1.  Company Snapshot

19.3.2.  Interview Transcript: Bayan Takizawa, Co-Founder and Chief Business Officer

 

19.4.     Snapdragon Chemistry

19.4.1.  Company Snapshot

19.4.2.  Interview Transcript: Eric Fang, Chief Scientific Officer

 

19.5.     Enzene Biosciences

19.5.1.  Company Snapshot

19.5.2.  Interview Transcript: Himanshu Gadgil, Director and Chief Scientific Officer

 

19.6.     Pfizer

19.6.1.  Company Snapshot

19.6.2.  Interview Transcript: Nick Thomson, Senior Director Chemical Research and Development

19.7.     University of Strathclyde

19.7.1.  Company Snapshot

19.7.2.  Interview Transcript: Ian Houson, Technical Project Manager

 

 

  1. APPENDIX 1: TABULATED DATA

 

  1. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com

 

Over 80 firms are involved in providing antibody drug discovery-related services; whereas close to 125 players are offering antibody discovery platforms


Submitted 100 day(s) ago by Harry sins

 

 

According to experts in this field, the industry is investigating antibodies against novel targets which are expected to drive the market in the coming years. In fact, many service provider and platform provider companies are offering support to the medical research community in order to develop an appropriate intervention to treat the illness caused by the SARS-CoV-2 virus.

 

To order this 500+ page report, which features 120+ figures and 140+ tables, please visit this link

 

The USD 6.5 billion (by 2030) financial opportunity within the antibody discovery services market has been analyzed across the following segments:

  • Steps Involved in the Antibody Discovery Process
  • Antigen Designing
  • Hit Generation
  • Lead Selection
  • Lead Optimization
  • Lead Characterization

 

  • Antibody Discovery Method Used
  • Phage Display
  • Hybridoma
  • Transgenic Animal
  • Yeast Display
  • Single Cell
  • Others

 

  • Nature of Antibody Generated
  • Humanized
  • Human
  • Chimeric
  • Murine

 

  • Key Geographical Regions 
  • North America
  • Europe
  • Asia Pacific and Rest of the World

 

The USD 5.9 billion (by 2030) financial opportunity within the antibody discovery platforms market has been analysed across the following segments:

  • Type of Payment
  • Upfront Payments
  • Milestone Payments

 

  • Key Geographical Regions 
  • North America
  • Europe
  • Asia Pacific

 

 

The Antibody Discovery: Services and Platforms Market (3rd Edition), 2020-2030 report features the following companies, which we identified to be key players in this domain:

  • Abzena
  • Abwiz Bio
  • Aragen Bioscience
  • BIOTEM
  • ChemPartner
  • Creative Biolabs
  • Distributed Bio

Press Release: Variation 3 (Format 4)

 

  • Harbour BioMed
  • HD Biosciences
  • ImmunoPrecise Antibodies
  • Integral Molecular
  • Kymab
  • LakePharma
  • Ligand Pharmaceuticals
  • MorphoSys
  • PX’Therapeutics
  • Syd Labs
  • Viva Biotech
  • Wuxi Biologics

 

Table of Contents

 

  1. Preface

    2. Executive Summary

  2. Introduction

  3. Antibody Discovery Process and Methods

 

  1. Antibody Discovery Service Providers: Current Market Landscape

 

  1. Company Competitiveness Analysis

  2. Company Profiles: Antibody Discovery Service Providers

  3. Antibody Discovery Technologies: Current Market Landscape

  4. Technology Competitiveness Analysis

  5. Company Profiles: Antibody Discovery Platform Providers

  6. Regional Capability Analysis

 

  1. Partnerships and Collaborations

 

  1. Funding and Investment Analysis

 

  1. Antibody Discovery Services: Market Forecast

 

  1. Antibody Discovery Technologies: Market Forecast

 

  1. Case in Point: Drug Discovery Processes of Top Selling Antibodies

 

  1. Case Study: Antibody Humanization and Affinity Maturation

 

  1. Future Growth Opportunities

 

  1. Executive Insights

 

  1. Concluding Remarks

 

  1. Appendix 1: Tabulated Data

 

  1. Appendix 2: List of Companies and Organizations

 

 

Press Release: Variation 3 (Format 4)

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/antibody-discovery-services-and-platforms/213.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

Gaurav.Chaudhary@rootsanalysis.com

The antibody discovery services and platforms market is projected to grow at an annualized rate of ~10%, till 2030


Submitted 100 day(s) ago by Harry sins

 

Roots Analysis has done a detailed study on Antibody Discovery: Services and Platforms Market (3rd Edition), 2020-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

 

To order this 450+ page report, which features 120+ figures and 140+ tables, please visit this link

 

Key Market Insights

  • Over 80 companies are offering antibody discovery services; of these, more than 75 players claim to offer services related to hit generation.
  • Nearly 180 innovative technology platforms have been developed by numerous firms for the purpose of antibody discovery.
  • Majority of stakeholders in the competitive market landscape are small / mid-sized firms, catering to the needs of a diverse clientele.
  • In order to get an edge over their competitors in the industry, companies have established their presence in different regions across the globe.
  • The rising interest in this field is reflected in the number of partnerships inked in the recent past, involving both international and indigenous stakeholders, and focused on antibody discovery for diverse range of indications.
  • Efforts of the players in the field of antibody discovery have garnered significant interest of several venture capital investors.
  • The antibody discovery services market is expected to witness growth at a CAGR of ~10%; the anticipated opportunity is likely to be distributed across various steps involved in antibody discovery, antibody discovery method, nature of antibody generated and geographies.
  • The market for antibody discovery platforms is currently being driven by the revenues from the licensing deals; it is anticipated to reach USD 5.9 billion by 2030.

 

For more information, please visit https://www.rootsanalysis.com/reports/view_document/antibody-discovery-services-and-platforms/213.html

                                                                                                               

Table of Contents

 

  1. PREFACE

1.1.        Scope of the Report

1.2.        Research Methodology

1.3.        Chapter Outlines

 

  1. EXECUTIVE SUMMARY

 

  1. INTRODUCTION

3.1.       Chapter Overview

3.2.       Structure of Antibodies

3.3.       History of Development

3.4.       Antibody Isotypes

3.5.       Mechanism of Action of Antibodies

3.6.       Classification of Antibodies

3.6.1.    Monoclonal Antibodies

3.6.2.    Polyclonal Antibodies

3.6.3.    Bispecific Antibodies

3.7.       Applications of Antibodies

 

 

 

Press Release: Variation 2 (Format 3)

 

  1. ANTIBODY DISCOVERY PROCESS AND METHODS

4.1.       Chapter Overview

4.2.       Antibody Discovery Process

4.2.1.    Target Selection and Validation

4.2.2.    Hit Generation

4.2.3.    Lead Selection

4.2.4.    Lead Optimization

4.2.4.1. Humanization

4.2.4.2. Affinity Maturation

4.2.4.3. Fc Engineering

4.2.5.    Lead Characterization

4.2.6.    Candidate Selection

 

4.3.       Antibody Discovery Methods

4.3.1.    Hybridoma Method

4.3.2.    In vitro Display Method

4.3.2.1. Phage Display

4.3.2.2. Yeast Display

4.3.2.3. Ribosomal Display

4.3.3.    Transgenic Animal-Based Method

4.3.4.    Single B Cell-Based Method

4.3.5.    Advantages and Disadvantages of Existing Antibody Discovery Techniques

 

4.4.       Evolution of Monoclonal Antibodies

4.4.1.    Fully Human Monoclonal Antibodies

 

  1. ANTIBODY DISCOVERY SERVICE PROVIDERS: CURRENT MARKET LANDSCAPE

5.1.       Chapter Overview

5.2.       Antibody Discovery Service Providers: List of Industry Players

5.2.1.    Analysis by Year of Establishment

5.2.2.    Analysis by Company Size

5.2.3.    Analysis by Location of Headquarters

5.2.4.    Analysis by Type of Service Offered

5.2.5.    Analysis by Type of Antibody Discovery Method

5.2.6.    Grid Representation: Analysis by Type of Service Offered, Type of Antibody Discovery Method and Company Size

5.2.7.    Analysis by Animal Model Used

5.2.8.    Analysis by Type of Antibody Discovered

5.2.9.    Analysis by Type of Antibody Discovery Method and Type of Antibody Discovered

5.2.10.  Analysis by Purpose of Antibody Discovery

5.2.11.  Analysis by Type of Antibody Discovery Method and Purpose of Antibody Discovery

 

  1. COMPANY COMPETITIVENESS ANALYSIS

6.1.       Chapter Overview

6.2.       Methodology

6.3.       Key Parameters

6.4.       Competitiveness Analysis: Antibody Discovery Service Providers

6.4.1.    Antibody Discovery Service Providers based in North America

6.4.2.    Antibody Discovery Service Providers based in Europe

6.4.3.    Antibody Discovery Service Providers based in Asia Pacific

 

  1. COMPANY PROFILES: ANTIBODY DISCOVERY SERVICE PROVIDERS

7.1.       Chapter Overview

7.2.       Antibody Discovery Service Providers in North America

7.2.1.    Abwiz Bio

7.2.1.1. Company Overview

Press Release: Variation 2 (Format 3)

 

7.2.1.2. Antibody Discovery Services

7.2.1.3. Recent Developments and Future Outlook

 

7.2.2.    Aragen Bioscience (A GVK BIO Company)

7.2.2.1. Company Overview

7.2.2.2. Antibody Discovery Services

7.2.2.3. Recent Developments and Future Outlook

 

7.2.3.    Distributed Bio

7.2.3.1. Company Overview

7.2.3.2. Antibody Discovery Services

7.2.3.3. Recent Developments and Future Outlook

 

7.2.4.    Integral Molecular

7.2.4.1. Company Overview

7.2.4.2. Antibody Discovery Services

7.2.4.3. Recent Developments and Future Outlook

 

7.2.5.    LakePharma

7.2.5.1. Company Overview

7.2.5.2. Antibody Discovery Services

7.2.5.3. Recent Developments and Future Outlook

 

7.3.       Antibody Discovery Service Providers in Europe

7.3.1.    Abzena

7.3.1.1. Company Overview

7.3.1.2. Financial Information

7.3.1.3. Antibody Discovery Services

7.3.1.4. Recent Developments and Future Outlook

 

7.3.2.    ImmunoPrecise Antibodies

7.3.2.1. Company Overview

7.3.2.2. Financial Information

7.3.2.3. Antibody Discovery Services

7.3.2.4. Recent Developments and Future Outlook

 

7.3.3.    PX'Therapeutics (Subsidiary of Aguettant Pharmaceutical Group)

7.3.3.1. Company Overview

7.3.3.2. Antibody Discovery Services

7.3.3.3. Recent Developments and Future Outlook

 

7.4.       Antibody Discovery Service Providers in Asia-Pacific

7.4.1.    ChemPartner

7.4.1.1. Company Overview

7.4.1.2. Antibody Discovery Services

7.4.1.3. Recent Developments and Future Outlook

 

7.4.2.    Viva Biotech

7.4.2.1. Company Overview

7.4.2.2. Financial Information

7.4.2.3. Antibody Discovery Services

7.4.2.4. Recent Developments and Future Outlook

 

7.4.3.    WuXi Biologics

7.4.3.1. Company Overview

7.4.3.2. Financial Information

Press Release: Variation 2 (Format 3)

 

7.4.3.3. Antibody Discovery Services

7.4.3.4. Recent Developments and Future Outlook

 

  1. ANTIBODY DISCOVERY TECHNOLOGIES: CURRENT MARKET LANDSCAPE

8.1.       Chapter Overview

8.2.       Antibody Discovery Platform Providers: List of Industry Players

8.2.1.    Analysis by Year of Establishment

8.2.2.    Analysis by Company Size

8.2.3.    Analysis by Location of Headquarters

8.2.4.    Analysis by Type of Antibody Discovered

8.3.       Antibody Discovery: List of Technologies and Platforms

8.3.1.    Analysis by Type of Antibody Discovery Method

8.3.2.    Analysis by Type of Antibody Discovery Method and Location of Headquarters

8.3.3.    Analysis by Animal Model Used

8.3.4.    Analysis by Patent Availability

 

  1. TECHNOLOGY COMPETITIVENESS ANALYSIS

9.1.       Chapter Overview

9.2.       Methodology

9.3.       Key Parameters

9.4.       Technology Competitiveness Analysis: Antibody Discovery Platforms

9.4.1.    Competitiveness Analysis: Library Based Antibody Discovery Platforms

9.4.2.    Competitiveness Analysis: Single Cell Based Antibody Discovery Platforms

9.4.3.    Competitiveness Analysis: Transgenic Animal Based Antibody Discovery Platforms

9.4.4.    Competitiveness Analysis: Other Antibody Discovery Platforms

 

  1. COMPANY PROFILES: ANTIBODY DISCOVERY PLATFORM PROVIDERS

10.1.     Chapter Overview

10.2.     ImmunoPrecise Antibodies

10.2.1.  Company Overview

10.2.2.  Financial Information

10.2.3.  Portfolio of Antibody Discovery Platforms

10.2.3.1. Abthena™

10.2.3.2. B cell Select™

10.2.3.3. DeepDisplay™

10.2.3.4. ModiFuse™

10.2.3.5. ModiPhage™

10.2.3.6. ModiSelect™

10.2.3.7. ModiTune™

10.2.4.   Recent Developments and Future Outlook

 

10.3.     Harbour BioMed

10.3.1.  Company Overview

10.3.2.  Portfolio of Antibody Discovery Platforms

10.3.2.1. H2L2 Platform

10.3.2.2. HCAb Platform

10.3.3.   Recent Developments and Future Outlook

 

10.4.     Kymab

10.4.1.  Company Overview

10.4.2.  Portfolio of Antibody Discovery Platforms

10.4.2.1. Kymouse™

10.4.2.2. IntelliSelect®

10.4.3.   Recent Developments and Future Outlook

 

10.5.     Ligand Pharmaceuticals

Press Release: Variation 2 (Format 3)

 

10.5.1.  Company Overview

10.5.2.  Financial Information

10.5.3.  Portfolio of Antibody Discovery Platforms

10.5.3.1. OmniAb®

10.5.3.1.1. OmniChicken®

10.5.3.1.2. OmniClic™

10.5.3.1.3. OmniFlic®

10.5.3.1.4. OmniMouse®

10.5.3.1.5. OmniRat®

10.5.4.  Recent Developments and Future Outlook

 

10.6.     MorphoSys

10.6.1.  Company Overview

10.6.2.  Financial Information

10.6.3.  Portfolio of Antibody Discovery Platforms

10.6.3.1. arYla® Technology

10.6.3.2. HuCAL® Technology

10.6.3.3. Ylanthia® Technology

10.6.4.  Recent Developments and Future Outlook

 

  1. REGIONAL CAPABILITY ANALYSIS

11.1.     Chapter Overview

11.2.     Key Assumptions and Methodology

11.3.     Regional Capability Analysis: Antibody Discovery Service Providers

11.3.1.  Regional Capability Analysis: Distribution of Antibody Discovery Service Providers based in North America

11.3.2.  Regional Capability Analysis: Distribution of Antibody Discovery Service Providers based in Europe

11.3.3.  Regional Capability Analysis: Distribution of Antibody Discovery Service Providers based in Asia-Pacific

 

11.4.     Regional Capability Analysis: Antibody Discovery Platform Providers

11.4.1.  Regional Capability Analysis: Distribution of Antibody Discovery Platform Providers based in North America

11.4.2.  Regional Capability Analysis: Distribution of Antibody Discovery Platform Providers based in Europe

11.4.3.  Regional Capability Analysis: Distribution of Antibody Discovery Platform Providers based in Asia-Pacific

 

11.5.     Concluding Remarks

 

  1. PARTNERSHIPS AND COLLABORATIONS

12.1.     Chapter Overview

12.2.     Partnership Models

12.3.     List of Partnerships and Collaborations

12.3.1.  Analysis by Year of Partnership

12.3.2.  Analysis by Type of Partnership

12.3.3.  Analysis by the Type of Company (Service / Platform Providers)

12.3.4.  Analysis by Type of Antibody Discovered

12.3.5.  Analysis by Year of Partnership and Type of Partner

12.3.6.  Analysis by Type of Partnership and Type of Partner

12.3.7.  Most Active Players: Analysis by Number of Partnerships

12.3.8.  Most Popular Technologies: Analysis by Number of Partnerships

12.3.9.  Regional Analysis

12.3.9.1. Intercontinental and Intracontinental Agreements

 

Press Release: Variation 2 (Format 3)

 

  1. FUNDING AND INVESTMENT ANALYSIS

13.1.     Chapter Overview

13.2.     Types of Funding

13.3.     Antibody Discovery Service and Platform Providers: Funding and Investment Analysis

13.3.1.  Analysis by Number of Instances

13.3.2.  Analysis by Amount Invested

13.3.3.  Analysis by Type of Funding

13.3.4.  Most Active Players: Analysis by Amount Invested

13.3.5.  Most Active Investors: Analysis by Number of Funding Instances

13.3.6.  Regional Analysis by Amount Invested

 

13.4.     Concluding Remarks

 

  1. ANTIBODY DISCOVERY SERVICES: MARKET FORECAST

14.1.     Chapter Overview

14.2.     Forecast Methodology

14.3.     Global Antibody Discovery Services Market, 2020-2030

14.4.     Global Antibody Discovery Services Market: Distribution by Steps Involved in Antibody Discovery Process, 2020-2030

14.4.1.  Antibody Discovery Services Market for Antigen Designing, 2020-2030

14.4.2.  Antibody Discovery Services Market for Hit Generation, 2020-2030

14.4.3.  Antibody Discovery Services Market for Lead Selection, 2020-2030

14.4.4.  Antibody Discovery Services Market for Lead Optimization, 2020-2030

14.4.5.  Antibody Discovery Services Market for Lead Characterization, 2020-2030

14.5.     Global Antibody Discovery Services Market: Distribution by Antibody Discovery Method, 2020-2030

14.5.1.  Antibody Discovery Services Market for Phage Display, 2020-2030

14.5.2.  Antibody Discovery Services Market for Yeast Display, 2020-2030

14.5.3.  Antibody Discovery Services Market for Hybridoma Method, 2020-2030

14.5.4.  Antibody Discovery Services Market for Transgenic Animal Based Method, 2020-2030

14.5.5.  Antibody Discovery Services Market for Single Cell Based Method, 2020-2030

14.5.6.  Antibody Discovery Services Market for Other Methods, 2020-2030

14.6.     Global Antibody Discovery Services Market: Distribution by Nature of Antibody Generated, 2020-2030

14.6.1.  Antibody Discovery Services Market for Humanized Antibodies, 2020-2030

14.6.2.  Antibody Discovery Services Market for Human Antibodies, 2020-2030

14.6.3.  Antibody Discovery Services Market for Chimeric Antibodies, 2020-2030

14.6.4.  Antibody Discovery Services Market for Murine Antibodies, 2020-2030

14.7.     Global Antibody Discovery Services Market: Distribution by Region, 2020-2030

14.7.1.  Antibody Discovery Services Market in North America, 2020-2030

14.7.2.  Antibody Discovery Services Market in Europe, 2020-2030

14.7.3.  Antibody Discovery Services Market in Asia-Pacific and Rest of the World, 2020-2030

14.7.4.  Antibody Discovery Services: Market Attractiveness Analysis by Region

 

  1. ANTIBODY DISCOVERY TECHNOLOGIES: MARKET FORECAST

15.1.     Chapter Overview

15.2.     Key Assumptions

15.3.     Forecast Methodology

15.4.     Global Antibody Discovery Platforms Market, 2020-2030

15.5.     Global Antibody Discovery Platforms Market: Distribution by Region, 2020-2030

15.5.1.  Antibody Discovery Platforms Market in North America, 2020-2030

15.5.2.  Antibody Discovery Platforms Market in Europe, 2020-2030

15.5.3.  Antibody Discovery Platforms Market in Asia-Pacific, 2020-2030

 

  1. CASE IN POINT: DRUG DISCOVERY PROCESSES OF TOP SELLING ANTIBODIES

16.1.     Chapter Overview

Press Release: Variation 2 (Format 3)

 

16.2.     Humira® (Adalimumab)

16.2.1.  Drug Overview

16.2.2.  Discovery Process and Method

16.2.3.  Historical Sales

 

16.3.     Keytruda® (Pembrolizumab)

16.3.1.  Drug Overview

16.3.2.  Discovery Process and Method

16.3.3.  Historical Sales

 

16.4.     Herceptin® (Trastuzumab)

16.4.1.  Drug Overview

16.4.2.  Discovery Process and Method

16.4.3.  Historical Sales

 

16.5.     Avastin® (Bevacizumab)

16.5.1.  Drug Overview

16.5.2.  Discovery Process and Method

16.5.3.  Historical Sales

 

16.6.     Rituxan® (Rituximab)

16.6.1.  Drug Overview

16.6.2.  Discovery Process and Method

16.6.3.  Historical Sales

 

  1. CASE STUDY: ANTIBODY HUMANIZATION AND AFFINITY MATURATION

17.1.     Importance of Antibody Humanization and Affinity Maturation

17.2.     Antibody Humanization and Affinity Maturation Service and Platform Providers: Market Landscape

17.3.     Antibody Humanization: Publication Analysis

17.3.1.  Publication Analysis: Year-Wise Trend

17.3.2.  Publication Analysis: Key Journals

17.3.3.  Publication Analysis: Distribution by Animal Model Used

17.3.4.  Publication Analysis: Distribution by Method Used for Humanization

17.4.     Antibody Humanization Service and Platform Providers: SWOT Analysis

 

  1. FUTURE GROWTH OPPORTUNITIES IN ANTIBODY DISCOVERY

18.1.     Chapter Overview

18.2.     Anticipated Shift from Monoclonal Antibodies to Other Novel Formats

18.3.     Technological Advancements to Overhaul Conventional Antibody Discovery Processes

18.4.     Transition to CADD-based Approaches to Help Achieve Better Operational Efficiencies

18.5.     Rising Demand for Antibody-based Treatment Options across Non-Oncology Indications

18.6.     Growing Market Opportunities in the Asia-Pacific Region

18.7.     Expected Increase in Number of Collaborations and Licensing Activity

18.8.     Concluding Remarks

 

  1. EXECUTIVE INSIGHTS

19.1.     Chapter Overview

 

19.2.     Abveris Antibody

19.2.1.  Company Snapshot

19.2.2.  Tracey Mullen, Chief Executive Officer (Q2 2020)

 

19.3.     Nidus Biosciences

19.3.1.  Company Snapshot

19.3.2.  Lisa Delouise, Founder and Chief Technology Officer (Q1 2020)

Press Release: Variation 2 (Format 3)

 

19.4.     AvantGen

19.4.1.  Company Snapshot

19.4.2.  Mark Kubik, Chief Business Officer (Q1 2020)

 

19.5.     Single Cell Technology

19.5.1.  Company Snapshot

19.5.2.  Chun-Nan Chen, Chief Executive Officer and Chief Scientific Officer (Q2 2018)

 

19.6.     Distributed Bio

19.6.1.  Company Snapshot

19.6.2.  Giles Day, Co-Founder and Chief Executive Officer (Q2 2018)

 

19.7.     AbCellera

19.7.1.  Company Snapshot

19.7.2.  Kevin Heyries, Co-Founder and Lead of Business Development Strategy (Q2 2018)

 

19.8.     AbGenics Life Sciences

19.8.1.  Company Snapshot

19.8.2.  Sanjiban K Banerjee, Director (Q2 2018)

 

19.9.     CDI Laboratories

19.9.1.  Company Snapshot

19.9.2.  Ignacio Pino, Chief Executive Officer and President (Q2 2017)

 

19.10.   AP Biosciences

19.10.1. Company Snapshot

19.10.2. Jeng Her, Chief Executive Officer (Q2 2017)

 

19.11.   YUMAB

19.11.1. Company Snapshot

19.11.2. Thomas Schirrmann, Chief Executive Officer and General Manager (Q2 2017)

 

19.12.   Antibody Solutions

19.12.1. Company Snapshot

19.12.2. Debra Valsamis, Business Development Associate (Q2 2017)

 

19.13.   Ligand Pharmaceuticals

19.13.1. Company Snapshot

19.13.2. Christel Iffland, Vice President (Q2 2017)

 

19.14.   LakePharma

19.14.1. Company Snapshot

19.14.2. Aaron Sato, Chief Scientific Officer (Q2 2017)

 

  1. CONCLUDING REMARKS

20.1.     Chapter Overview

20.2.     Key Takeaways

 

  1. APPENDIX 1: TABULATED DATA

 

  1. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

Gaurav.Chaudhary@rootsanalysis.com

The “Bispecific Antibody Therapeutics Market (4th Edition), 2019-2030” report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapeutics over the next decade.


Submitted 101 day(s) ago by Harry sins

 

To order this detailed 370+ page report, please visit this link

 

Key Inclusions

  • A detailed review of the overall landscape of bispecific antibody therapeutics, including information on drug developers, phase of development (marketed, clinical, and preclinical / discovery) of the pipeline candidates, target antigen, type of antibody format, mechanism of action, target disease indication(s), therapeutic area, broader disease segment, route of administration, mode of administration and patient segment. 
  • A comprehensive list of novel technology platforms that are either currently available or being developed by various firms for the generation of bispecific antibody therapeutics, along with detailed profiles of key technologies. The chapter also includes an insightful competitiveness analysis, featuring a three-dimensional bubble representation that highlights the key technologies that are being used for the development of bispecific antibodies, taking into consideration the early stage (discovery, preclinical, IND and phase I) and late stage (phase II and above) development activity based on the technology (in terms of the number of drugs across different phases of development), number of partnerships established related to the technology and size of the developer company. In addition, it consists of a schematic world map representation, highlighting the geographical locations of technology developers engaged in this domain.
  • Detailed profiles of marketed and clinical stage (phase II and phase III) bispecific antibody therapeutics. Each profile features an overview of the drug, details of the developer, along with its financial performance, mechanism of action and targets, dosage information, current clinical development status, development process, as well as details on annual sales (wherever available).
  • Key takeaways from the bispecific antibody therapeutics pipeline, featuring a [A] grid analysis, representing the distribution of the pipeline (on the basis of mechanisms of action of product candidates) across different therapeutic areas and stages of development, [B] a five-dimensional spider-web analysis, highlighting the most popular mechanisms of action based on a number of relevant parameters, including number of bispecific antibodies in early stage (phase I) and late stage of development (phase II and above), number of ongoing clinical trials, target therapeutic areas and the number of companies that are developing these molecules, [C] a two-dimensional scattered plot competitiveness analysis, for the various target combinations for clinical-stage bispecific antibodies and [D] the chapter also includes an insightful summary representation using the logos of different industry stakeholders, highlighting the distribution of companies based on the company size.
  • An analysis of the big biopharma players engaged in this domain, featuring a heat map based on various parameters, such as number of bispecific antibody therapeutics under development, target antigen, type of antibody format, mechanism of action and target therapeutic area.
  • An analysis of recent partnerships and collaboration agreements inked in this domain since 2016, covering research collaborations, product and technology licensing agreements, product development and commercialization agreements, manufacturing agreements, mergers / acquisitions, joint ventures, product development agreements and other deals.
  • A review on the key steps involved and challenges associated with the manufacturing of bispecific antibodies. In addition, it includes a list of contract manufacturing organizations (CMOs) and contract research organizations (CROs). The chapter also highlights the key considerations for bispecific antibody developers while selecting a suitable CRO / CMO.
  • A clinical trial analysis of ongoing and planned studies related to bispecific antibody therapeutics, taking into consideration a number of relevant parameters, including trial registration year, trial recruitment status, trial phase, trial design, disease indication(s), focus therapeutic area, most active industrial and non-industrial players, and geographical location of the trial.
  • A review of the key promotional strategies that have been adopted by the developers of the marketed bispecific antibodies, namely Blincyto® and Hemlibra®. It includes a detailed comparison of both the drugs based on the information available on their respective websites, such as patient support offerings, informative downloadable content, and product visibility in scientific conferences.
  • A discussion on important, industry-specific trends, key market drivers and challenges, under a SWOT framework, featuring a qualitative Harvey ball analysis that highlights the relative impact of each SWOT parameter on the overall market.

 

The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:

  • Therapeutic Area 
  • Autoimmune Disorders
  • Eye Disorders
  • Genetic Disorders
  • Hematological Malignancies
  • Infectious Diseases
  • Inflammatory Disorders
  • Skin Disorders 

 

  • Mechanism of Action
  • Cytokines Retargeting / Neutralization
  • Dual Ligands Blocking
  • T-cell Retargeting / Activation
  • Others

 

  • Target Antigens
  • CD3 x CD19
  • CD30 x CD16A
  • Factor IXa x Factor X
  • IL-1α x IL-1β
  • IL-13 x IL-4
  • IL-17A x Albumin
  • IL-17A x IL-17F
  • Psl x PcrV
  • VEGF-A x ANG2
  • Others

 

  • Key Players 
  • Astra Zeneca
  • Amgen
  • AbbVie
  • Affirmed
  • Affibody
  • Merck
  • Roche
  • Sanofi
  • Taisho Pharmaceutical 

 

  • Key Geographical Regions 
  • North America
  • Europe
  • Asia-Pacific 

 

The report features inputs from eminent industry stakeholders, according to whom this relatively novel class of antibody therapeutics is likely to garner significant interest among therapy developers and end users alike. The report includes detailed transcripts of discussions held with the following experts:

  • Martin Steiner (Chief Executive Officer, Synimmune)
  • Ludger Große-Hovest (Chief Scientific Officer, Synimmune)
  • Jane Dancer (Chief Business Officer, F-Star)
  • Siobhan Pomeroy (Senior Director, Business Development, Cytom X)
  • Yinjue Wang (Associate Director, Process Development, Innovent Biologics)

 

To request sample pages, please visit this link

 

Key Questions Answered

  • What are the key technologies used for the development of bispecific antibodies?
  • What are the key biological target combinations and antibody formats that are being explored for bispecific antibody development?
  • Who are the leading industry and non-industry players engaged in this market?
  • What kind of partnership models are commonly adopted by bispecific antibody developers?
  • Which CMOs offer services for manufacturing bispecific antibodies?
  • What are the regulatory guidelines issued by different organizations related to the development of bispecific antibodies?
  • What kind of promotional strategies are being used by developers of marketed bispecific antibody developers?
  • How is the current and future market opportunity (related to bispecific antibodies) likely to be distributed across key market segments?

 

You may also be interested in the following titles:

Global Preventive Vaccines Market, 2020-2030

Endocannabinoid System Targeted Therapeutics Market, 2019-2030

Antibody Contract Manufacturing Market, 2020-2030

 

Contact Us

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com

With two approved drugs and close to 300 clinical / preclinical product candidates, the bispecific antibody therapeutics pipeline has evolved significantly over the past few years, claims Roots Analysis


Submitted 101 day(s) ago by Harry sins

 

With various target combinations and novel mechanisms of action, bispecific antibodies are presently recognized as a potent class of targeted therapies, with the potential to be used as treatment options for a variety of disease indications. Several pipeline candidates have recently entered mid to late-stage (phase II and above) trials and are anticipated to enter the market over the next 5-10 years.

 

To order this 370+ page report, which features 90+ figures and 110+ tables, please visit this link

 

The USD 6.9 billion financial opportunity (by 2030) within the bispecific antibody therapeutics market has been analyzed across the following segments:

  • Therapeutic Area 
  • Autoimmune Disorders
  • Eye Disorders
  • Genetic Disorders
  • Hematological Malignancies
  • Infectious Diseases
  • Inflammatory Disorders
  • Skin Disorders

 

  • Mechanism of Action
  • Cytokines Retargeting / Neutralization
  • Dual Ligands Blocking
  • T-cell Retargeting / Activation
  • Others

 

  • Target Antigens
  • CD3 x CD19
  • CD30 x CD16A
  • Factor IXa x Factor X
  • IL-1α x IL-1β
  • IL-13 x IL-4
  • IL-17A x Albumin
  • IL-17A x IL-17F
  • Psl x PcrV
  • VEGF-A x ANG2
  • Others

 

  • Antibody Formats
  • Asymmetric
  • Fragments
  • Symmetric
  • Others

 

  • Key Geographical Regions 
  • North America
  • Europe
  • Asia-Pacific

 

The Bispecific Antibody Therapeutics Market (4th Edition), 2020-2030 report features the following companies, which we identified to be key players in this domain:

  • Amgen
  • Ablynx
  • AbbVie
  • Affibody
  • Affimed
  • Alphamab
  • AstraZeneca
  • Avillion
  • Chugai Pharmaceuticals
  • Eddingpharm
  • GSK
  • Merck
  • Merus
  • Roche
  • Regeneron Pharmaceuticals
  • Taisho Pharmaceuticals
  • Zymeworks

 

Table of Contents

 

  1. Preface

    2. Executive Summary

  2. Introduction

  3. Market Overview

  4. Bispecific Antibody Therapeutics: Technology Platforms

  5. Drug Profiles

  6. Key Insights

  7. Benchmark Analysis: Big Pharma Players

  8. Partnerships and Collaborations

  9. Contract Services for Bispecific Antibody Therapeutics

  10. Clinical Trial Analysis

  11. Case Study: Regulatory Guidelines for Bispecific Antibodies

  12. Case Study: Promotional / Marketing Strategies

  13. SWOT Analysis

 

  1. Market Forecast and Opportunity Analysis

 

  1. Concluding Remarks

 

  1. Executive Insights

 

  1. Appendix 1: Tabulated Data

 

  1. Appendix 2: List of Companies and Organizations

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/bispecific-antibodies/286.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com 

 

 

The bispecific antibody therapeutics market is projected to grow at an annualized rate of ~16%, in the span of 2019 to 2030


Submitted 101 day(s) ago by Harry sins

 

Roots Analysis has done a detailed study on Bispecific Antibody Therapeutics Market (4th Edition), 2020-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

 

To order this 370+ page report, which features 90+ figures and 110+ tables, please visit this link

 

Key Market Insights         

  • With two approved drugs and close to 300 clinical / preclinical product candidates, the bispecific antibody therapeutics pipeline has evolved significantly over the past few years
  • The pipeline features drug candidates that target a wide range of biological antigens based on different antibody formats through novel mechanisms of action; more than 50% of these act by retargeting or activation of T-Cells
  • To gain a competitive edge in the market, developers are actively exploring novel biological targets and mechanisms of action to treat diverse disease indications
  • Although start-ups and mid-sized firms are spearheading the innovation, several big pharmaceutical companies are also actively engaged
  • In order to cater to the evolving needs of developers, technology providers have established presence across different regions; the US and EU have emerged as the key hubs
  • Close to 50,000 patients were estimated to have been enrolled in clinical trials evaluating bispecific antibody therapeutics, across various geographical locations and phases of development
  • The increasing interest of stakeholders in this domain can also be gauged by the rising product development / commercialization, R&D and technology licensing deals being signed across various regions
  • Given the complexities associated with the development of bispecific antibodies, contract organizations have become an indispensable part of the development and manufacturing process of antibody therapeutics
  • In order to keep patients and healthcare professionals informed and aware of the developments, companies are deploying diverse promotional strategies for their respective products

 

For more information, please visit https://www.rootsanalysis.com/reports/view_document/bispecific-antibodies/286.html

 

Table of Contents

 

  1. PREFACE
    1.1.                   Chapter Outlines
    1.2.                   Research Methodology
    1.3.                   Chapter Outlines

  2. EXECUTIVE SUMMARY

 

  1. INTRODUCTION

3.1.                   Chapter Overview

3.2.                   Concept of an Antibody

3.3.                   Structure of an Antibody

3.4.                   Functions of an Antibody

3.5.                   Mechanism of Action of an Antibody

3.6.                   Concept of Monoclonal Antibodies

3.7.                   Antibody Therapeutics

3.8.                   Historical Evolution of Antibody Therapeutics

                       

3.9.                   Types of Advanced Antibody Therapeutics        

3.9.1.                Fc Engineered and Glycoengineered Antibodies

3.9.2.                Antibody Fragments

3.9.3.                Fusion Proteins

3.9.4.                Intrabodies

3.9.5.                Bispecific Antibodies

                       

3.10.                 Bispecific Antibody Formats

3.10.1.              Single-Chain-based Formats (Fc Independent Antibody Formats)

3.10.1.1.           Tandem scFvs (single-chain variable fragments) and Triple bodies         

3.10.1.2.           Bispecific Single-Domain Antibody Fusion Proteins        

3.10.1.3.           Diabodies / Diabody Derivatives

3.10.1.4.           Fusion Proteins

3.10.1.5.           Fusion Proteins Devoid of Fc Regions   

3.10.2.              Immunoglobulin G (IgG)-based Formats (Fc Dependent Antibody Formats)         

3.10.2.1.           Quadromas      

3.10.2.2.           Knobs-Into-Holes         

3.10.2.3.           Dual Variable Domain Ig           

3.10.2.4.           IgG-scFv          

3.10.2.5.           Two-in-one or Dual Action Fab (DAF) Antibodies

3.10.2.6.           Half Molecule Exchange

3.10.2.7.           κλ- Bodies       

                       

3.11.                 Mechanisms of Action of Bispecific Antibodies   

3.11.1.              Retargeting Immune Effectors (NK Cells and T Cells) to Tumor Cells      

3.11.2.              Directly Targeting Malignant / Tumor Cells

3.11.3.              Retargeting of Toxins

3.11.5.              Targeting Tumor Angiogenesis

3.11.6.              Other Mechanisms

                       

3.12.                 Applications of Bispecific Antibodies

                       

4                      MARKET OVERVIEW

4.1.                   Chapter Overview

4.2.                   Bispecific Antibody Therapeutics: Developer Landscape

4.2.1.                Analysis by Year of Establishment

4.2.2.                Analysis by Company Size

4.2.3.                Analysis by Geographical Location

                       

4.3.                   Bispecific Antibody Therapeutics: Clinical Pipeline

4.3.1.                Analysis by Phase of Development

4.3.2.                Analysis by Target Antigen

4.3.3.                Analysis by Type of Antibody Format

4.3.4.                Analysis by Mechanism of Action

4.3.5.                Analysis by Disease Indication

4.3.6.                Analysis by Therapeutic Area

4.3.7.                Analysis by Broader Disease Segment

4.3.8.                Analysis by Route of Administration

4.3.9.                Analysis by Mode of Administration

4.3.10.              Analysis by Patient Segment

4.4.                   Bispecific Antibody Therapeutics: Early Stage Pipeline

4.4.1.                Analysis by Phase of Development

4.4.2.                Analysis by Target Antigen

4.4.4.                Analysis by Mechanism of Action

4.4.5.                Analysis by Therapeutic Area

4.4.6.                Analysis by Broader Disease Segment

4.6.                   Bispecific Antibody Therapeutics: Combination Therapy Candidates

4.7.                   Bispecific Antibody Therapeutics: Non-Industry Players

4.8.                   Emerging Novel Antibody Therapeutic Modalities

                       

5                      Bispecific Antibody Therapeutics: Technology Platforms 

5.1.                   Chapter Overview

5.2.                   Bispecific Antibody Therapeutics: List of Technology Platforms

5.3.                   Bispecific Antibody Therapeutics: Technology Platform Profiles

                       

5.3.1.                Bispecific T-cell Engager (BiTE®) (Amgen)

5.3.1.1.             Overview          

5.3.1.2.             Technology Details       

5.3.1.3.             Structure of BiTE® Bispecific Antibodies

5.3.1.4.             Pipeline of BiTE® Bispecific Antibodies 

5.3.1.5.             Advantages of BiTE® Bispecific Antibodies       

5.3.1.6.             Partnerships and Collaborations

                       

5.3.2.                DuoBody® (Genmab)

5.3.2.1.             Overview          

5.3.2.2.             Technology Details       

5.3.2.3.             Structure of DuoBody® Bispecific Antibodies     

5.3.2.4.             Pipeline of DuoBody® Bispecific Antibodies      

5.3.2.5.             Advantages of DuoBody® Bispecific Antibodies 

5.3.2.6.             Partnerships and Collaborations

                       

5.3.3.                Xmab™ Antibody Engineering Platform (Xencor)

5.3.3.1.             Overview          

5.3.3.2.             Technology Details       

5.3.3.3.             Pipeline of Xmab™ Bispecific Antibodies

5.3.3.4.             Advantages of Xmab™ Bispecific Antibodies     

5.3.3.5.             Partnerships and Collaborations

                       

5.3.4.                WuXibodyTM Bispecific Engineering Platform (WuXi Biologics)

5.3.4.1.             Overview          

5.3.4.2.             Pipeline of WuXibodyTM Bispecific Antibodies  

5.3.4.3.             Advantages of WuXibodyTM Bispecific Antibodies         

5.3.4.4.             Partnerships and Collaborations

                       

5.3.5.                Anticalin® (Pieris Pharmaceuticals)

5.3.5.1.             Overview          

5.3.5.2.             Structure of Anticalin® Bispecific Fusion Proteins          

5.3.5.3.             Pipeline of Anticalin® Bispecific Fusion Proteins

5.3.5.4.             Advantages of Anticalin® Bispecific antibody Platform   

5.3.5.5.             Partnerships and Collaborations

                       

5.3.6.                Azymetric™ (Zymeworks)

5.3.6.1.             Overview          

5.3.6.2.             Technology Details       

5.3.6.3.             Structure of Azymetric™ Bispecific Antibodies   

5.3.6.4.             Pipeline of Azymetric™ Bispecific Antibodies     

5.3.6.5.             Advantages of the AzymetricTM Bispecific Antibodies    

5.3.6.6.             Partnerships and Collaborations

                       

5.4.                   Geographical Distribution of Technology Providers        

5.5.                   Bispecific Antibody Technology Platforms: Comparative Analysis

                       

6                      DRUG PROFILES

6.1.                   Chapter Overview

6.2.                   Marketed Drug Profiles

                       

6.2.1.                Blincyto™ / Blinatumomab / AMG103 / MT103 (Amgen)

6.2.1.1.             Company Overview      

6.2.1.1.1.          Financial Performance  

6.2.1.2.             Drug Overview 

6.2.1.2.1.          Mechanism of Action and Targets          

6.2.1.2.2.          Dosage

6.2.1.2.3.          Current Development Status     

6.2.1.2.4.          Development Process  

6.2.1.2.5.          Annual Sales    

                       

6.2.2.                Hemlibra® / Emicizumab / RG6013 / ACE910 / RO5534262 (Chugai Pharmaceutical / Roche)      

6.2.2.1.             Company Overview      

6.2.2.1.1.          Financial Performance  

6.2.2.2.             Drug Overview 

6.2.2.2.1.          Mechanism of Action and Targets          

6.2.2.2.2.          Dosage

6.2.2.2.4.          Development Process  

6.2.2.2.5.          Annual Sales    

                       

6.3.                   Late Stage Drug Profiles

6.4.                   RG7716 / RO6867461 / Faricimab (Roche / Genentech) 

6.4.1                 Drug Overview 

6.5.                   Ozoralizumab / TS-152 / ATN103 (Ablynx / Eddingpharm / Taisho Pharmaceuticals)        

6.5.1                 Drug Overview 

6.6.                   ABT-165 (AbbVie)        

6.6.1                 Overview of Drug, Current Development Status and Clinical Results       

6.7.                   ABY-035 (Affibody)      

6.7.1.                Drug Overview 

6.8.                   AFM13 (Affimed)         

6.8.1                 Drug Overview 

6.9.                   AMG 570 / MEDI0700 (Amgen) 

6.9.1.                Drug Overview 

6.10.                 KN026 (Alphamab)       

6.10.1.              Drug Overview 

6.11.                 KN046 (Alphamab)

6.11.1.              Drug Overview 

6.12.                 M1095 / ALX-0761 (Merck / Ablynx / Avillion)     

6.12.1.              Drug Overview 

6.13.                 M7824 / Bintrafusp Alfa (Merck / GlaxoSmithKline)         

6.13.1.              Drug Overview 

6.14.                 MCLA-128 (Merus)       

6.14.1.              Drug Overview 

6.15.                 MEDI3902 / Gremubamab (MedImmune /AstraZeneca)  

6.15.1.              Drug Overview 

6.16.                 Drug Overview 

6.17.                 REGN1979 (Regeneron)           

6.17.1.              Drug Overview  6.18.     ZW25 (Zymeworks)      

6.18.1.              Drug Overview

                       

7                      KEY INSIGHTS

7.1.                   Chapter Overview

7.2.                   Bispecific Antibody Therapeutics: Analysis by Therapeutic Area and Phase of Development        

7.3.                   Bispecific Antibody Therapeutics: Spider-Web Analysis based on Mechanism of Action   

7.4.                   Bispecific Antibody Therapeutics: Two-Dimensional Scatter Plot Analysis based on Target Combinations   

7.4.1                 Key Parameters

7.5.                   Logo Landscape: Analysis of Developers by Company Size        

                       

8                      BENCHMARK ANALYSIS: BIG PHARMA PLAYERS

8.1.                   Chapter Overview

8.2.                   Top Pharmaceutical Companies

8.2.1.                Analysis by Target Antigen

8.2.2.                Analysis by Type of Antibody Format

8.2.3.                Analysis by Mechanism of Action

8.2.4.                Analysis by Therapeutic Area

8.2.5.                Analysis by Type of Partnership

                       

9                      PARTNERSHIPS AND COLLABORATIONS

9.1.                   Chapter Overview

9.2.                   Partnership Models

9.3.                   Bispecific Antibody Therapeutics: Partnerships and Collaborations

9.3.1.                Analysis by Year of Partnership

9.3.2.                Analysis by Type of Partnership

9.3.3.                Analysis by Therapeutic Area

9.3.4.                Most Active Developers: Analysis by Number of Partnerships

9.3.5.                Most Active Contract Manufacturers: Analysis by Number of Manufacturing Agreements  

9.3.6.                Regional Analysis

9.3.7.                Intercontinental and Intracontinental Agreements

                       

10                     CONTRACT SERVICES FOR BISPECIFIC ANTIBODY THERAPEUTICS           

10.1.                 Chapter Overview

10.2.                 Manufacturing of Bispecific Antibody Therapeutics

10.2.1.              Key Manufacturing Considerations and Challenges         

10.2.2.              Contract Manufacturing Organizations (CMOs)

10.2.2.1.           Introduction to CMOs    

10.2.2.2.           Bispecific Antibody Therapeutics: List of CMOs  

                       

10.2.3.              Contract Research Organizations (CROs)

10.2.3.1.           Introduction to CROs    

10.2.3.2.           Bispecific Antibody Therapeutics: List of CROs  

                       

10.3.                 Key Considerations for Selecting a Suitable CMO / CRO Partner

                       

11                     CLINICAL TRIAL ANALYSIS

11.1.                 Chapter Overview

11.2.                 Methodology

11.3.                 Bispecific Antibody Therapeutics: Clinical Trial Analysis  

11.3.1.              Analysis by Trial Registration Year

11.3.2.              Analysis by Trial Recruitment Status

11.3.3.              Analysis by Trial Phase

11.3.4.              Analysis by Trial Design

11.3.5.              Analysis by Disease Indication

11.3.6.              Analysis by Therapeutic Area

11.3.7.              Most Active Players

11.3.8.              Analysis by Number of Clinical Trials and Geography

11.3.9.              Analysis by Enrolled Patient Population and Geography

                       

12                     CASE STUDY: REGULATORY GUIDELINES FOR BISPECIFIC ANTIBODIES  

12.1.                 Chapter Overview

12.2.                 Guidelines Issued by Regulatory Authorities

12.2.1.              US Food and Drug Administration (FDA)

12.2.1.1.           Pharma Companies Response to the FDA Draft Guidance          

                       

12.2.2.              World Health Organization (WHO)

12.2.3.              The International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use     

                       

13                     CASE STUDY: PROMOTIONAL / MARKETING STRATEGIES

13.1.                 Chapter Overview

13.2.                 Overview of Channels Used for Promotional Campaigns

13.3.                 Summary: Product Website Analysis

13.4.                 Summary: Patient Support Services and Informative Downloads

                       

13.5.                 Promotional Analysis: Blincyto™

13.5.1.              Drug Overview

13.5.2.              Product Website analysis

13.5.2.1.           Messages for Healthcare Professionals 

13.5.2.1.1.         For MRD Positive B‑cell precursor ALL  

13.5.2.1.2.         For Relapsed or Refractory B-cell precursor ALL

13.5.2.2.           Message for Patients    

13.5.3.              Patient Support Services and Informative Downloads

13.5.4.              Other Promotional Strategies

13.5.4.1.           Presence in Conferences          

                       

13.6.                 Promotional Analysis:  Hemlibra®

13.6.1.              Drug Overview

13.6.2.              Product Website Analysis

13.6.2.1.           Messages for Healthcare Professionals 

13.6.2.1.1.         For Hemophilia A without Factor VIII Inhibitors   

13.6.2.1.2.         For Hemophilia A with Factor VIII Inhibitors        

13.6.2.3.           Messages for Patients  

13.6.3.              Patient Support Services and Informative Downloads

13.6.3.1.           Co-pay Program           

13.6.3.2.           Independent Co-pay Assistance Foundation      

13.6.3.3.           Genentech Patient Foundation  

13.6.4.              Other Promotional Strategies

13.6.4.1.           Presence in Conferences          

                       

14                     SWOT ANALYSIS

14.1.                 Chapter Overview

14.2.                 Strengths

14.3.                 Weaknesses

14.4.                 Opportunities

14.5.                 Threats

14.6.                 Concluding Remarks

                       

15                     MARKET FORECAST AND OPPORTUNITY ANALYSIS

15.1.                 Chapter Overview

15.2.                 Scope and Limitations

15.3.                 Forecast Methodology and Key Assumptions

                       

15.4.                 Overall Bispecific Antibody Therapeutics Market, 2019-2030

15.4.1.              Bispecific Antibody Therapeutics Market: Analysis by Therapeutic Area

15.4.2.              Bispecific Antibody Therapeutics Market: Analysis by Mechanism of Action

15.4.3.              Bispecific Antibody Therapeutics Market: Analysis by Target Antigen

15.4.4.              Bispecific Antibody Therapeutics Market: Analysis by Antibody Format

15.4.5.              Bispecific Antibody Therapeutics Market: Analysis by Key Players

15.4.6.              Bispecific Antibody Therapeutics Market: Analysis by Geography

15.5.                 Bispecific Antibody Market: Value Creation Analysis

15.6.                 Bispecific Antibody Therapeutics Market: Product-wise Sales Forecasts

                       

15.6.1.              Blincyto

15.6.1.1.           Target Patient Population         

15.6.1.2.           Sales Forecast 

15.6.1.3.           Net Present Value        

15.6.1.4.           Value Creation Analysis

                       

15.6.2.              Hemlibra

15.6.2.1.           Target Patient Population         

15.6.2.2.           Sales Forecast 

15.6.2.3.           Net Present Value        

15.6.2.4.           Value Creation Analysis

                       

15.6.3.              RG7716

15.6.3.1.           Target patient Population          

15.6.3.2.           Sales Forecast 

15.6.3.3.           Net Present Value        

15.6.3.4.           Value Creation Analysis

                       

15.6.4.              Ozoralizumab

15.6.4.1.           Target Patient Population         

15.6.4.2.           Sales Forecast 

15.6.4.3.           Net Present Value        

15.6.4.4.           Value Creation Analysis

                       

15.6.5.              ABY-035

15.6.5.1.           Target Patient Population         

15.6.5.2.           Sales Forecast 

15.6.5.3.           Net Present Value        

15.6.5.4.           Value Creation Analysis

                       

15.6.6.              AFM13

15.6.6.1.           Target Patient Population         

15.6.6.2.           Sales Forecast 

15.6.6.3.           Net Present Value        

15.6.6.4.           Value Creation Analysis

                       

15.6.7.              M1095

15.6.7.1.           Target Patient Population         

15.6.7.2.           Sales Forecast 

15.6.7.3.           Net Present Value        

15.6.7.4.           Value Creation Analysis

                       

15.6.8.              MEDI3902

15.6.8.1.           Target Patient Population         

15.6.8.2.           Sales Forecast 

15.6.8.3.           Net Present Value        

15.6.8.4.           Value Creation Analysis

                       

15.6.9.              ABT-981

15.6.9.1.           Target Patient Population         

15.6.9.2.           Sales Forecast 

15.6.9.3.           Net Present Value        

15.6.9.4.           Value Creation Analysis

                       

15.6.10.            SAR156597      

15.6.10.1.          Target Patient Population         

15.6.10.2.          Sales Forecast 

15.6.10.3.          Net Present Value        

15.6.10.4.          Value Creation Analysis

                       

16                     CONCLUDING REMARKS

                       

17                     EXECUTIVE INSIGHTS

17.1.                 Chapter Overview         

17.2.                 CytomX Therapeutics    

17.2.1.             Company Snapshot      

17.2.2.              Interview Transcript: Siobhan Pomeroy, Senior Director, Business Development (Q3 2017)          

                       

17.3.                 F-star   

17.3.1.             Company Snapshot      

17.3.2.             Interview Transcript: Jane Dancer, Chief Business Officer (Q3 2017)       

                       

17.4.                 Innovent Biologics       

17.4.1.             Company Snapshot      

17.4.2.             Interview Transcript: Yinjue Wang, Associate Director, Process Development (Q3 2017)   

                       

17.5.                 Synimmune      

17.4.1.             Company Snapshot      

17.4.2.              Interview Transcript: Ludger Große-Hovest, Chief Scientific Officer, and Martin Steiner, Chief Executive Officer

 

  1. APPENDIX 1: TABULATED DATA

 

  1. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com

 

The “Antibody Contract Manufacturing Market, 2020-2030” report features an extensive study of the current market landscape and future opportunities associated with the contract manufacturing of antibodies.


Submitted 101 day(s) ago by Harry sins

 

 

To order this detailed 285+ page report, please visit this link

 

Key Inclusions

  • A detailed review of the overall landscape of companies, offering contract services for the manufacturing of antibodies, along with information on year of establishment, company size, scale of operation (preclinical, clinical and commercial), location of headquarters, number of manufacturing facilities and location of these facilities, type of antibody manufactured (monoclonal antibodies, bispecific antibodies and polyclonal antibodies), type of expression systems used (mammalian, microbial and others), fill / finish operations and affiliations to regulatory agencies.
  • A competitiveness analysis of key players engaged in this domain, featuring an assessment based on their supplier strength (related to the experience of a contract manufacturer), and service strength (which takes into account the size of service portfolio and scale of operation).
  • A benchmark analysis, highlighting the key focus areas of small, mid-sized and large companies, comparing their existing capabilities within and beyond their respective (geography-based) peer groups.
  • An analysis of the various partnerships pertaining to contract manufacturing of antibodies, which have been established since 2013, based on several parameters, such as the year of agreement, type of partnership, project scale and focus therapeutic area.
  • An analysis of the various expansion initiatives undertaken by service providers, in order to augment their respective antibody manufacturing capabilities, over the period 2017-2019 (till October), taking into consideration parameters, such as year of expansion, type of expansion (capacity expansion, facility expansion and new facility), type of antibodies manufactured and location of manufacturing facility.
  • An estimate of the overall, installed capacity for manufacturing antibodies based on data reported by industry stakeholders in the public domain; it highlights the distribution of available antibody production capacity on the basis of company size (small, mid-sized, large and very large firms), scale of operation (preclinical, clinical and commercial), and key geographical regions (North America, Europe, Asia).
  • Informed estimates of the annual commercial and clinical demand for antibodies, based on various relevant parameters, such as target patient population, dosing frequency and dose strength.
  • Elaborate profiles of the key industry players that offer contract manufacturing services at all scales of operation and have more than two manufacturing facilities. Each profile features a brief overview of the company, information on its service portfolio, details related to its manufacturing capabilities and facilities, and an informed future outlook.
  • A case study comparing the key characteristics of large molecule and small molecule drugs, along with details on the various steps and challenges involved in their respective manufacturing processes.
  • A discussion on affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact the industry’s evolution, including a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall pharmaceutical industry.

 

The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:

  • Type of Antibodies
  • Monoclonal Antibodies
  • Bispecific Antibodies
  • ADCs
  • Others

 

  • Company Size
  • Small
  • Mid-sized
  • Large / Very Large

 

  • Scale of Operation
  • Preclinical / Clinical
  • Commercial

 

  • Type of expression system used
  • Mammalian
  • Microbial

 

  • Key geographical regions
  • North America
  • Europe
  • Asia and RoW

 

The report includes detailed transcripts of discussions held with the following experts:

  • Dietmar Katinger (Chief Executive Officer, Polymun Scientific)
  • David C Cunningham (Director, Corporate Development, Goodwin Biotechnology)
  • Claire Otjes (Marketing Manager, Batavia Biosciences)

 

To request sample pages, please visit this link

 

Key Questions Answered

  • Who are the leading CMOs engaged in the production of antibody-based therapeutics?
  • What kind of partnership models are commonly adopted by stakeholders in this industry?
  • What is the annual clinical and commercial demand for antibody-based products?
  • What is the current installed capacity for manufacturing of antibodies?
  • What are the various expansion initiatives undertaken by antibody CMOs?
  • How is the current and future market opportunity likely to be distributed across key market segments?

 

You may also be interested in the following titles:

  1. Bispecific Antibody Therapeutics Market (4th Edition), 2019-2030
  2. Antibody Drug Conjugates (ADCs) - Linker and Conjugation Technologies Market, 2019-2030
  3. Antibody Drug Conjugates Market (5th Edition), 2019-2030

 

Contact Us

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com

 

Several companies worldwide claim to possess the required expertise and infrastructure to offer contract manufacturing services for a variety of antibody-based products


Submitted 101 day(s) ago by Harry sins

 

 

Although biopharmaceuticals offer significant profit margins and have been proven to be effective in treating a myriad of diseases, they are generally associated with high costs of development and complex manufacturing protocols; this is true for antibody-based products as well. Presently, there are a number of companies that claim to offer end-to-end solutions, ranging from antibody development to commercial production. Further, prevalent trends suggest that sponsor companies are likely to continue relying on contract service providers for various aspects of antibody-based product development and manufacturing.

 

To order this 285+ page report, which features 100+ figures and 110+ tables, please visit this link

 

The USD 17 billion (by 2030) financial opportunity within the antibody contract manufacturing market has been analyzed across the following segments:

  • Type of Antibodies
  • Monoclonal Antibodies
  • Bispecific Antibodies
  • ADCs
  • Others

 

  • Company Size
  • Small
  • Mid-sized
  • Large / Very Large

 

  • Scale of Operation
  • Preclinical / Clinical
  • Commercial

 

  • Type of expression system used
  • Mammalian
  • Microbial

 

  • Key geographical regions
  • North America
  • Europe
  • Asia and RoW

 

The Antibody Contract Manufacturing Market, 2020-2030 report features the following companies, which we identified to be key players in this domain: 

  • AGC Biologics
  • Aldevron
  • AMRI
  • Boehringer Ingelheim BioXcellence
  • Emergent BioSolutions
  • Eurofins CDMO
  • FUJIFILM Diosynth Biotechnologies
  • KBI Biopharma
  • Lonza
  • Nitto Avecia Pharma Services
  • Novasep
  • Pierre Fabre
  • Samsung BioLogics
  • Synthon
  • Thermo Fisher Scientific

 

Table of Contents

 

  1. Preface

 

  1. Executive Summary

 

  1. Introduction

 

  1. Market Landscape

 

  1. Company Competitive Analysis

 

  1. Company Profiles

 

  1. Case Study: Comparison of Small and Large Molecules (Biologics) Drugs / Therapies

 

  1. Benchmark Analysis

 

  1. Partnerships

 

  1. Recent Expansions

 

  1. Capacity Analysis

 

  1. Demand Analysis

 

  1. Market Sizing and Opportunity Analysis

 

  1. SWOT Analysis

 

  1. Future of The Antibody CMO Market

 

  1. Interview Transcripts

 

  1. Appendix 1: List of Antibody Custom Manufacturers

 

  1. Appendix 2: Tabulated Data

 

  1. Appendix 3: List of Companies and Organizations

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/antibody-cmo-market/295.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com

 

 

The antibody contract manufacturing market is projected to grow at an annualized rate of 12%, till 2030


Submitted 101 day(s) ago by Harry sins

 

Roots Analysis has done a detailed study on Antibody Contract Manufacturing Market, 2020-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

 

To order this 285+ page report, which features 100+ figures and 110+ tables, please visit this link

 

Key Market Insights

  • Several companies worldwide claim to possess the required expertise and infrastructure to offer contract manufacturing services for a variety of antibody-based products.
  • The market landscape is highly fragmented, featuring the presence of both established players and new entrants; majority of antibody CMOs claim to operate as one stop shops and have presence across different regions.
  • In recent years, a steady increase in partnership activity has been observed in this domain; a variety of deals have been inked related to antibodies for use across a number of different disease indications.
  • At present, the installed, global antibody contract manufacturing capacity is estimated to be approximately 2.2 million liters, distributed across companies of all sizes worldwide.
  • In order to enhance core competencies related to this field of research, CMOs are actively investing in upgrading existing infrastructure and expanding their respective manufacturing capacities.
  • In fact, ongoing capability improvement efforts and facility upgrades have led to the establishment of industry benchmarks, which serve as a standard for new product development initiatives in this domain.
  • Given that there are several antibody-based drug / therapy candidates being evaluated across various stages of development, the demand for such products is anticipated to rise significantly over the next decade.
  • Antibody-based product developers are likely to continue to outsource their manufacturing operations in mid to long term, resulting in a multi-billion growth opportunity for contract service providers.

 

For more information, please visit https://www.rootsanalysis.com/reports/view_document/antibody-cmo-market/295.html

 

Table of Contents

 

  1. PREFACE

1.1.       Scope of the Report

1.2.       Research Methodology

1.3.       Chapter Outlines

 

  1. EXECUTIVE SUMMARY

 

  1. INTRODUCTION

3.1.       Chapter Overview

3.2.       Concept of an Antibody

3.3.       Structure of an Antibody

3.4.       Antibody Isotypes

3.5.       Mechanism of Action of Antibodies

 

3.6.       Types of Antibodies

3.6.1.    Monoclonal Antibodies

3.6.2.    Bispecific Antibodies

3.6.3.    Polyclonal Antibodies

 

3.7.       Overview of Contract Manufacturing

3.8.       Need for Outsourcing in the Biopharmaceutical Industry

3.9.       Advantages of Outsourcing Manufacturing Services

 

  1. MARKET LANDSCAPE

4.1.       Chapter Overview 

4.2.       Antibody Contract Manufacturers: Overall Market Landscape

4.2.1.    Analysis by Year of Establishment 

4.2.2.    Analysis by Number of Employees 

4.2.3.    Analysis by Scale of Operation 

4.2.4.    Analysis by Location of Headquarters

4.2.5.    Analysis by Location of Antibody Manufacturing Facilities

4.2.6.    Analysis by Type of Antibodies Manufactured 

4.2.7.    Analysis by Expression Systems Used

4.2.8.    Analysis by Regulatory Accreditations / Certifications

4.2.9.    Additional Services Offered

 

  1. COMPANY COMPETITIVE ANALYSIS

5.1.       Chapter Overview

5.2.       Assumptions and Key Input Parameters

5.3.       Methodology

5.4.       Company Competitiveness Analysis: Antibody Contract Manufacturers in North America

5.5.       Company Competitiveness Analysis: Antibody Contract Manufacturers in Europe

5.6.       Company Competitiveness Analysis: Antibody Contract Manufacturers in Asia

 

  1. COMPANY PROFILES

6.1.       Chapter Overview

6.2.       AGC Biologics

6.2.1.    Company Overview

6.2.2.    Service Portfolio

6.2.3.    Manufacturing Facilities and Capabilities

6.2.4.    Future Outlook

 

6.3.       Aldevron

6.3.1.    Company Overview

6.3.2.    Service Portfolio

6.3.3.    Manufacturing Facilities and Capabilities

6.3.4.    Future Outlook

 

6.4.       AMRI

6.4.1.    Company Overview

6.4.2.    Service Portfolio

6.4.3.    Manufacturing Facilities and Capabilities

6.4.4.    Future Outlook

 

6.5.       BioXcellence (Boehringer Ingelheim)

6.5.1.    Company Overview

6.5.2.    Service Portfolio

6.5.3.    Manufacturing Facilities and Capabilities

6.5.4.    Future Outlook

 

6.6.       Emergent BioSolutions

6.6.1.    Company Overview

6.6.2.    Service Portfolio

6.6.3.    Manufacturing Facilities and Capabilities

6.6.4.    Future Outlook

 

6.7.       Eurofins CDMO

6.7.1.    Company Overview

6.7.2.    Service Portfolio

6.7.3.    Manufacturing Facilities and Capabilities

6.7.4.    Future Outlook

 

6.8.       FUJIFILM Diosynth Biotechnologies

6.8.1.    Company Overview

6.8.2.    Service Portfolio

6.8.3.    Manufacturing Facilities and Capabilities

6.8.4.    Future Outlook

 

6.9.       KBI Biopharma

6.9.1.    Company Overview

6.9.2.    Service Portfolio

6.9.3.    Manufacturing Facilities and Capabilities

6.9.4.    Future Outlook

 

6.10.     Lonza

6.10.1.  Company Overview

6.10.2.  Service Portfolio

6.10.3.  Manufacturing Facilities and Capabilities

6.10.4.  Future Outlook

 

 

6.11.     Nitto Avecia Pharma Services

6.11.1.  Company Overview

6.11.2.  Service Portfolio

6.11.3.  Manufacturing Facilities and Capabilities

6.11.4.  Future Outlook

 

6.12.     Novasep

6.12.1.  Company Overview

6.12.2.  Service Portfolio

6.12.3.  Manufacturing Facilities and Capabilities

6.12.4.  Future Outlook

 

6.13.     Pierre Fabre

6.13.1.  Company Overview

6.13.2.  Service Portfolio

6.13.3.  Manufacturing Facilities and Capabilities

6.13.4.  Future Outlook

 

6.14.     Samsung BioLogics

6.14.1.  Company Overview

6.14.2.  Service Portfolio

6.14.3.  Manufacturing Facilities and Capabilities

6.14.4.  Future Outlook

 

6.15.     Synthon

6.15.1.  Company Overview

6.15.2.  Service Portfolio

6.15.3.  Manufacturing Facilities and Capabilities

6.15.4.  Future Outlook

 

6.16.     Thermo Fisher Scientific

6.16.1.  Company Overview

6.16.2.  Service Portfolio

6.16.3.  Manufacturing Facilities and Capabilities

6.16.4.  Future Outlook

 

  1. CASE STUDY: COMPARISON OF SMALL AND LARGE MOLECULES (BIOLOGICS) DRUGS / THERAPIES

7.1.       Chapter Overview

7.2.       Small Molecule Drugs and Biologics

7.2.1.    Comparison of Strengths and Weakness of Small Molecules and Biologics

7.2.2.    Comparison of Key Specifications

7.2.3.    Comparison of Manufacturing Processes

7.2.4.    Comparison of Key Manufacturing related Challenges

 

  1. BENCHMARK ANALYSIS

8.1.       Chapter Overview

8.2.       Methodology

8.3.       Region-wise Benchmarking

8.3.1.    North America, Peer Group I

8.3.2.    North America, Peer Group II

8.3.3.    North America, Peer Group III

8.3.4.    Europe, Peer Group IV

8.3.5.    Europe, Peer Group V

8.3.6.    Europe, Peer Group VI

8.3.7.    Asia, Peer Group VII

8.3.8.    Asia, Peer Group VIII

 

8.4.       Concluding Remarks

 

  1. PARTNERSHIPS

9.1.       Chapter Overview

9.2.       Partnerships Models

 

9.3.       Antibody Contract Manufacturing: List of Partnerships

9.3.1.    Analysis by Year of Partnership

9.3.2.    Analysis by Type of Partnership

9.3.3.    Analysis by Year and Type of Partnership

9.3.4.    Analysis by Type of Antibody

9.3.5.    Analysis by Project Scale

9.3.6.    Analysis by Focus Therapeutic Area

 

9.3.7.    Most Active Players: Analysis by Number of Partnerships and Type of Partnership

9.3.8.    Geographical Analysis

9.3.8.1. Continent-wise Distribution

9.3.8.2. Country-wise Distribution

 

  1. RECENT EXPANSIONS

10.1.     Chapter Overview

10.2.     Antibody Contract Manufacturers: List of Expansions

10.2.1. Analysis by Year of Expansion

10.2.2. Analysis by Type of Expansion

10.2.3. Analysis by Type of Antibody

10.2.4. Analysis by Location of Manufacturing Facility

10.2.5. Analysis by Location of Manufacturing Facility and Type of Expansion

10.2.6.  Analysis of Most Active Players by Number of Expansions

10.2.7.  Geographical Analysis

10.2.7.1. Country-wise Distribution

 

  1. CAPACITY ANALYSIS

11.1.     Chapter Overview

11.2.     Assumptions and Methodology

11.3.     Antibody Contract Manufacturing: Installed Global Capacity

11.3.1. Analysis by Company Size

11.3.2. Analysis by Scale of Operation

11.3.3.  Analysis by Expression System

11.3.4. Analysis by Location of Manufacturing Facility

11.3.5.  Analysis by Geography and Scale of Operation

11.3.6.  Analysis by Geography and Company Size        

11.4.     Concluding Remarks

 

  1. DEMAND ANALYSIS

12.1      Chapter Overview

12.2      Assumptions and Methodology

12.3      Antibody Contract Manufacturing Market: Overall Annual Demand

12.3.1. Analysis by Scale of Operation

12.3.2. Analysis by Geography

 

  1. MARKET SIZING AND OPPORTUNITY ANALYSIS

13.1.     Chapter Overview

13.2.     Assumptions and Forecast Methodology

 

13.3.     Overall Antibody Contract Manufacturing Market, 2020-2030

13.4.     Antibody Contract Manufacturing Market, 2020-2030: Distribution by Type of Antibody

13.5.     Antibody Contract Manufacturing Market, 2020-2030: Distribution by Company Size

13.6.     Antibody Contract Manufacturing Market, 2020-2030: Distribution by Scale of Operation

13.7.     Antibody Contract Manufacturing Market, 2020-2030: Distribution by Expression System Used

 

13.8.     Antibody Contract Manufacturing Market, 2020-2030: Distribution by Geography

13.8.1. Antibody Contract Manufacturing Market in North America, 2020-2030

13.8.1.1. Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Small   Companies

13.8.1.2. Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Mid-sized         Companies

13.8.1.3. Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Large / Very      Large Companies

 

13.8.1.4. Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Preclinical /       Clinical Scale Operations

13.8.1.5. Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Commercial      Scale Operations

 

13.8.1.6. Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Mammalian      Cell-based Operations

13.8.1.7. Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Microbial Cell-   based Operations

 

13.8.2. Antibody Contract Manufacturing Market in Europe, 2020-2030

13.8.2.1. Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Small Companies

13.8.2.2. Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Mid-sized Companies

13.8.2.3. Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Large / Very Large       Companies

 

13.8.2.4. Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Preclinical / Clinical      Scale Operations

13.8.2.5. Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Commercial Scale       Operations

 

13.8.2.6. Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Mammalian Cell-          based Operations

13.8.2.7. Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Microbial Cell-based    Operations

 

13.8.3. Antibody Contract Manufacturing Market in Asia, 2020-2030

13.8.3.1. Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Small Companies

13.8.3.2. Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Mid-sized Companies

13.8.3.3. Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Large / Very Large           Companies

 

13.8.3.4. Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Preclinical / Clinical Scale             Operations

13.8.3.5. Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Commercial Scale           Operations

 

13.8.3.6. Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Mammalian Cell-based    Operations

13.8.3.7. Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Microbial Cell-based        Operations

 

  1. SWOT ANALYSIS

14.1.     Chapter Overview

14.2.     Strengths

14.3.     Weaknesses

14.4.     Opportunities

14.5.     Threats

14.6.     Comparison of SWOT Factors

14.7.     Concluding Remarks  

 

  1. FUTURE OF THE ANTIBODY CMO MARKET

15.1.     Chapter Overview

15.2.     Outsourcing Activity Anticipated to Witness Significant Growth

15.3.     Shift from One-time Contractual Engagements to Strategic Partnerships

15.4.     Adoption of New and Innovative Technologies

15.5.     Growing Biosimilars Market to Contribute to the Growth of the Contract Services Segment

15.6.     Capability and Expertise Expansions by CMOs to become One Stop Shops

15.7.     Offshoring Outsourcing Activities to Maximize Profits and Expand Existing Capacities

15.8.     Challenges Faced by both Sponsors and Service Providers

15.9.     Concluding Remarks

 

  1. INTERVIEW TRANSCRIPTS

16.1.     Chapter Overview 

16.2.     Dietmar Katinger, Chief Executive Officer, Polymun Scientific

16.3.     David C Cunningham, Director Corporate Development, Goodwin Biotechnology 

16.4.     Claire Otjes, Assistant Marketing Manager, Batavia Biosciences  

 

  1. APPENDIX 1: LIST OF ANTIBODY CUSTOM MANUFACTURERS

 

  1. APPENDIX 2: TABULATED DATA

 

  1. APPENDIX 3: LIST OF COMPANIES AND ORGANIZATIONS

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com

 

 

 

The “Targeted Protein Degradation Market, 2020-2030” report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapeutics and affiliated technologies, over the next decade.


Submitted 102 day(s) ago by Harry sins

 

 

To order this 330+ page report, please visit this link

 

Key Inclusions

  • A detailed assessment of the current market landscape of targeted protein degradation-based therapeutics, providing information on drug / therapy developer(s) (such as year of establishment, company size and location of headquarters), clinical study sponsor(s) and collaborator(s), type of protein degrader (degronimids, ENDTACs, epichaperome inhibitors, hydrophobic tags, IMiDs, LYTACs, molecular glues, PHOTACs, PROTACs, protein homeostatic modulators, SARDs, SERDs, SNIPERs, and specific BET and DUB inhibitors), phase of development (clinical, preclinical, and discovery stage) of product candidates, target indication(s), key therapeutic area(s), type of target protein(s), target enzyme(s) (if available), target signaling pathway (if available), mechanism of action (if available), type of therapy (monotherapy and combination therapy), route of administration (oral, intravenous and others), and information on special drug designations (if any). In addition, the chapter highlights the various technology platforms that are being actively used for the development of targeted protein degraders.
  • Elaborate profiles of key players that are engaged in the development of targeted protein degraders (shortlisted on the basis of phase of development of pipeline products), featuring a brief overview of the company, its financial information (if available), detailed descriptions of their respective lead drug candidates, and an informed future outlook. Additionally, each drug profile features information on the type of drug, route of administration, target indications, current status of development and a brief summary of its developmental history.
  • Brief tabulated profiles of industry players (shortlisted on the basis of the number of pipeline products), featuring details on the innovator company (such as year of establishment, location of headquarters, number of employees, and key members of the executive team), recent developments, along with descriptions of their respective drug candidates.
  • A detailed clinical trial analysis of completed, ongoing and planned studies of various targeted protein degraders, highlighting prevalent trends across various relevant parameters, such as current trial status, trial registration year, enrolled patient population and regional distribution of trials, type of protein degrader, phase of development, study design, leading industry and non-industry players (in terms of number of trials conducted), study focus, target therapeutic area, key indications, and clinical endpoints.
  • An assessment of the relative experience of key opinion leaders (KOLs) within this domain, (shortlisted based on their involvement in various clinical studies), featuring detailed 2X2 matrices (based on the strength and activeness of KOLs), a schematic world map representation (highlighting the geographical locations of eminent scientists / researchers) and an analysis evaluating the (relative) level of expertise of different KOLs, based on parameters such as number of publications, number of citations, participation in clinical trials, number of affiliations and strength of professional network (based on information available on ResearchGate).
  • A detailed publication analysis of more than 210 peer-reviewed, scientific articles that have been published since 2017, highlighting the research focus within the industry. It also highlights the key trends observed across the publications, including information on novel protein degraders, potential target proteins, target disease indications, and analysis based on various relevant parameters, such as year of publication, and most popular journals (in terms of number of articles published in the given time period) within this domain.
  • An analysis of the partnerships that have been established in the domain, over the period 2014-Q3 2019, covering research agreements, product / technology licensing agreements, mergers / acquisitions, asset purchase agreements, R&D and commercialization agreements, IP licensing agreements, clinical trial agreements, product development agreements, and other relevant deals.
  • An analysis of the investments made at various stages of development, such as seed financing, venture capital financing, debt financing, grants / awards, capital raised from IPOs and subsequent offerings, by companies that are engaged in this field.

 

The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:

  • Type of payment of licensing agreements
  • Upfront payments
  • Milestone payments

 

  • Type of protein degrader
  • Degronimids
  • PROTACs
  • SARDs / SERDs
  • Specific BET and DUB inhibitors
  • Other protein degraders

 

  • Therapeutic area
  • Neurodegenerative disorders
  • Oncological disorders
  • Other therapeutic areas

 

  • Route of administration
  • Oral
  • Intravenous
  • Other routes

 

  • Key geographical region
  • North America
  • Europe
  • Asia-Pacific

 

To request a sample pages, please visit this link

 

Key Questions Answered

  • What are the prevalent R&D trends related to targeted protein degradation?
  • Which clinical conditions can be treated using targeted protein degradation-based therapeutics?
  • What are the most popular proteins being targeted by bifunctional degrader molecules?
  • What are the key challenges faced by stakeholders engaged in this domain?
  • What are the key technology platforms that leverage the concept of targeted protein degradation?
  • Who are the leading industry and non-industry players in this market?
  • What are the contributions of big pharma players in this field?
  • What are the key geographies where research on targeted protein degradation is being conducted?
  • Who are the key investors in this domain?
  • Who are the key opinion leaders / experts in this field?
  • What kind of partnership models are commonly adopted by industry stakeholders?
  • What are the factors that are likely to influence the evolution of this upcoming market?
  • How is the current and future market opportunity likely to be distributed across key market segments?

 

You may also be interested in the following titles:

  1. DNA-Encoded Libraries: Platforms and Services Market
  2. Global Stem Cells Market: Focus on Clinical Therapies, 2020–2030
  3. The Human Microbiome Market: Focus on Therapeutics (including gut-brain axis targeting drugs), Diagnostics and Fecal Microbiota Therapies (3rd Edition), 2019-2030

 

 

Contact Details:

Gaurav Chaudhary

+1 (415) 800 3415

Gaurav.Chaudhary@rootsanalysis.com

 

  More than 85 small molecule protein degraders are currently being evaluated for the treatment of various disease indications; in addition, there are over 25 technology platforms available for use in therapy development efforts


Submitted 102 day(s) ago by Harry sins

 

The concept of targeted protein degradation presents revolutionary drug development opportunities and is anticipated to bring about a paradigm shift in modern healthcare. The first targeted protein degrader, called proteolysis targeting chimera (PROTAC), was developed about a decade ago. Presently, a variety of other such chemical entities and molecular glues are under investigation. In fact, certain pipeline candidates are already in the mid to late-phase trials and are anticipated to soon enter the market.

 

To order this 330+ page report, which features 130+ figures and 145+ tables, please visit this link

 

The USD 3.6 billion (by 2030) financial opportunity within the target protein degradation market has been analyzed across the following segments:

  • Type of payment of licensing agreements
  • Upfront payments
  • Milestone payments

 

  • Type of protein degrader
  • Degronimids
  • PROTACs
  • SARDs / SERDs
  • Specific BET and DUB inhibitors
  • Other protein degraders

 

  • Therapeutic area
  • Neurodegenerative disorders
  • Oncological disorders
  • Other therapeutic areas

 

  • Route of administration
  • Oral
  • Intravenous
  • Other routes

 

  • Key geographical region
  • North America
  • Europe
  • Asia-Pacific

 

The Targeted Protein Degradation Market: Focus on Therapeutics and Technology Platforms (based on Degronimids, ENDTACs, Epichaperome Inhibitors, Hydrophobic Tags, IMiDs, LYTACs, Molecular Glues, PHOTACs, PROTACs, Protein Homeostatic Modulators, SARDs, SERDs, SNIPERs, and Specific BET and DUB Inhibitors), 2020-2030 report features the following companies, which we identified to be key players in this domain:

  • Arvinas
  • Captor Therapeutics
  • Celgene
  • Genetech
  • Kymera Therapeutics
  • Mission Therapeutics
  • Progenra
  • Radius Health
  • Sanofi Genzyme
  • Zenopharm

 

Table of Contents

 

  1. Preface

  2. Executive Summary

  3. Introduction

  4. Current Market Landscape

  5. Company Profiles

  6. Clinical Trial Analysis

  7. KOL Analysis

  8. Publication Analysis

  9. Funding and Investment Analysis

  10. Partnerships and Collaborations

  11. Market Sizing and Opportunity Analysis

  12. Executive Insights

 

  1. Concluding Remarks

 

  1. Appendix 1: Tabulated Data

 

  1. Appendix 2: List of Companies and Organizations

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/protein-degradation-market/289.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com

 

 

The targeted protein degradation market is projected to grow at an annualized rate of more than 30% till 2030


Submitted 102 day(s) ago by Harry sins

 

Roots Analysis has done a detailed study on Targeted Protein Degradation Market: Focus on Therapeutics and Technology Platforms (based on Degronimids, ENDTACs, Epichaperome Inhibitors, Hydrophobic Tags, IMiDs, LYTACs, Molecular Glues, PHOTACs, PROTACs, Protein Homeostatic Modulators, SARDs, SERDs, SNIPERs, and Specific BET and DUB Inhibitors), 2020-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

 

To order this 330+ page report, which features 130+ figures and 145+ tables, please visit this link

 

Key Market Insights

  • More than 85 small molecule protein degraders are currently being evaluated for the treatment of various disease indications; in addition, there are 25+ technology platforms available for use in therapy development efforts
  • The pipeline features a variety of candidate drugs that target a wide range of disease-causing / associated proteins; majority of the existing drug candidates are designed for administration via non-invasive routes
  • Although start-ups and mid-sized firms are spearheading the innovation, several big pharmaceutical companies are also engaged in this domain
  • Close to 5,500 patients were estimated to have been enrolled in clinical trials worldwide, evaluating a number of relevant pre-marketing end points across various phases of development
  • A number of prominent scientists from renowned universities have emerged as key opinion leaders, owing to their active involvement in clinical development efforts
  • Published scientific literature indicates that both industry and academic players have made equal contributions to the innovation in this field; the major focus of such studies is presently on PROTACs
  • Foreseeing a lucrative future, several private and public investors have invested over USD 3.5 billion across close to 100 instances of funding since 2014
  • The increasing interest in this field is also reflected in recent partnership activity; most of these deals are focused on novel technology platforms, involving the active participation of both international and indigenous companies
  • Short term opportunity in this market is likely to be driven by licensing activity, depending on the capability of novel technologies to meet protein degrader design and development needs
  • As multiple mid-late stage drug candidates are approved for marketing, the long term opportunity is likely to be distributed across different types of protein degraders, target therapeutic areas and various global regions

 

For more information please visit:

https://www.rootsanalysis.com/reports/view_document/protein-degradation-market/289.html

 

Table of Contents

 

  1. PREFACE

1.1.                  Scope of the Report

1.2.                  Research Methodology

1.3.                  Chapter Outlines


  1. EXECUTIVE SUMMARY

 

  1. INTRODUCTION

3.1.                  Context and Background

3.2.                  Concept of Protein Homeostasis

3.3.                  Discovery of the Ubiquitin Proteasome System

3.3.1.                Ubiquitin: Structure and Function

3.3.2.                Fundamentals of the UPS

3.3.3.                Components of the UPS

 

3.4.                  Key Steps Involved in the UPS

3.4.1.                Ubiquitination: The First Step

3.4.2.                Proteasomal Degradation: The Second Step

 

3.5.                  Therapeutic Applications of the UPS

3.6.                  Advantages and Challenges Associated with Ubiquitin Enzyme Inhibitors

3.7.                  Targeted Protein Degradation: Enhancing Ubiquitination to Degrade Undruggable Targets

3.7.1.                Brief History of Targeted Protein Degradation

 

3.8.                  Types of Protein Degraders

3.8.1.                Selective Hormone Receptor Degraders (SHRDs)

3.8.2.                Immumodulatory Imide Drugs (IMiDs)

3.8.3.                PROTACs

3.8.4.                Other Chimeras (ENDTACs, LYTACs and PHOTACs)

3.8.4.1.             Endosome Targeting Chimeras (ENDTACs)

3.8.4.2.             Lysozyme targeting chimeras (LYTACs)

3.8.5.                Specific and Nongenetic Inhibitor-of-Apoptosis Proteins (IAP)-dependent Protein Erasers (SNIPERS)

3.8.6.                Hydrophobic Tag

3.8.7.                Molecular Glues

3.8.8.                DUB Inhibitors 

 

3.9.                  Growth Drivers and Roadblocks

 

  1. CURRENT MARKET LANDSCAPE

4.1.                  Chapter Overview

4.2.                  Targeted Protein Degradation-based Therapeutics and Technologies: Development Pipeline

4.2.1.                Analysis by Type of Protein Degrader

4.2.2.                Analysis by Phase of Development

4.2.3.                Analysis by Therapeutic Area

4.2.4.                Analysis by Target Indication

4.2.5.                Analysis by Type of Target Enzyme

4.2.6.                Analysis by Type of Target Protein

4.2.7.                Analysis by Type of Therapy

4.2.8.                Analysis by Route of Administration

 

4.3.                  Targeted Protein Degradation-based Therapeutics and Technologies: List of Research Tools / Key Technology Platforms

 

4.4.                  Targeted Protein Degradation-based Therapeutics and Technologies: Developer Landscape

4.4.1.                Analysis by Year of Establishment

4.4.2.                Analysis by Location of Headquarters

4.4.3.                Analysis by Size of Company

4.4.4.                Analysis by Type of Protein Degrader

 

  1. COMPANY PROFILES

5.1.                  Chapter Overview

5.2.                  Developers with Clinical Candidates

5.2.1.                Radius Health

5.2.1.1.             Company Overview

5.2.1.2.             Targeted Protein Degradation-based Drug Portfolio

5.2.1.2.1.          Product Description: Elacestrant

5.2.1.3.             Recent Developments and Future Outlook

 

5.2.2.                Celgene

5.2.2.1.             Company Overview

5.2.2.2.             Financial Information

5.2.2.3.             Targeted Protein Degradation-based Drug Portfolio

5.2.2.3.1.          Avadomide (CC-122)

5.2.2.3.2.          Iberdomide (CC-220)

5.2.2.4.             Recent Developments and Future Outlook

 

5.2.3.                Sanofi Genzyme

5.2.3.1.             Company Overview

5.2.3.2.             Financial Information

5.2.3.3.             Targeted Protein Degradation-based Drug Portfolio

5.2.3.3.1.          Product Description: SAR439859

5.2.3.4.             Recent Developments and Future Outlook

 

5.3.                  Developers with Preclinical / Early-stage Clinical Candidates

5.3.1.                Arvinas

5.3.2.                Captor Therapeutics

5.3.3.                Genentech

5.3.4.                Kymera Therapeutics

5.3.5.                Mission Therapeutics

5.3.6.                Progenra

5.3.7.                Zenopharm

 

  1. CLINICAL TRIAL ANALYSIS

6.1.                  Chapter Overview

6.2.                  Scope and Methodology

6.3.                  Targeted Protein Degradation-based Therapeutics and Technologies: List of Clinical Trials

6.3.1.                Analysis by Trial Registration Year

6.3.2.                Geographical Analysis by Number of Clinical Trials

6.3.3.                Geographical Analysis by Enrolled Patient Population

6.3.4.                Analysis by Type of Protein Degrader

6.3.5.                Analysis by Phase of Development

6.3.6.                Analysis by Study Design

6.3.7.                Analysis by Type of Sponsor / Collaborator

6.3.8.                Most Active Players: Analysis by Number of Registered Trials

6.3.9.                Analysis by Trial Focus

6.3.10.              Analysis by Therapeutic Area

6.3.11.              Analysis by Clinical Endpoints

 

  1. KOL ANALYSIS

7.1.                  Chapter Overview

7.2.                  Scope and Methodology

7.3.                  Targeted Protein Degradation-based Therapeutics and Technologies: List of Principal Investigators Involved in Clinical Trials

7.3.1.                Analysis by Type of Organization

7.3.2.                Analysis by Designation

7.3.3.                Geographical Distribution

7.3.4.                Analysis by Therapeutic Focus

7.3.5.                Analysis by Phase of Development and Type of Degrader

 

7.4.                  Prominent Key Opinion Leaders

7.5.                  KOL Benchmarking: Roots Analysis versus Third Party Scoring (ResearchGate Score)

 

7.6.                  Most Active Key Opinion Leaders

7.6.1.                KOL Profile (Hagop Youssoufian)

7.6.2.                KOL Profile (Patricia LoRusso)

7.6.3.                KOL Profile (Johann De Bono)

7.6.4.                KOL Profile (John N Nemunaitis)

7.6.5.                KOL Profile (Robert Morgan)

7.6.6.                KOL Profile (Edward O’Mara)

 

  1. PUBLICATION ANALYSIS

8.1.                  Chapter Overview

8.2.                  Scope and Methodology

8.3.                  Targeted Protein Degradation-Based Therapeutics and Technologies: Recent Publications

8.3.1.                Analysis by Year of Publication

8.3.2.                Analysis by Study Objective

8.3.3.                Emerging Focus Areas

8.3.4.                Analysis by Type of Protein Degrader

8.3.5.                Analysis by Target Protein

8.3.6.                Analysis by Target Enzyme

8.3.7.                Analysis by Target Indication

8.3.8.                Analysis by Type of Publisher

8.3.9.                Leading Players: Analysis by Number of Publications

8.3.10.              Leading Players: Geographical Analysis by Number of Publications

8.3.11.              Key Journals: Analysis by Number of Publications

 

  1. FUNDING AND INVESTMENT ANALYSIS

9.1.                  Chapter Overview

9.2.                  Types of Funding

9.3.                  Targeted Protein Degradation: Funding and Investment Analysis

9.3.1.                Analysis by Number of Funding Instances

9.3.2.                Analysis by Amount Invested

9.3.3.                Analysis by Type of Funding

9.3.4.                Analysis by Number of Funding Instances and Amount Invested across Different Protein Degraders

9.3.5.                Analysis by Number of Funding Instances and Amount Invested across Different Therapeutic Areas

9.3.6.                Analysis by Amount Invested across Different Protein Degradation Technology Platforms

9.3.7.                Most Active Players: Analysis by Number of Funding Instances

9.3.8.                Most Active Investors: Analysis by Number of Funding Instances

9.3.9.                Geographical Analysis by Amount Invested

9.4.                  Concluding Remarks

 

  1. PARTNERSHIPS AND COLLABORATIONS

10.1.                 Chapter Overview

10.2.                 Partnership Models

10.3.                 Targeted Protein Degradation-based Therapeutics and Technologies: Recent Collaborations and Partnerships

10.3.1.              Analysis by Year of Partnership

10.3.2.              Analysis by Type of Partnership

10.3.3.              Analysis by Type of Protein Degrader

10.3.4.              Analysis by Therapeutic Area

10.3.5.              Analysis by Different Protein Degradation Technology

10.3.6.              Most Active Players: Analysis by Number of Partnerships

10.3.7.              Geographical Analysis

10.3.7.1.           Most Active Players: Regional Analysis by Number of Partnerships

10.3.7.2.           Intercontinental and Intracontinental Agreements

 

  1. MARKET SIZING AND OPPORTUNITY ANALYSIS

11.1.                 Chapter Overview

11.2.                 Key Assumptions and Forecast Methodology

11.3.                 Overall Targeted Protein Degradation-based Therapeutics and Technologies Market, 2020-2030

                       

11.3.1.              Targeted Protein Degradation-based Therapeutics and Technologies Market by Upfront Payments, 2020-2030

11.3.2.              Targeted Protein Degradation-based Therapeutics and Technologies Market by Milestone Payments, 2020-2030

 

11.3.3.              Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Type of Protein Degrader

11.3.3.1.           Targeted Protein Degradation-based Therapeutics and Technologies Market for Degronimids, 2020-2030

11.3.3.2.           Targeted Protein Degradation-based Therapeutics and Technologies Market for PROTACs, 2020-2030

11.3.3.3.           Targeted Protein Degradation-based Therapeutics and Technologies Market for SARDs / SERDs, 2020-2030

11.3.3.4.           Targeted Protein Degradation-based Therapeutics and Technologies Market for Specific BET and DUB Inhibitors, 2020-2030

11.3.3.5.           Targeted Protein Degradation-based Therapeutics and Technologies Market for Other Protein Degraders, 2020-2030

 

11.3.4.              Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Therapeutic Area

11.3.4.1.           Targeted Protein Degradation-based Therapeutics and Technologies Market for Neurodegenerative Disorders, 2020-2030

11.3.4.2.           Targeted Protein Degradation-based Therapeutics and Technologies Market for Oncological Disorders, 2020-2030

11.3.4.3.           Targeted Protein Degradation-based Therapeutics and Technologies Market for Other Therapeutic Areas, 2020-2030

 

11.3.5.              Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Route of Administration

11.3.5.1.           Targeted Protein Degradation-based Therapeutics and Technologies Market for Oral Route, 2020-2030

11.3.5.2.           Targeted Protein Degradation-based Therapeutics and Technologies Market for Intravenous Route, 2020-2030

11.3.5.3.           Targeted Protein Degradation-based Therapeutics and Technologies Market for Other Routes, 2020-2030

 

11.3.6.              Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Geography

11.3.6.1.           Targeted Protein Degradation-based Therapeutics and Technologies Market in North America, 2020-2030

11.3.6.2.           Targeted Protein Degradation-based Therapeutics and Technologies Market in Europe, 2020-2030

11.3.6.3.           Targeted Protein Degradation-based Therapeutics and Technologies Market in Asia-Pacific, 2020-2030

 

  1. EXECUTIVE INSIGHTS

 

  1. CONCLUDING REMARKS

13.1.                 Chapter Overview

13.2.                 Key Takeaways

 

  1. APPENDIX 1: TABULATED DATA

 

  1. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com

 

 

Over 235 companies worldwide claim to offer contract manufacturing services for various types of biopharmaceutical drug / therapy products


Submitted 102 day(s) ago by Harry sins

 

 

Owing to the ever-increasing number of start-ups that are involved in R&D of novel biologics, there is an enormous opportunity for the CMOs in this domain. It is worth emphasizing that, since 2000, more than 115 new CMOs have been established in order to serve to the growing demand for novel biologics that have specific manufacturing requirements. The contemporary contract services market features a mix of large and small-sized CMOs and is characterized by multiple mergers and acquisitions as stakeholders strive to broaden their respective service portfolios. This has enabled several CMOs to offer end-to-end services, ranging from drug development, including preliminary R&D, preclinical and clinical trials, to commercial scale production and regulatory filings

 

To order this 750+ page report, which features 200+ figures and 250+ tables, please visit this link

 

The USD 13.9 billion (by 2030) financial opportunity within the biopharmaceutical manufacturing market has been analyzed across the following segments:

  • Commonly Outsourced Business Operations
  • Active Pharmaceutical Ingredients (API)
  • Finished Dosage Formulations (FDF)
  • Types of Expression System
  • Mammalian
  • Microbial
  • Others
  • Company Size
  • Small
  • Mid-Sized
  • Large and Very Large
  • Scale of Operation
  • Preclinical
  • Clinical
  • Commercial
  • Key Geographical Region 
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World 

 

The Biopharma Contract Manufacturing Market (3rd Edition), 2019-2030. report features the following companies, which we identified to be key players in this domain:

  • 3P Biopharmaceuticals
  • Abzena
  • Albany Molecular Research
  • BioVectra
  • BioXcellence (Boehringer Ingelheim)
  • Celonic
  • Charles River Laboratories
  • ChemPartner
  • Cobra Biologics
  • CordenPharma
  • Cytovance Biologics
  • GE Healthcare
  • Goodwin Biotechnology
  • Grand River Aseptic Manufacturing
  • IDT Biologika
  • KBI BioPharma
  • Kemwell Biopharma
  • LFB Biomanufacturing
  • Meridian Life Science
  • Patheon
  • Pfizer CentreOne
  • PX'Therapeutics
  • Samsung BioLogics
  • Sanofi, CEPiA
  • Thermo Fisher Scientific
  • Vetter Pharma International

 

 

Table of Contents

 

  1. Preface

    2. Executive Summary

  2. Introduction

  3. Competitive Landscape

  4. Biopharmaceutical Contract Manufacturing in North America

  5. Biopharmaceutical Contract Manufacturing in Europe

  6. Biopharmaceutical Contract Manufacturing in Asia Pacific And the Rest of The World

  7. Biopharmaceutical Contract Manufacturing in Asia Pacific And the Rest of The World

 

  1. Case Study: Outsourcing of Biosimilars

  2. Case Study: Comparison of Small Molecule and Large Molecule Drugs / Therapies

 

  1. Case Study on In-House Manufacturing

  2. Collaborations

  3. Recent Developments

  4. Capacity Analysis

 

  1. Demand Analysis

 

  1. Market Forecast

 

  1. SWOT Analysis

 

  1. Future of The Biopharmaceutical CMO Market

 

  1. Survey Analysis

 

  1. Interview Transcripts

 

  1. Appendix 1: List of Non-Industry Players

 

  1. Appendix 1: List of Non-Industry Players

 

  1. Appendix 3: List of Companies and Organizations

 

To purchase a copy, please visit https://rootsanalysis.com/reports/view_document/biopharma-contract-manufacturing-market-3rd-edition-2019-2030/250.html

 

Contact Details

 

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com  

 

 

The biopharmaceutical contract manufacturing market is projected to grow at an annualized rate of ~8%, till 2030


Submitted 102 day(s) ago by Harry sins

 

Roots Analysis has done a detailed study on Biopharma Contract Manufacturing Market (3rd Edition), 2019-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

 

To order this 750+ page report, which features 200+ figures and 250+ tables, please visit this link

 

Key Market Insights

  • Over 235 companies worldwide claim to offer contract manufacturing services for various types of biopharmaceutical drug / therapy products.
  • The market landscape is highly fragmented featuring the presence of both established players and new entrants; majority of biopharmaceutical CMOs are based in the developed geographies.
  • Case study: CMOs focusing on niche biologic markets, primarily novel product candidates for which in-house biomanufacturing expertise is low, are likely to experience significant growth in the coming years.
  • The installed global contract manufacturing capacity, spread across various geographies, is currently estimated to be over 4.5 million liters.
  • The demand for contract manufacturing services is expected to rise across different therapeutic areas; closer inspection of available capacity and expected utilization trend are required to optimize supply parameters.
  • With over 450 deals inked in the past six years, there has been a surge in the partnership activity; majority of the collaborations have been signed for the development and manufacturing of cell therapies and antibodies.
  • In order to cater the increasing demand for biologics, stake holders are actively expanding their existing capabilities; this is evident from the various acquisitions that have recently been reported.
  • We expect the developers to continue to outsource their manufacturing operations in the short to mid-term, resulting in an annualized growth rate of more than 8%.
  • In the long term, the projected opportunity is anticipated to be well distributed across various types of expression systems used for biomanufacturing, scale of operation and size of contract service providers

 

For more information, please visit https://rootsanalysis.com/reports/view_document/biopharma-contract-manufacturing-market-3rd-edition-2019-2030/250.html

 

Table of Contents

 

  1. PREFACE

1.1.       Scope of the Report

1.2.       Research Methodology

1.3.       Chapter Outlines

 

  1. EXECUTIVE SUMMARY

 

  1. INTRODUCTION

3.1.      Context and Background

3.2.      An Overview of Biopharmaceuticals

3.3.      Biopharmaceutical Manufacturing

3.3.1.    Types of Expression Systems

3.3.1.1. Bacterial Expression Systems

3.3.1.2. Yeast Expression Systems

3.3.1.3. Fungal Expression Systems

3.3.1.4. Insect Expression Systems

3.3.1.5. Plant Expression Systems

3.3.1.6. Mammalian Expression Systems

 

3.3.2.    Manufacturing Steps

3.3.2.1. Upstream Processing

3.3.2.2. Downstream Processing

 

3.4.      An Overview of Contract Manufacturing

3.5.      Need for Outsourcing in the Biopharmaceutical Industry

3.6.      Commonly Outsourced Operations in the Biopharmaceutical Industry

3.7.      Basic Guidelines for Selecting a CMO Partner

3.8.      Advantages of Outsourcing Manufacturing Services

3.9.      Risks and Challenges Associated with Biopharmaceutical Contract Manufacturing

3.10.     Concluding Remarks

 

  1. COMPETITIVE LANDSCAPE

4.1.      Chapter Overview

4.2.      Biopharmaceuticals Contract Manufacturers: Overall Market Landscape

4.2.1.    Analysis by Size of Employee Base

4.2.2.    Analysis by Location of Headquarters

4.2.3.    Analysis by Year of Establishment

4.2.4.    Analysis by Location of Manufacturing Facilities

4.2.5.    Analysis by Type of Biologics Manufactured

4.2.6.    Analysis by Scale of Operation

4.2.7.    Analysis by Expression Systems

4.2.8.    Analysis by Type of Bioreactor and Modes of Operation

4.2.9.    Analysis by Biomanufacturing Capacity

4.2.10.  Analysis by Packaging Form

4.3.      Concluding Remarks

 

  1. BIOPHARMACEUTICAL CONTRACT MANUFACTURING IN NORTH AMERICA

5.1.      Chapter Overview

5.2.      Biopharmaceutical Outsourcing in the US: Regulatory Scenario

5.2.1.    Impact of Current Political Situation

5.3.      Leading Biopharma CMOs in North America

5.3.1.    AMRI (OsoBio)

5.3.1.1. Company Overview

5.3.1.2. Services Portfolio

5.3.1.3. Financial Information

5.3.1.4. Manufacturing Facilities

5.3.1.5. Partnerships

5.3.1.6. Recent Developments

5.3.1.7. Future Outlook

 

5.3.2.    Baxter BioPharma Solutions

5.3.2.1. Company Overview

5.3.2.2. Services Portfolio

5.3.2.3. Financial Information

5.3.2.4. Manufacturing Facilities

5.3.2.5. Partnerships

5.3.2.6. Recent Developments

5.3.2.7. Future Outlook

 

5.3.3.    Catalent Biologics (Catalent Pharma Solutions)

5.3.3.1. Company Overview

5.3.3.2. Services Portfolio

5.3.3.3. Financial Information

5.3.3.4. Manufacturing Facilities

5.3.3.5. Partnerships

5.3.3.6. Recent Developments

5.3.3.7. Future Outlook

 

5.3.4.    Cytovance Biologics

5.3.4.1. Company Overview

5.3.4.2. Services Portfolio

5.3.4.3. Partnerships

5.3.4.4. Recent Developments

5.3.4.5. Future Outlook

 

5.3.5.    Patheon

5.3.5.1. Company Overview

5.3.5.2. Services Portfolio

5.3.5.3. Financial Information

5.3.5.4. Manufacturing Facilities

5.3.5.5. Partnerships

5.3.5.6. Recent Developments

5.3.5.7. Future Outlook

 

5.3.6.    Piramal Pharma Solutions

5.3.6.1. Company Overview

5.3.6.2. Services Portfolio

5.3.6.3. Financial Information

5.3.6.4. Facilities

5.3.6.5. Partnerships

5.3.6.6. Recent Developments

5.3.6.7. Future Outlook

 

  1. BIOPHARMACEUTICAL CONTRACT MANUFACTURING IN EUROPE

6.1.      Chapter Overview

6.2.      Biopharmaceutical Outsourcing in Europe: Regulatory Scenario

6.3.      Leading Biopharmaceutical CMOs in Europe

6.3.1.    3P Biopharmaceuticals

6.3.1.1. Company Overview

6.3.1.2. Services Portfolio

6.3.1.3. Manufacturing Facilities

6.3.1.4. Partnerships

6.3.1.5. Recent Developments

6.3.1.6. Future Outlook

 

6.3.2.    Boehringer Ingelheim BioXcellence™

6.3.2.1. Company Overview

6.3.2.2. Services Portfolio

6.3.2.3. Financial Information

6.3.2.4. Manufacturing Facilities

6.3.2.5. Partnerships

6.3.2.6. Recent Developments

6.3.2.7. Future Outlook

 

6.3.3.    Celonic

6.3.3.1. Company Overview

6.3.3.2. Services Portfolio

6.3.3.3. Manufacturing Facilities

6.3.3.4. Partnerships

6.3.3.5. Recent Developments

6.3.3.6. Future Outlook

 

6.3.4.    FUJIFILM Diosynth Biotechnologies

6.3.4.1. Company Overview

6.3.4.2. Services Portfolio

6.3.4.3. Financial Information

6.3.4.4. Manufacturing Capabilities

6.3.4.5. Partnerships

6.3.4.6. Recent Developments

6.3.4.7. Future Outlook

 

6.3.5.    LFB Group

6.3.5.1. Company Overview

6.3.5.2. Services Portfolio

6.3.5.3. Financial Information

6.3.5.4. Manufacturing Facilities

6.3.5.5. Partnerships

6.3.5.6. Recent Developments

6.3.5.7. Future Outlook

 

6.3.6.    Lonza

6.3.6.1. Company Overview

6.3.6.2. Services Portfolio

6.3.6.3. Financial Information

6.3.6.4. Manufacturing Facilities

6.3.6.5. Partnerships

6.3.6.6. Recent Developments

6.3.6.7. Future Outlook

 

6.3.7.    Menarini Biotech

6.3.7.1. Company Overview

6.3.7.2. Services Portfolio

6.3.7.3. Partnerships

6.3.7.4. Future Outlook

 

6.3.8.    Novasep

6.3.8.1. Company Overview

6.3.8.2. Services Portfolio

6.3.8.3. Financial Information

6.3.8.4. Partnerships

6.3.8.5. Recent Developments

6.3.8.6. Future Outlook

 

6.3.9.    Rentschler BioPharma

6.3.9.1. Company Overview

6.3.9.2. Services Portfolio

6.3.9.3. Manufacturing Facilities

6.3.9.4. Partnerships

6.3.9.5. Recent Developments

6.3.9.6. Future Outlook

 

  1. BIOPHARMACEUTICAL CONTRACT MANUFACTURING IN ASIA PACIFIC AND THE REST OF THE WORLD

7.1.      Chapter Overview

 

7.2.      Biopharmaceutical Contract Manufacturing in China

7.2.1.    Biopharmaceutical Outsourcing in China: Regulatory Scenario

7.2.2.    Challenges Faced while Outsourcing to China

 

7.3.      Biopharmaceutical CMOs in China

7.3.1.    AutekBio

7.3.1.1. Company Overview

7.3.1.2. Services Portfolio

7.3.1.3. Manufacturing Facilities

7.3.1.4. Future Outlook

 

7.3.2.    WuXi AppTec (WuXi Biologics)

7.3.2.1. Company Overview

7.3.2.2. Services Portfolio

7.3.2.3. Financial Information

7.3.2.4. Manufacturing Facilities

7.3.2.5. Partnerships

7.3.2.6. Recent Developments

7.3.2.7. Future Outlook

 

7.4.      Biopharmaceutical Contract Manufacturing in India

7.4.1.    Biopharmaceutical Outsourcing in India: Regulatory Scenario

7.4.2.    Challenges Faced while Outsourcing to India

 

7.5.      Biopharmaceutical CMOs in India

7.5.1.    Intas Pharmaceuticals

7.5.1.1. Company Overview

7.5.1.2. Services Portfolio

7.5.1.3. Financial Information

7.5.1.4. Manufacturing Facilities

7.5.1.5. Future Outlook

 

7.5.2.    Kemwell Biopharma

7.5.2.1. Company Overview

7.5.2.2. Services Portfolio

7.5.2.3. Manufacturing Facilities

7.5.2.4. Partnerships

7.5.2.5. Recent Developments

7.5.2.6. Future Outlook

 

7.5.3.    Shasun Pharmaceuticals

7.5.3.1. Company Overview

7.5.3.2. Services Portfolio

7.5.3.3. Financial Information

7.5.3.4. Future Outlook

 

7.5.5.    Syngene

7.5.5.1. Company Overview

7.5.5.2. Services Portfolio

7.5.5.3. Financial Information

7.5.5.4. Manufacturing Facilities

7.5.5.5. Partnerships

7.5.5.6. Recent Developments

7.5.5.7. Future Outlook

 

7.6.      Biopharmaceutical Contract Manufacturing in Japan

7.6.1.    Biopharmaceutical Outsourcing in Japan: Regulatory Scenario

 

7.6.      Biopharmaceutical CMOs in Japan

7.6.1.    Asahi Glass

7.6.1.1. Company Overview

7.6.1.2. Services Portfolio

7.6.1.3. Financial Information

7.6.1.4. Manufacturing Facilities

7.6.1.5. Partnerships

7.7.1.6. Recent Developments

7.7.1.7. Future Outlook

 

7.7.      Biopharmaceutical Contract Manufacturing in South Korea

7.7.1.    Biopharmaceutical Outsourcing in South Korea: Regulatory Scenario

 

7.7.      Biopharmaceutical CMOs in South Korea

7.7.1.    DM Bio

7.7.1.1. Company Overview

7.7.1.2. Services Portfolio

7.7.1.3. Manufacturing Facilities

7.7.1.4. Future Outlook

 

7.7.2.    Samsung BioLogics

7.7.2.1. Company Overview

7.7.2.2. Services Portfolio

7.7.2.3. Financial Information

7.7.2.4. Manufacturing Facilities

7.7.2.5. Partnerships

7.7.2.6. Recent Developments

7.7.2.7. Future Outlook

 

7.8.      Biopharmaceutical Contract Manufacturing in Australia

7.8.1.    Biopharmaceutical Outsourcing in Australia: Regulatory Scenario

 

7.8.      Biopharmaceutical CMOs in Australia

7.8.2.    Cell Therapies

7.8.2.1. Company Overview

7.8.2.2. Services Portfolio

7.8.2.3. Manufacturing Facilities

7.8.2.4. Partnerships

7.8.2.5. Recent Developments

7.8.2.6. Future Outlook

 

7.8.3.    Luina Bio

7.8.3.1. Company Overview

7.8.3.2. Services Portfolio

7.8.3.3. Manufacturing Facilities

7.8.3.4. Partnerships

7.8.3.5. Future Outlook

 

  1. NICHE BIOPHARMACEUTICAL SECTORS

8.1.      Chapter Overview

8.2.      Antibody Drug Conjugates

8.2.1.    Introduction

8.2.1.1. Manufacturing Process

8.2.1.2. Key Technologies and Technology Providers

 

8.2.2.    Pipeline Analysis

8.2.2.1. ADC Pipeline: Marketed and Clinical Molecules

8.2.2.2. ADC Pipeline: Preclinical and Discovery Stage Molecules

8.2.2.3. ADC Manufacturing: Key Challenges

 

8.3.      Bispecific Antibodies

8.3.1.    Introduction

8.3.1.1. The Bispecific Advantage

8.3.2.    Pipeline Analysis

8.3.3.    Bispecific Antibody Technology Providers

8.3.4.    Contract Manufacturing Scenario

 

8.4.      Cell Therapies

8.4.1.    Introduction

8.4.2.    Current Market Landscape

8.4.3.    Cell Therapy Manufacturing

8.4.4.    Cell Therapy Manufacturing Models

8.4.4.1. Centralized Manufacturing Model

8.4.4.2. Decentralized Manufacturing Model

 

8.4.5.    Cell Therapy Manufacturing: Key Challenges and Growth Drivers

8.4.6.    Important Factors for Cell Therapy Manufacturing

8.4.6.1. Cell Characterization

8.4.6.2. Cost of Goods

8.4.7.    Contract Manufacturing Scenario

8.4.7.1. Analysis by Type of Cells Manufactured

8.4.7.2. Analysis by Scale of Operation

 

8.5.      Gene Therapy

8.5.1.    Introduction

8.5.2.    Gene Therapy: Pipeline Analysis

8.5.2.1. Analysis by Phase of Development

8.5.2.2. Analysis by Type of Vector

8.5.2.3. Analysis by Therapeutic Area

 

8.5.3.    Contract Manufacturing Market Landscape

8.5.3.1. Analysis by Location

8.5.3.2. Analysis by Type of Viral Vector

8.5.3.3. Analysis by Scale of Production

 

8.6.      Plasmid DNA

8.6.1.    Introduction

8.6.2.    Contract Manufacturing Market Landscape

8.6.3.    Analysis by Location of Manufacturing Facility

8.6.4.    Analysis by Scale of Production

 

  1. CASE STUDY: OUTSOURCING OF BIOSIMILARS

9.1.      Chapter Overview

9.2.      Biosimilars: An Introduction

9.3.      Biosimilars: Development Stages

9.4.      Regulatory Requirements for Licensing of Biosimilars

9.5.      Need for Outsourcing Biosimilar Development and Manufacturing

9.6.      Impact of Biosimilars on the Global Contract Manufacturing Market

9.6.1.    Region-wise Distribution of Biosimilar Development / Manufacturing Activity

9.7.      List of Biosimilars Contract Manufacturing Service Provider

9.8.      Challenges Associated with Biosimilar Outsourcing

 

  1. CASE STUDY: COMPARISON OF SMALL AND LARGE MOLECULE DRUGS / THERAPIES

10.1.     Chapter Overview

10.2.     Small Molecule and Large Molecule Drugs / Therapies

10.2.1. Comparison of General Characteristics

10.2.2. Comparison of Key Specifications

10.2.3. Comparison of Manufacturing Processes

10.2.4. Comparison of Key Manufacturing Challenges

 

  1. CASE STUDY ON IN-HOUSE MANUFACTURING

11.1.     Chapter Overview

11.2.     In-House Manufacturing

11.2.1. Benefits Associated with In-House Manufacturing

11.2.2. Risks Associated with In-House Manufacturing

 

11.3.     Outsourcing in the Biomanufacturing Industry

11.3.1. Types of Outsourcing Partners

 

11.4.     Manufacturing Approaches Used for Approved Biologics (2016-2018)

11.4.1. Approved Biologics: Distribution by Size of Type of Manufacturing Approach

11.4.2. Approved Biologics: Distribution by Size of Developer and Type of Biologic

 

11.5.     Choosing the Right Strategy: In-House Manufacturing versus Outsourcing

 

  1. COLLABORATIONS

12.1.     Chapter Overview

12.2.     Partnership Models

12.3.     Biopharmaceutical Contract Manufacturing: List of Partnerships and Collaborations

12.3.1.  Analysis by Year of Partnerships

12.3.2.  Analysis by Type of Partnerships

12.3.2.1. Year-Wise Trend of Product-based Agreements

12.3.2.2. Year-Wise Trend of Process-based Agreements

12.3.2.3. Year-Wise Trend of Licensing Agreements

12.3.2.4. Year-Wise Trend of Co-service Agreements / Ventures

12.3.2.5. Year-Wise Trend of R&D Agreements

12.3.2.6. Year-Wise Trend of Out-sourcing Services Agreements

 

12.3.3. Analysis by Focus Area

12.3.4. Analysis by Type of Biologics

12.3.4.1. Analysis by Type of Biologic and Type of Partnership Model

12.3.4.2. Analysis of Cell Therapy-related Deals by Year and Type of Partnership Model

12.3.4.3. Analysis of Monoclonal Antibody-related Deals by Year and Type of Partnership Model

12.3.4.4. Analysis of Vaccine-related Deals by Year and Type of Partnership Model

12.3.4.5. Analysis of Protein-related Deals by Year and Type of Partnership Model

12.3.4.6. Analysis of Antibody Drug Deals by Year and Type of Partnership Model

12.3.4.7. Analysis of Vector-related Deals by Year and Type of Partnership Model

12.3.4.8. Analysis of Gene Therapy-related Deals by Year and Type of Partnership Model

12.3.4.9. Analysis of Biosimilar-related Deals by Year and Type of Partnership Model

12.3.4.10. Analysis of Other Biologic-related Deals by Type of Partnership Model

12.3.4.11. Analysis by Type of Biologics and Geography

 

12.3.5.  Analysis by Therapeutic Area

12.3.6.  Analysis of Most Active Players by Number of Partnerships

12.3.7.  Regional Analysis

12.3.7.1. Intercontinental and Intracontinental Agreements

 

12.4.     Mergers and Acquisitions

12.4.1.  Acquisitions Models

12.4.2.  Biopharmaceutical Contract Manufacturing: Mergers and Acquisitions

12.4.3.  Cumulative Year-wise Trend

12.4.4.  Analysis by Type of Acquisition

12.4.5.  Geographical Activity

12.4.5.1. Mergers and Acquisitions: Continent-wise Distribution

12.4.5.2. Mergers and Acquisitions: Country-wise Distribution

12.4.5.3. Mergers and Acquisitions: Intercontinental and Intracontinental Deals

 

12.4.6.  Most Active Acquirers: Analysis by Number of Acquisitions

12.4.7   Mergers and Acquisitions: Distribution by Key Value Drivers and Type of Biologics

12.4.7.1. Mergers and Acquisitions: Analysis by Key Value Drivers

12.4.7.2. Mergers and Acquisitions: Analysis by Key Value Drivers and Year of Acquisition

12.4.7.3. Mergers and Acquisitions: Analysis by Type of Biologics

12.4.7.4. Mergers and Acquisitions: Analysis by Type of Biologics and Key Value Drivers

12.5.     Key Acquisitions: Deal Multiples

 

  1. RECENT DEVELOPMENTS

13.1.     Chapter Overview

13.2.     Biopharma Contract Manufacturing Market: Facility Expansions

13.2.1.  Cumulative Year-wise Distribution

13.2.2.  Analysis by Purpose of Facility Expansion

13.2.3.  Analysis by Type of Biologics

13.2.4.  Analysis by Type of Biologics and Purpose of Expansion

13.2.5.  Analysis by Location of Manufacturing Facility

13.2.6.  Regional Analysis

13.2.7. Most Active Players: Analysis by Number of Recent Expansions

13.2.8. Analysis by Headquarters and Purpose

13.2.9. Facility Expansions: Pre-2015 and Post-2015

13.3.     Biopharmaceutical Contract Manufacturing Market: Funding Instances

13.4.     Technological Advancements

13.4.1. Single Use Technology

13.4.2.  Process Analytical Technology (PAT)

13.4.3. Continuous Processing

13.4.3.  Quality by Design in Bioprocessing

 

 

13.3.     Biopharmaceutical Contract Manufacturing Market: Funding Instances

13.4.     Technological Advancements

13.4.1.  Single Use Technology

13.4.2.  Process Analytical Technology

13.4.3.  Continuous Processing

13.4.4.  Quality by Design in Bioprocessing

 

  1. CAPACITY ANALYSIS

14.1.     Chapter Overview

14.2.     Assumptions and Methodology

14.3.     Biopharmaceutical Contract Manufacturers: Global Production Capacity

14.3.1.  Analysis by Size of the CMO

14.3.2. Analysis by Expression Systems

14.3.3.  Analysis by Scale of Operation

14.3.4. Analysis by Region

14.3.4.1. Capacity Analysis: North America

14.3.4.2. Capacity Analysis: Europe

14.3.4.3. Capacity Analysis: Asia and Middle East

14.4.     Emerging Biologics: Capacity Analysis

14.4.1.  ADC Manufacturing Installed Global Capacity: Regional Distribution

14.5.     Cell Therapy Manufacturing Capacity: Regional Distribution

14.6.     Viral Vectors Installed Manufacturer Capacity: Distribution by Location of Manufacturing Facility

14.7.     Concluding Remarks

 

  1. DEMAND ANALYSIS

15.1.     Chapter Overview

15.2.     Key Assumptions and Methodology

15.3.     Overall Annual Demand for Biopharmaceutical Market, 2019-2024

15.3.1. Analysis by Therapeutic Area

 

15.4.     Relationship Between Annual Demand and Capacity

15.5.     Demand for Emerging Novel Biologics

15.5.1. ADCs: Overall Annual Demand

15.5.1. ADCs: Demand and Supply Analysis

 

  1. MARKET FORECAST

16.1.     Chapter Overview

16.2.     Forecast Methodology and Key Assumptions

 

16.3.     Overall Biopharmaceutical Contract Manufacturing Market, 2019-2030

16.3.1. Biopharmaceutical Contract Manufacturing Market for API Manufacturing, 2019-2030

16.3.2. Biopharmaceutical Contract Manufacturing Market for FDF Manufacturing, 2019-2030

 

16.4.     Biopharmaceutical Contract Manufacturing Market, 2019-2030: Distribution by Expression Systems Used

16.5.     Biopharmaceutical Contract Manufacturing Market, 2019-2030: Distribution by Scale of Operation

16.6.     Biopharmaceutical Contract Manufacturing Market, 2019-2030: Distribution by Size of Manufacturers

 

16.7.     Biopharmaceutical Contract Manufacturing Market, 2019-2030: Distribution by Geography

16.7.1.  Biopharmaceutical Contract Manufacturing Market in North America, 2019-2030

16.7.1.1. Biopharmaceutical Contract Manufacturing Market in the US, 2019-2030

16.7.1.2. Biopharmaceutical Contract Manufacturing Market in Canada, 2019-2030

16.7.1.3. Biopharmaceutical Contract Manufacturing Market in North America, 2019-2030: Share of Mammalian Cell-based Operations

16.7.1.4. Biopharmaceutical Contract Manufacturing Market in North America, 2019-2030: Share of Microbial Cell-based Operations

16.7.1.5. Biopharmaceutical Contract Manufacturing Market in North America, 2019-2030: Share of Other Expression System-based Operations

16.7.1.6. Biopharmaceutical Contract Manufacturing Market in North America, 2019-2030: Share of Preclinical / Clinical Scale Operations

16.7.1.7. Biopharmaceutical Contract Manufacturing Market in North America, 2019-2030: Share of Commercial Scale Operations

16.7.1.8. Biopharmaceutical Contract Manufacturing Market in North America, 2019-2030: Share of Small-sized Companies

16.7.1.9. Biopharmaceutical Contract Manufacturing Market in North America, 2019-2030: Share of Mid-sized Companies

16.7.1.10. Biopharmaceutical Contract Manufacturing Market in North America, 2019-2030: Share of Large / Very Large Companies

 

16.7.2.  Biopharmaceutical Contract Manufacturing Market in Europe, 2019-2030

16.7.2.1. Biopharmaceutical Contract Manufacturing Market in Italy, 2019-2030

16.7.2.2. Biopharmaceutical Contract Manufacturing Market in Germany, 2019-2030

16.7.2.3. Biopharmaceutical Contract Manufacturing Market in France, 2019-2030

16.7.2.4. Biopharmaceutical Contract Manufacturing Market in Spain, 2019-2030

16.7.2.5. Biopharmaceutical Contract Manufacturing Market in the UK, 2019-2030

16.7.2.6. Biopharmaceutical Contract Manufacturing Market in Rest of Europe, 2019-2030

 

16.7.2.7. Biopharmaceutical Contract Manufacturing Market in Europe, 2019-2030: Share of Mammalian Cell-based Operations

16.7.2.8. Biopharmaceutical Contract Manufacturing Market in Europe, 2019-2030: Share of Microbial Cell-based Operations

16.7.2.9. Biopharmaceutical Contract Manufacturing Market in Europe, 2019-2030: Share of Other Expression System-based Operations

 

16.7.2.10. Biopharmaceutical Contract Manufacturing Market in Europe, 2019-2030: Share of Preclinical / Clinical Operations

16.7.2.11. Biopharmaceutical Contract Manufacturing Market in Europe, 2019-2030: Share of Commercial Operations

16.7.2.12. Biopharmaceutical Contract Manufacturing Market in Europe, 2019-2030: Share of Small-sized Companies

16.7.2.13. Biopharmaceutical Contract Manufacturing Market in Europe, 2019-2030: Share of Mid-sized Companies

16.7.2.14. Biopharmaceutical Contract Manufacturing Market in Europe, 2019-2030: Share of Large / Very Large Companies

 

16.7.3.  Biopharmaceutical Contract Manufacturing Market in Asia and Rest of the World, 2019-2030

16.7.3.1. Biopharmaceutical Contract Manufacturing Market in China, 2019-2030

16.7.3.2. Biopharmaceutical Contract Manufacturing Market in India, 2019-2030

16.7.3.3. Biopharmaceutical Contract Manufacturing Market in South Korea, 2019-2030

16.7.3.4. Biopharmaceutical Contract Manufacturing Market in Japan, 2019-2030

16.7.3.5. Biopharmaceutical Contract Manufacturing Market in Australia, 2019-2030

16.7.3.6. Biopharmaceutical Contract Manufacturing Market in Rest of Asia and Other Regions, 2019-2030

 

16.7.3.7. Biopharmaceutical Contract Manufacturing Market in Asia and Rest of the World, 2019-2030: Share of Mammalian Cell-based Operations

16.7.3.8. Biopharmaceutical Contract Manufacturing Market in Asia and Rest of the World, 2019-2030: Share of Microbial Cell-based Operations

16.7.3.9. Biopharmaceutical Contract Manufacturing Market in Asia and Rest of the World, 2019-2030: Share of Other Expression System-based Operations

 

16.7.3.10. Biopharmaceutical Contract Manufacturing Market in Asia and Rest of the World, 2019-2030: Share of Preclinical / Clinical Operations

16.7.3.11. Biopharmaceutical Contract Manufacturing Market in Asia and Rest of the World, 2019-2030: Share of Commercial Scale Operations

 

16.7.3.12. Biopharmaceutical Contract Manufacturing Market in Asia and Rest of the World, 2019-2030: Share of Small-sized Companies

16.7.3.13. Biopharmaceutical Contract Manufacturing Market in Asia and Rest of the World, 2019-2030: Share of Mid-sized Companies

16.7.3.14. Biopharmaceutical Contract Manufacturing Market in Asia and Rest of the World, 2019-2030: Large / Very Large Companies

16.7.4   Overall Biopharmaceutical Contract Manufacturing, 2019-2030: Share by Others Segment

 

  1. SWOT ANALYSIS

17.1      Chapter Overview

17.2.     Strengths

17.3.     Weaknesses

17.4.     Opportunities

17.5.     Threats

17.6.     Comparison of Swot Factors

17.7.     Concluding Remarks

 

  1. FUTURE OF THE BIOPHARMACEUTICAL CMO MARKET

18.1.     Chapter Overview

18.2.     Outsourcing Activities to Witness Significant Growth in the Coming Years

18.3.     Shift from One-time Contracts to Strategic Partnerships

18.4.     Integration / Adoption of New and Innovative Technologies

18.4.1. Single use Bioreactors

18.4.2. Novel Bioprocess Techniques

18.4.3. Bioprocess Automation

 

18.5.     Focus on Niche Therapeutic Areas

18.6.     Growing Biosimilars Market to Contribute to the Growth of the Contract Services Segment

18.7.     Capability and Expertise Expansions by CMOs to become One Stop Shops

18.8.     Offshoring Outsourcing Activities to Maximize Profits and Expand Existing Capacities

18.9.     Increase in Financial Inflow and Outsourcing Budgets

18.10.   The Need for Humanized Products to Drive the Growth of Mammalian Expression Technologies

 

18.11.   Challenges Faced by both Sponsors and Service Providers

18.11.1. Concerns related to Single Use Systems

18.11.2. Issues Related to Capacity Fluctuations

 

18.12.   Concluding Remarks

 

  1. SURVEY ANALYSIS

19.1.     Chapter Overview

19.1.1. Overview of Respondents

19.1.2. Designation of Respondents

 

19.2.     Biologics Manufacturing Expertise

19.3.     Scale of Manufacturing

19.4.     Location of Production Facilities

19.5.     Types of Expression Systems Used

19.6.     Types of Bioreactors

19.7.     Modes of Operation of Bioreactors

 

  1. INTERVIEW TRANSCRIPTS

20.1.     Chapter Overview

20.2.     Astrid Brammer, Senior Manager Business Development, Richter-Helm

20.3.     Birgit Schwab, Senior Manager Strategic Marketing, Rentschler Biotechnologie

20.4.     Christian Bailly, Director of CDMO, Pierre Fabre

20.5.     Claire Otjes, Assistant Marketing Manager, Batavia Biosciences

20.6.     David C Cunningham, Director Corporate Development, Goodwin Biotechnology

20.7.     Dietmar Katinger, Chief Executive Officer, Polymun Scientific

20.8.     Denis Angioletti, Chief Commercial Officer, Cerbios-Pharma

20.9.     Jeffrey Hung, Chief Commercial Officer, Vigene Biosciences

20.10.   Kevin Daley, Director Pharmaceuticals, Novasep

20.11.   Mark Wright, Site Head, Grangemouth, Piramal Healthcare

20.12.   Nicolas Grandchamp, R&D Leader, GEG Tech

20.13.   Raquel Fortunato, Chief Executive Officer, GenIbet Biopharmaceuticals

20.14.   Sebastian Schuck, Head of Business Development, Wacker Biotech

20.15.   Stephen Taylor, Senior Vice President Commercial, FUJIFILM Diosynth Biotechnologies

20.16.   Tatjana Buchholz, Marketing Manager, PlasmidFactory and Marco Schmeer, Project Manager, Plasmid Factory

20.17.  Tim Oldham, Chief Executive Officer, Cell Therapies

 

  1. APPENDIX 1: LIST OF NON-INDUSTRY PLAYERS

 

  1. APPENDIX 2: TABULATED DATA

 

  1. APPENDIX 3: LIST OF COMPANIES AND ORGANIZATIONS

 

 

Contact Details

 

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com

 

About 75 drug candidates based on synlet gene pairs are being evaluated for the treatment of various types of cancers; presently, there are over 20 screening platforms enabling therapy development efforts


Submitted 103 day(s) ago by Harry sins

 

 

Advances in screening technologies have enabled the identification of interactive gene combinations, enabling the development of lead candidates that leverage the principle of synthetic lethality for cancer treatment

 

To order this 485+ page report, which features 195+ figures and 200+ tables, please visit this link

 

The USD 8 billion (by 2030) financial opportunity within the synthetic lethality-based drugs and targets market has been analyzed across the following segments:

  • Type of molecule
  • Small Molecule
  • Biologic

 

  • Target disease indication
  • Breast Cancer
  • Colorectal Cancer
  • Fallopian Tube Cancer
  • Gastric Cancer
  • Head and Neck Cancer
  • Lung Cancer
  • Ovarian Cancer
  • Peritoneal Cancer
  • Others

 

  • Type of synlet target
  • APE1 / Ref-1
  • Chk1
  • GLS1
  • PARP
  • Pol θ
  • PP2A
  • Wee1

 

  • Route of administration
  • Oral
  • Intravenous

 

  • Key geographical regions
  • North America
  • Europe
  • Asia Pacific
  • Rest of the World

 

The https://www.rootsanalysis.com/reports/view_document/synthetic-lethality-based-drugs-and-targets-market-2019-2030-focus-on-dna-repair-including-parp-inhibitors-and-other-novel-cellular-pathways/267.html, report features the following companies, which we identified to be key players in this domain:

  • AbbVie
  • AstraZeneca
  • AtlasMedx
  • BeiGene
  • Chordia Therapeutics
  • Clovis Oncology
  • GlaxoSmithKline
  • IDEAYA Biosciences
  • Mission Therapeutics
  • Pfizer
  • Repare Therapeutics
  • Sierra Oncology
  • SyntheX Labs

 

Table of Contents

 

  1. Preface

    2. Executive Summary

  2. Introduction to DNA Damage and Repair Systems

  3. Introduction to Synthetic Lethality

  4. Market Overview

  5. Company Profiles

  6. Emerging Trends on Social Media

  7. Publication Analysis

  8. Abstract Analysis

  9. Academic Grants Analysis

  10. Funding and Investment Analysis

  11. Target Benchmark Analysis

 

  1. Role of Companion Diagnostics in Synthetic Lethality

 

  1. Market Forecast

  2. Concluding Remarks

  3. Executive Insights

 

  1. Appendix 1: Tabulated Data

 

  1. Appendix 2: List of Companies and Organizations

 

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/synthetic-lethality-based-drugs-and-targets-market-2019-2030-focus-on-dna-repair-including-parp-inhibitors-and-other-novel-cellular-pathways/267.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com

 

The synthetic lethality-based drugs and targets market is projected to grow at an annualized rate of ~18%, till 2030


Submitted 103 day(s) ago by Harry sins

 

 

Roots Analysis has done a detailed study on “Synthetic Lethality-based Drugs and Targets Market, 2019-2030: Focus on DNA Repair (including PARP Inhibitors) and Other Novel Cellular Pathways” covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

 

To order this 485+ page report, which features 195+ figures and 200+ tables, please visit this link

 

Key Market Insights

  • An analysis of recent activity on Twitter confirms the rising interest in this domain as stakeholders attempt to harness the therapeutic potential of synthetic lethality
  • About 75 drug candidates based on synlet gene pairs are being evaluated for the treatment of various types of cancers; presently, there are over 20 screening platforms enabling therapy development efforts
  • The pipeline features both small molecules and biologic drugs based on different synlet targets for treating a variety of oncological and non-oncological indications
  • Innovation in this domain is evident across the plethora of scientific articles published in prestigious journals, highlighting key focus areas and prevalent / upcoming trends
  • Over time, several non-profit organizations have extended financial support to aid research efforts in this domain; the current focus appears to be on the identification of novel synlet targets across different clinical conditions
  • Significant advances in research have led to the discovery of a wide array of synlet targets; over time, substantial intellectual capital has been generated and validated by eminent scientists from renowned research institutes
  • To support innovation, several private and public investors have made substantial capital investments, totalling to approximately USD 5.1 billion, across 100 instances of funding
  • The personalized approach offered by companion diagnostics presents enormous opportunities for drug developers to partner with diagnostic test providers to improve patient / subject selection in clinical trials
  • Future growth of the market is likely to be driven by the success of clinical outcomes of late-stage molecules; industry stakeholders are optimistic about the vast potential of PARP inhibitors
  • In the mid to long term, the anticipated market opportunity is likely to be well distributed across advanced cancer indications, delivery routes and various global regions

 

For more information, please visit https://www.rootsanalysis.com/reports/view_document/synthetic-lethality-based-drugs-and-targets-market-2019-2030-focus-on-dna-repair-including-parp-inhibitors-and-other-novel-cellular-pathways/267.html

 

Table of Contents

 

  1. PREFACE

1.1.                  Scope of the Report

1.2.                  Research Methodology

1.3.                  Chapter Outlines

 

  1. EXECUTIVE SUMMARY

 

  1. INTRODUCTION TO DNA DAMAGE AND REPAIR SYSTEMS

3.1.                  Chapter Overview

3.2.                  Overview of Deoxyribonucleic Acid (DNA) Damage

3.3.                  DNA Damaging Agents

3.3.1.                Endogenous DNA Damaging Agents

3.3.2.                Exogenous DNA Damaging Agents

3.3.3.                Other DNA Damaging Agents

3.4.                  DNA Damage Response System

3.4.1.                Key Components of DNA Repair System

 

3.5.                  Types of DNA Repair Systems

3.5.1.                Direct Repair

3.5.1.1.             Photoreactivation

3.5.1.2.             Alkyl Transferase Mediated Direct DNA Repair

3.5.1.3.             AlkB Mediated Direct DNA Repair

3.5.1.4.             DNA Ligase Mediated Direct DNA Repair

 

3.5.2.                Excision Repair

3.5.2.1.             Base Excision Repair (BER)

3.5.2.1.1.          BER Pathway: Key Enzymes

3.5.2.1.1.1.       DNA Glycosylases

3.5.2.1.1.2.       Apurinic / Apyrimidinic (AP) Endonucleases

3.5.2.1.1.3.       Other Enzymes

3.5.2.1.2.          Short-Patch Base Excision Repair

3.5.2.1.3.          Long-Patch Base Excision Repair

3.5.2.2.             Nucleotide Excision Repair (NER)

3.5.2.3.             Mismatch Repair

 

3.5.3.                Indirect Repair

3.5.3.1.             Homologous Recombination Repair (HRR)

3.5.3.2.             Non-Homologous End-Joining

 

3.6.                  Mutations in DNA Repair Genes

 

  1. INTRODUCTION TO SYNTHETIC LETHALITY

4.1.                  Chapter Overview

4.2.                  Concept of Synthetic Lethality

4.2.1.                Historical Evolution of Synthetic Lethality

4.2.2.                HRR and Synthetic Lethality

4.2.3.                Other Synthetic Lethal Gene Interactions

4.2.4.                Advantages of Synthetic Lethality

4.2.5.                Limitations of Synthetic Lethality

 

4.3.                  Identification of Synlet Interactions

4.3.1.                Hypothesis-Driven Approach

4.3.2.                Screening-Based Approaches

4.3.2.1.             Chemical Library-Based Screening Approaches

4.3.2.1.1.          Non-Annotated Libraries

4.3.2.1.2.          Annotated Libraries

4.3.2.2.             Genome-Wide Interference-Based Screening Approaches

4.3.2.2.1.          Ribonucleic Acid Interference (RNAi) Based Synlet Target Identification

4.3.2.2.2.          Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Based                                     Synlet Target Identification

4.3.3.                In Silico Approaches

 

4.4.                  Prevalent Trends Related to Synthetic Lethality

4.4.1.                Recent News on Google: Emerging Focus Areas

4.4.2.                Google Trends Analysis: Historical Timeline

4.4.3.                Google Trends Analysis: Geographical Activity

4.4.4.                Google Trends Analysis: Other Key Terms Related to Synthetic Lethality

 

4.5                   Concluding Remarks

 

  1. MARKET OVERVIEW

5.1.                  Chapter Overview

5.2.                  Synthetic Lethality-based Drugs: Marketed and Development Pipeline

5.2.1.                Analysis by Phase of Development

5.2.2.                Analysis by Type of Molecule

5.2.3.                Analysis by Type of Therapy

5.2.4.                Analysis by Type of Synlet Target

5.2.5.                Analysis by Therapeutic Area

5.2.6.                Analysis by Target Indication

5.2.7.                Analysis by Patient Segment

5.2.8.                Analysis by Route of Administration

 

5.3.                  Synthetic Lethality-based Drugs: List of Screening Platforms

5.4                   Synthetic Lethality-based Drugs: List of Drug Developers / Screening Platform Providers

5.4.1.                Analysis by Year of Establishment

5.4.2.                Analysis by Location of Headquarters

5.4.3.                Analysis by Company Size

5.4.4.                Analysis by Company Size and Location of Headquarters

5.4.5.                Leading Drug Developers

 

  1. COMPANY PROFILES

6.1.                  Chapter Overview

6.2.                  Profiles of Established Players

6.2.1.                AbbVie

6.2.1.1.             Company Overview

6.2.1.2.             Synthetic Lethality-based Drug Portfolio

6.2.1.2.1.          Veliparib (ABT-888)

6.2.1.3.             Recent Developments and Future Outlook

 

6.2.2.                AstraZeneca

6.2.2.1.             Company Overview

6.2.2.2.             Synthetic Lethality-based Drug Portfolio

6.2.2.2.1.          Olaparib (Lynparza®)

6.2.2.2.2.          AZD6738

6.2.2.2.3.          AZD1775

6.2.2.3.             Recent Developments and Future Outlook

 

6.2.3.                BeiGene

6.2.3.1.             Company Overview

6.2.3.2.             Synthetic Lethality-based Drug Portfolio

6.2.3.2.1.          Pamiparib (BGB-290)

6.2.3.3.             Recent Developments and Future Outlook

 

6.2.4.                Clovis Oncology

6.2.4.1.             Company Overview

6.2.4.2.             Synthetic Lethality-based Drug Portfolio

6.2.4.2.1.          Rucaparib (Rubraca®)

6.2.4.3.             Recent Developments and Future Outlook

 

6.2.5.                GlaxoSmithKline

6.2.5.1.             Company Overview

6.2.5.2.             Synthetic Lethality-based Drug Portfolio

6.2.5.2.1.          Niraparib (Zejula®)

6.2.5.3.             Recent Developments and Future Outlook

 

6.2.6.                Pfizer

6.2.6.1.             Company Overview

6.2.6.2.             Synthetic Lethality-based Drug Portfolio

6.2.6.2.1.          Talazoparib (TALZENNA®)

6.2.6.3.             Recent Developments and Future Outlook

 

6.3.                  Profiles of Small and Mid-Sized Players

6.3.1.                AtlasMedx

6.3.2.                Chordia Therapeutics

6.3.3.                IDEAYA Biosciences

6.3.4.                Mission Therapeutics

6.3.5.                Repare Therapeutics

6.3.6.                Sierra Oncology

6.3.7.                SyntheX Labs

 

  1. EMERGING TRENDS ON SOCIAL MEDIA

7.1.                  Chapter Overview

7.2.                  Scope and Methodology

7.3.                  Synthetic Lethality: Trends on Twitter

7.3.1.                Cumulative Year-Wise Activity

7.3.2.                Historical Trends in Volume of Tweets

7.3.3.                Evolutionary Trend Analysis

7.3.4.                Trending Words / Phrases on Twitter

7.3.5.                Most Prolific Contributors on Twitter

7.3.6.                Most Popular Synlet Targets / Patient Mutations on Twitter

7.3.7.                Most Popular Indications on Twitter

7.3.8.                Heat Map Analysis: Distribution by Synlet Targets / Patient Mutations and                                     Indications

 

7.4.                  Most Popular Tweets

7.5.                  Concluding Remarks

 

  1. PUBLICATION ANALYSIS

8.1.                  Chapter Overview

8.2.                  Scope and Methodology

 

8.3.                  Synthetic Lethality: List of Recent Publications, 2019

8.3.1.                Analysis by Type of Publication

8.3.2.                Analysis by Study Objective

 

8.4.                  Synthetic Lethality: Publication Analysis, 2017–2019

8.4.1.                Analysis by Year of Publication

 

8.4.2.                Emerging Focus Areas

8.4.3.                Analysis by Synlet Targets / Patient Mutations

8.4.3.1.             Most Popular Synlet Targets / Patient Mutations

8.4.3.2.             Year-Wise Trend in Activity for Popular Synlet Targets / Patient Mutations

8.4.4.                Analysis by Target Indications

8.4.4.1.             Most Popular Target Indications

8.4.4.2.             Year-Wise Trend in Activity for Popular Target Indications

 

8.4.5.                Analysis by Key Research Journals

8.4.5.1.             Key Journals Based on Number of Publications

8.4.5.2.             Analysis by Journal Impact Factor

8.4.5.3.             Key Journals Based on Journal Impact Factor

 

8.4.6.                Key Research Hubs

8.4.7.                Most Popular Authors

 

8.4.8.                Analysis of Publications with Grant Support

8.4.8.1.             Most Popular Grant Bodies

8.4.8.2.             Location of Grant Bodies

 

8.5.                  Publication Benchmark Analysis

 

  1. ABSTRACT ANALYSIS

9.1.                  Chapter Overview

9.2.                  Scope and Methodology

 

9.3.                  Synthetic Lethality: List of American Society of Clinical Oncology Abstracts

9.3.1.                Analysis by Year of Publication

9.3.2.                Emerging Focus Areas

9.3.3.                Most Popular Drugs

9.3.4.                Most Popular Synlet Targets / Patient Mutations

9.3.5.                Most Popular Target Indications

9.3.6.                Most Popular Principal Authors

9.3.6.1.             Analysis by Locations of Principal Authors

9.3.6.2.             Analysis by Type of Organization of Principal Authors

9.3.6.3.             Analysis by Active Organization

9.3.6.4.             Analysis by Author Designation

9.3.6.5.             Most Popular Authors

           

  1. ACADEMIC GRANTS ANALYSIS

10.1.                 Chapter Overview

10.2.                 Scope and Methodology

 

10.3.                 Synthetic Lethality: List of Grants Awarded by National Institutes of Health

10.3.1.              Analysis by Year of Award

10.3.2.              Analysis by Amount Awarded

10.3.3.              Analysis by Administering Institute Center

10.3.4.              Analysis by Funding Institute Center

10.3.5.              Analysis by Support Period

10.3.6.              Analysis by Funding Institute Center and Support Period

10.3.7.              Most Popular National Institute of Health (NIH) Funding Categorization

10.3.8.              Analysis by Funding Mechanism

10.3.9.              Analysis by Emerging Focus Areas

10.3.10.            Most Popular Synlet Targets / Patient Mutations

10.3.11.            Most Popular Target Indications

10.3.12.            Analysis by Type of Grant Application

10.3.13.            Most Popular NIH Departments

10.3.14.            Analysis by Study Section

10.3.15.            Analysis by Type of Recipient Organization

10.3.16.            Most Popular Recipient Organization

10.3.17.            Most Popular Recipient Organization and NIH Spending Sectors

10.3.18.            Analysis by Grant Activity

10.3.19.            Most Prominent Program Officers

10.3.20.            Regional Distribution of Recipient Organization

 

10.4.                 Grant Attractiveness Analysis

 

  1. FUNDING AND INVESTMENT ANALYSIS

11.1.                 Chapter Overview

11.2.                 Types of Funding

 

11.3.                 Synthetic Lethality: List of Funding and Investments

11.3.1.              Analysis by Number of Instances

11.3.2.              Analysis by Amount Invested

11.3.3.              Analysis by Type of Funding

11.3.4.              Analysis by Type of Company

11.3.5.              Analysis by Purpose of Funding

11.3.6.              Analysis by Type of Molecule

11.3.7.              Analysis by Synlet Target

11.3.8.              Analysis by Therapeutic Area

11.3.9.              Analysis by Target Indication

11.3.10.            Analysis by Geography

11.3.11.            Most Active Players

11.3.12.            Most Active Investors

 

11.4.                 Concluding Remarks

 

  1. TARGET BENCHMARK ANALYSIS

12.1.                 Chapter Overview

12.2.                 Scope and Methodology

12.3.                 Target Benchmark Analysis

12.3.1.              Clinically Validated Synlet Targets

12.3.2.              Preclinically Validated Synlet Targets

12.3.3.              Early Stage Research Validated Synlet Targets

12.4.                 Initiatives of Big Pharmaceutical Players

12.5.                 Concluding Remarks

 

  1. ROLE OF COMPANION DIAGNOSTICS IN SYNTHETIC LETHALITY

13.1.                 Chapter Overview

13.2.                 Concept of Companion Diagnostics

13.3.                 Development of Companion Diagnostics

13.3.1.              Co-development / Parallel Development Approach

13.3.2.              Development of Companion Diagnostics Post Drug Approval

13.3.3.              Development of already Approved Companion Diagnostics for New Drugs / Disease                        Indications

 

13.4.                 Advantages of Companion Diagnostics

13.5.                 Applications of Companion Diagnostics in Synthetic Lethality

 

13.6.                 Companion Diagnostics: List of Available / Under Development Tests

13.6.1.              Analysis by Synlet Target

13.6.2.              Analysis by Type of Biomarker

13.6.3.              Analysis by Type of Biomarker and Technology

13.6.4.              Analysis by Target Indication

13.6.5.              Analysis by Developer and Synlet Target

13.6.6.              Most Prominent Developers

 

13.7.                 Case-in-Point: Companion Diagnostics for Commercially Available Poly-ADP Ribose              Polymerase (PARP) Inhibitors

13.7.1.              Companion Diagnostics Test for Niraparib

13.7.1.1.           Product Overview

13.7.1.2.           Working Process

13.7.1.3.           Collaborations

 

13.7.2.              Companion Diagnostics Test for Olaparib

13.7.2.1.           Product Overview

13.7.2.2.           Working Process

13.7.2.3.           Collaborations

 

13.7.3.              Companion Diagnostics Test for Rucaparib

13.7.3.1.           Product Overview

13.7.3.2.           Collaborations

 

13.7.4.              Companion Diagnostics Test for Talazoparib

13.7.4.1.           Product Overview

13.7.4.2.           Collaborations

 

13.8.                 Future Perspective

 

  1. MARKET FORECAST

14.1.                 Chapter Overview

14.2.                 Scope and Limitations

14.3.                 Forecast Methodology and Key Assumptions

 

14.4.                 Overall Synthetic Lethality-based Drugs Market, 2019-2030

14.4.1.              Synthetic Lethality-based Drugs Market: Distribution by Type of Molecule, 2019 and 2030

14.4.1.1.           Synthetic Lethality-based Drugs Market for Small Molecule, 2019-2030

14.4.1.2.           Synthetic Lethality-based Drugs Market for Biologic, 2019-2030

 

14.4.2.              Synthetic Lethality-based Drugs Market: Distribution by Synlet Target, 2019 and 2030

14.4.2.1.           Synthetic Lethality-based Drugs Market for APE1 / REF-1, 2019-2030

14.4.2.2.           Synthetic Lethality-based Drugs Market for CHK1, 2019-2030

14.4.2.3.           Synthetic Lethality-based Drugs Market for GLS1, 2019-2030

14.4.2.4.           Synthetic Lethality-based Drugs Market for PARP, 2019-2030

14.4.2.5.           Synthetic Lethality-based Drugs Market for Polθ, 2019-2030

14.4.2.6.           Synthetic Lethality-based Drugs Market for WEE1, 2019-2030

 

14.4.3.              Synthetic Lethality-based Drugs Market: Distribution by Target Indication, 2019 and 2030

14.4.3.1.           Synthetic Lethality-based Drugs Market for Breast Cancer, 2019-2030

14.4.3.2.           Synthetic Lethality-based Drugs Market for Cervical / Anogenital Cancer, 2019-2030

14.4.3.3.           Synthetic Lethality-based Drugs Market for Diabetic Macular Edema, 2019-2030

14.4.3.4.           Synthetic Lethality-based Drugs Market for Gastric Cancer, 2019-2030

14.4.3.5.           Synthetic Lethality-based Drugs Market for Lung Cancer, 2019-2030

14.4.3.5.           Synthetic Lethality-based Drugs Market for Ovarian Cancer, 2019-2030

14.4.3.7.           Synthetic Lethality-based Drugs Market for Renal Cell Cancer, 2019-2030

 

14.4.4.              Synthetic Lethality-based Drugs Market: Distribution by Route of Administration, 2019                  and 2030

14.4.4.1.           Synthetic Lethality-based Drugs Market for Oral Therapies, 2019-2030

14.4.4.2.           Synthetic Lethality-based Drugs Market for Intravenous Therapies, 2019-2030

 

14.4.5.              Synthetic Lethality-based Drugs Market: Distribution by Geography, 2019 and 2030

14.4.5.1.           Synthetic Lethality-based Drugs Market in the US, 2019-2030

14.4.5.2.           Synthetic Lethality-based Drugs Market in France, 2019-2030

14.4.5.3.           Synthetic Lethality-based Drugs Market in Germany, 2019-2030

14.4.5.4.           Synthetic Lethality-based Drugs Market in Italy, 2019-2030

14.4.5.5.           Synthetic Lethality-based Drugs Market in Spain, 2019-2030

14.4.5.6.           Synthetic Lethality-based Drugs Market in the UK, 2019-2030

14.4.5.8.           Synthetic Lethality-based Drugs Market in Australia, 2019-2030

14.4.5.7.           Synthetic Lethality-based Drugs Market in China, 2019-2030

14.4.5.8.           Synthetic Lethality-based Drugs Market in Japan, 2019-2030

 

14.4.6.              Product-wise Sales Forecast

14.4.6.1            Niraparib (GlaxoSmithKline)

14.4.6.1.1.        Target Patient Population

14.4.6.1.2.        Sales Forecast (USD Million)

14.4.6.1.3.        Net Present Value (USD Million)

14.4.6.1.4.        Value Creation Analysis

 

14.4.6.2.           Olaparib (AstraZeneca)

14.4.6.2.1.        Target Patient Population

14.4.6.2.2.        Sales Forecast (USD Million)

14.4.6.2.3.        Net Present Value (USD Million)

14.4.6.2.4.        Value Creation Analysis

 

14.4.6.3.           Rucaparib (Clovis Oncology)

14.4.6.3.1.        Target Patient Population

14.4.6.3.2.        Sales Forecast (USD Million)

14.4.6.3.3.        Net Present Value (USD Million)

14.4.6.3.4.        Value Creation Analysis

 

14.4.6.4.           Talazoparib (Pfizer)

14.4.6.4.1.        Target Patient Population

14.4.6.4.2.        Sales Forecast (USD Million)

14.4.6.4.3.        Net Present Value (USD Million)

14.4.6.4.4.        Value Creation Analysis

 

14.4.6.5.           Pamiparib (BeiGene)

14.4.6.5.1.        Target Patient Population

14.4.6.5.2.        Sales Forecast (USD Million)

14.4.6.5.3.        Net Present Value (USD Million)

14.4.6.5.4.        Value Creation Analysis

 

14.4.6.6.           Veliparib (AbbVie)

14.4.6.6.1.        Target Patient Population

14.4.6.6.2.        Sales Forecast (USD Million)

14.4.6.6.3.        Net Present Value (USD Million)

14.4.6.6.4.        Value Creation Analysis

 

14.4.6.7.           Adavosertib (AstraZeneca)

14.4.6.7.1.        Target Patient Population

14.4.6.7.2.        Sales Forecast (USD Million)

14.4.6.7.3.        Net Present Value (USD Million)

14.4.6.7.4.        Value Creation Analysis

 

14.4.6.8.           APX3330 (Apexian Pharmaceuticals)

14.4.6.8.1.        Target Patient Population

14.4.6.8.2.        Sales Forecast (USD Million)

14.4.6.8.3.        Net Present Value (USD Million)

14.4.6.8.4.        Value Creation Analysis

 

14.4.6.9.           CX-5461 (Senhwa Biosciences)

14.4.6.9.1.        Target Patient Population

14.4.6.9.2.        Sales Forecast (USD Million)

14.4.6.9.3.        Net Present Value (USD Million)

14.4.6.9.4.        Value Creation Analysis

 

14.4.6.10.         SRA737-01 (Sierra Oncology)

14.4.6.10.1.      Target Patient Population

14.4.6.10.2.      Sales Forecast (USD Million)

14.4.6.10.3.      Net Present Value (USD Million)

14.4.6.10.4.      Value Creation Analysis

 

14.4.6.11.         SRA737-02 (Sierra Oncology)

14.4.6.11.1.      Target Patient Population

14.4.6.11.2.      Sales Forecast (USD Million)

14.4.6.11.3.      Net Present Value (USD Million)

14.4.6.11.4.      Value Creation Analysis

 

14.4.6.12.         Telaglenastat (Calithera Biosciences)

14.4.6.12.1.      Target Patient Population

14.4.6.12.2.      Sales Forecast (USD Million)

14.4.6.12.3.      Net Present Value (USD Million)

14.4.6.12.4.      Value Creation Analysis

 

14.4.7.              Concluding Remarks

 

  1. CONCLUDING REMARKS

 

  1. EXECUTIVE INSIGHTS

16.1.                 Chapter Overview

16.2.                 Artios Pharma

16.2.1.              Company / Organization Snapshot

16.2.2.              Interview Transcript: Simon Boulton, Vice President, Science Strategy

 

16.3.                 IMPACT Therapeutics

16.3.1.              Company / Organization Snapshot

16.3.2.              Interview Transcript: Yi Xu, Associate Director

 

16.4.                 Harvard Medical School

16.4.1.              Company / Organization Snapshot

16.4.2.              Interview Transcript: Norbert Perrimon, Professor, Department of Genetics

 

16.5.                 Panjab University

16.5.1.              Company / Organization Snapshot

16.5.2.              Interview Transcript: Vivek Dharwal, Professor, Department of Biochemistry

 

16.6.                 UbiQ

16.6.1.              Company / Organization Snapshot

16.6.2.              Interview Transcript: Alfred Nijkerk, Chief Executive Officer

 

  1. APPENDIX 1: TABULATED DATA

 

  1. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com

 

More than 100 subcutaneous biologics have been approved and over 350 such drug candidates are being evaluated in the clinical stages of development, for the treatment of a wide variety of disease indications, claims Roots Analysis


Submitted 103 day(s) ago by Harry sins

 

Several approved therapeutic products, which are currently available as intravenous dosage forms, are being reformulated and evaluated for subcutaneous administration. Further, many existing drug delivery devices, including prefilled syringes, pen injectors, autoinjectors, needle-free injectors and large volume wearable injectors, have been / are being designed for subcutaneous administration of biologics.

 

To order this 530+ page report, which features 160+ figures and 190+ tables, please visit this link

 

The USD 180+ billion (by 2030) financial opportunity associated with subcutaneous biologics, affiliated drug delivery systems and subcutaneous formulation technology licensing deals, has been analyzed across the following segments:

  • Phase of development
  • Approved
  • Pre-registration & Phase III
  • Phase II & Phase II/III

 

  • Type of molecule
  • Cell and gene therapies
  • Monoclonal antibodies
  • Proteins
  • Peptides (recombinant)
  • Vaccines
  • Others

 

  • Target therapeutic area
  • Autoimmune disorders
  • Blood disorders
  • Bone disorders
  • Genetic disorders
  • Metabolic disorders
  • Neurological disorders
  • Oncological disorders
  • Respiratory disorders
  • Others

 

  • Type of drug delivery system
  • Large volume wearable injectors
  • Autoinjectors
  • Prefilled syringes
  • Needle-free injectors
  • Drug reconstitution systems

 

  • Revenues from licensing deals
  • Upfront payments
  • Milestone payments

 

  • Key geographical regions
  • North America
  • Europe
  • Asia Pacific
  • Rest of the World

 

The Subcutaneous Biologics, Technologies and Drug Delivery Systems (3rd Edition), 2020-2030 report features the following companies, which we identified to be key players in this domain:

  • Adocia
  • Ajinomoto Bio-Pharma Services
  • Arecor
  • Alteogen
  • Ascendis Pharma
  • Avadel Pharmaceuticals
  • Camurus
  • Creative BioMart
  • Creative Biolabs
  • DURECT
  • Eagle Pharmaceuticals
  • Halozyme Therapeutics
  • MedinCell
  • Xeris Pharmaceuticals
  • Serina Therapeutics

 

Table of Contents

  1. Preface

 

  1. Executive Summary

 

  1. Introduction

 

  1. Subcutaneous Biologics: Current Market Landscape

 

  1. Case Study: Leading Subcutaneous Biologics

 

  1. Subcutaneous Formulation Technologies: Current Market Landscape

 

  1. Subcutaneous Formulation Technology Developers: Company Competitiveness Analysis

 

  1. Subcutaneous Formulation Technology Developers: Company Profiles

 

  1. Partnerships and Collaborations

 

  1. Subcutaneous Drug Delivery Systems: Current Market Landscape

 

  1. Swot Analysis

 

  1. Market Forecast and Opportunity Analysis

 

  1. Concluding Remarks

 

  1. Executive Insights

 

  1. Appendix 1: Tabulated Data

 

  1. Appendix 2: List Of Companies And Organization

 

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/subcutaneous-biologics-delivery/314.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

+44 (122) 391 1091

Gaurav.Chaudhary@rootsanalysis.com

 

The subcutaneous biologic drugs and affiliated technologies market is projected to be worth over USD 180 billion by 2030


Submitted 103 day(s) ago by Harry sins

 

Roots Analysis has done a detailed report on Subcutaneous Biologics, Technologies and Drug Delivery Systems (3rd Edition), 2020-2030 covering key aspects of the industry and identifying future growth opportunities

 

To order this 530+ page report, which features 160+ figures and 190+ tables, please visit this link

 

Key Market Insights

  • Eminent representatives from biopharmaceutical companies confirm the rising interest in the concept of subcutaneous drug delivery, highlighting some of the key drivers and upcoming trends in this domain
  • More than 100 subcutaneous biologics have been approved and over 350 such drug candidates are being evaluated in the clinical stages of development, for the treatment of a wide variety of disease indications
  • Antibodies and protein therapeutics represent the majority of subcutaneous biologics that are available / under investigation, designed for use against various therapeutic areas and having different dosing regimens
  • Advances in drug delivery have led to the development of novel technology platforms, enabling the administration of highly viscous formulations, and supporting the development of subcutaneous dosage forms
  • Several technology developers have out-licensed their proprietary platforms to pharmaceutical companies in order to enable them to develop subcutaneous formulations of their approved / pipeline products
  • The increasing interest in this field is reflected in the yearly growth in partnership activity, including a number of licensing and product development deals related to subcutaneous formulations of various drug candidates
  • There are several new and innovative drug delivery systems that facilitate subcutaneous administration; we identified over 300 such systems that are presently available / under development
  • With several self-medication enabling devices, such as wearable injectors and autoinjectors, available in the market, developers are actively differentiating their offerings by incorporating advanced, patient-friendly features
  • The market is anticipated to be worth over USD 180 billion in 2030; the projected opportunity is likely to be distributed across various types of molecules that are developed / being developed for different disease indications
  • Pre-filled syringes continue to dominate the current market of subcutaneous drug delivery systems; technology developers are expected to continue relying on licensing agreements as their primary source of revenues333

 

For more information, please visit https://www.rootsanalysis.com/reports/view_document/subcutaneous-biologics-delivery/314.html or email sales@rootsanalysis.com

 

Table of Contents

 

  1. PREFACE

1.1.                  Scope of the Report

1.2.                  Research Methodology

1.3.                  Chapter Outlines

 

  1. EXECUTIVE SUMMARY

 

  1. INTRODUCTION

3.1.                  Chapter Overview

3.2.                  Types of Therapeutic Molecules

3.3.                  Biologically Derived Therapeutics

3.3.1.                Types of Products

3.3.2.                Routes of Administration and Formulations

3.3.3.                Subcutaneous Formulations

3.3.3.1.             Approaches in Subcutaneous Delivery of Biologics

3.3.3.1.1.          Reformulation

3.3.3.1.2.          Differing Potencies

3.3.3.1.3.          Novel Technologies

           

3.3.3.2.             Method of Subcutaneous Administration

3.3.3.3.             Advantages of Subcutaneous Administration

3.3.3.4.             Limitations of Subcutaneous Administration

 

3.4.                  Regulatory Considerations

3.4.1.                Medical Devices

3.4.2.                Drug Device Combination Products

 

3.5.                  Future Perspectives

 

  1. SUBCUTANEOUS BIOLOGICS: CURRENT MARKET LANDSCAPE

4.1.                  Chapter Overview

4.2.                  Subcutaneous Administration of Biologics

4.3.                  Subcutaneous Biologics: List of Approved Drugs

4.3.1.                Analysis by Approval Year

4.3.2.                Analysis by Type of Pharmacological Molecule

4.3.3.                Analysis by Target Therapeutic Area

4.3.4.                Analysis by Type of Formulation

4.3.5.                Analysis by Dosing Frequency

4.3.6.                Analysis by Dosage Form

4.3.7.                Key Players: Analysis by Number of Drugs Approved

 

4.4.                  Subcutaneous Biologics: List of Clinical-Stage Drug Candidates

4.4.1.                Analysis by Phase of Development

4.4.2.                Analysis by Type of Pharmacological Molecule

4.4.3.                Analysis by Target Therapeutic Area

4.4.4.                Analysis by Dosing Frequency

4.4.5.                Key Players: Analysis by Number of Drug Candidates in Trials

 

  1. CASE STUDY: LEADING SUBCUTANEOUS BIOLOGICS

5.1.                  Chapter Overview

5.2.                  Subcutaneous Biologics: Leading Drugs by Annual Sales

 

5.3.                  Case Studies

5.3.1.                HUMIRA® (AbbVie, Eisai)

5.3.1.1.             Drug Overview

  1. 3.1.2. Development History
  2. 3.1.3. Target Indications and Dosage Forms
  3. 3.1.4. Historical Sales

 

5.3.2.                Enbrel® (Amgen, Pfizer, Takeda Pharmaceutical)

5.3.2.1.             Overview

  1. 3.2.2. Development History
  2. 3.2.3. Target Indications and Dosage Forms
  3. 3.2.4. Historical Sales

 

5.3.3.                RITUXAN® / MabThera® (Biogen, Roche, Chugai Pharmaceutical)

5.3.3.1.             Overview

  1. 3.3.2. Development History
  2. 3.3.3. Target Indications and Dosage Forms
  3. 3.3.4. Historical Sales
  4. 3.3.5. ENHANZE™ Technology (Halozyme Therapeutics)
  5. 3.3.6. Advantages of Subcutaneous RITUXAN® / MabThera® Over Intravenous RITUXAN® / MabThera®

 

5.3.4.                Herceptin® (Roche, Chugai Pharmaceutical)

5.3.4.1.             Overview

  1. 3.4.2. Development History
  2. 3.4.3. Target Indications and Dosage Forms
  3. 3.4.4. Historical Sales
  4. 3.4.5. ENHANZE™ Technology (Halozyme Therapeutics)
  5. 3.4.6. Advantages of Subcutaneous Herceptin® Over Intravenous Herceptin®
  6. 3.4.7. Herceptin® - Large Volume Wearable Injector Combination Product

 

5.3.5.                Neulasta® (Amgen, Kyowa Hakko Kirin)

5.3.5.1.             Overview

5.3.5.2.             Development History

5.3.5.3.             Target Indications and Dosage Forms

5.3.5.4.             Historical Sales

 

  1. SUBCUTANEOUS FORMULATION TECHNOLOGIES: CURRENT MARKET LANDSCAPE

6.1.                  Chapter Overview

6.2.                  Subcutaneous Formulation Technologies: List of Technology Developers

6.2.1.                Analysis by Year of Establishment

6.2.2.                Analysis by Company Size

6.2.3.                Analysis by Geographical Location

6.3.                  Subcutaneous Formulation Technologies: List of Technologies

6.3.1.                Analysis by Type of Pharmacological Molecule

6.3.2.                Analysis by Route of Administration

6.3.3.                Analysis by Advantage(s) Offered

 

  1. SUBCUTANEOUS FORMULATION TECHNOLOGY DEVELOPERS: COMPANY COMPETITIVENESS ANALYSIS

7.1.                  Chapter Overview

7.2.                  Subcutaneous Formulation Technology Developers: Competitive Landscape

7.2.1.                Methodology

7.2.2.                Three-Dimensional Bubble Analysis based on Supplier Power, Pipeline Strength and Primary Advantage(s)

 

7.3.                  Subcutaneous Formulation Technology Developers: Benchmark Analysis

7.3.1.                Methodology

7.3.2.                North America

7.3.3.                Europe

 

  1. SUBCUTANEOUS FORMULATION TECHNOLOGY DEVELOPERS: COMPANY PROFILES

8.1.                  Chapter Overview

8.2.                  Adocia

8.2.1.                Company Overview

8.2.2.                Technology Overview

8.2.2.1.             BioChaperone® Technology

8.2.3.                Product Portfolio

8.2.4.                Financial Performance

8.2.5.                Recent Developments and Future Outlook

 

8.3.                  Ajinomoto Althea

8.3.1.                Company Overview

8.3.2.                Technology Overview

8.3.2.1.             Crystalomics® Formulation Technology

8.3.3.                Product Portfolio

8.3.4.                Financial Performance

8.3.5.                Recent Developments and Future Outlook

 

8.4.                  Arecor

8.4.1.                Company Overview

8.4.2.                Technology Overview

8.4.2.1.             Arestat™ Technology

8.4.3.                Product Portfolio

8.4.4.                Recent Developments and Future Outlook

 

8.5.                  Alteogen

8.5.1.                Company Overview

8.5.2.                Technology Overview

8.5.2.1.             Hybrozyme Technology

8.5.3.                Product Portfolio

8.5.4.                Recent Developments and Future Outlook

 

8.6.                  Ascendis Pharma

8.6.1.                Company Overview

8.6.2.                Technology Overview

8.6.2.1.             TransCon Technology

8.6.3.                Product Portfolio

8.6.4.                Financial Performance

8.6.5.                Recent Developments and Future Outlook

 

8.7.                  Avadel Pharmaceuticals

8.7.1.                Company Overview

8.7.2.                Technology Overview

8.7.2.1.             Medusa™ Technology

8.7.3.                Product Portfolio

8.7.4.                Financial Performance

8.7.5.                Recent Developments and Future Outlook

 

8.8.                  Camurus

8.8.1.                Company Overview

8.8.2.                Technology Overview

8.8.2.1.             FluidCrystal® Injection Depot Technology

8.8.3.                Product Portfolio

8.8.4.                Financial Performance

8.8.5.                Recent Developments and Future Outlook

 

8.9.                  Creative BioMart

8.9.1.                Company Overview

8.9.2.                Technology Overview

8.9.2.1.             High Concentration Formulation Technology

8.9.3.                Product Portfolio

8.9.4.                Recent Developments and Future Outlook

 

8.10.                 Creative Biolabs

8.10.1.              Company Overview

8.10.2.              Technology Overview

8.10.2.1.           Long-Acting Injectable Technology

8.10.3.              Product Portfolio

8.10.4.              Recent Developments and Future Outlook

 

8.11.                 DURECT

8.11.1.              Company Overview

8.11.2.              Technology Overview

8.11.2.1.           SABER® Platform

8.11.2.2.           CLOUD™ PLATFORM

8.11.3.              Product Portfolio

8.11.4.              Financial Performance

8.11.5.              Recent Developments and Future Outlook

 

8.12.                 Eagle Pharmaceuticals

8.12.1.              Company Overview

8.12.2.              Technology Overview

8.12.2.1.           Unnamed Technology

8.12.3.              Product Portfolio

8.12.4.              Financial Performance

8.12.5.              Recent Developments and Future Outlook

 

8.13.                 Halozyme Therapeutics

8.13.1.              Company Overview

8.13.2.              Technology Overview

8.13.2.1.           ENHANZE® Technology

8.13.3.              Product Portfolio

8.13.4.              Financial Performance

8.13.5.              Recent Developments and Future Outlook

 

8.14.                 MedinCell

8.14.1.              Company Overview

8.14.2.              Technology Overview

8.14.2.1.           BEPO® Technology

8.14.3.              Product Portfolio

8.14.4.              Recent Developments and Future Outlook

 

8.15.                 Xeris Pharmaceuticals

8.15.1.              Company Overview

8.15.2.              Technology Overview

8.15.2.1.           XeriJect™ Technology

8.15.2.2.           XeriSol™ Technology

8.15.3.              Product Portfolio

8.15.4.              Recent Developments and Future Outlook

 

8.16.                 Serina Therapeutics

8.16.1.              Company Overview

8.16.2.              Technology Overview

8.16.2.1.           POZ™ Drug Delivery Technology

8.16.3.              Product Portfolio

8.16.4.              Recent Developments and Future Outlook

 

  1. PARTNERSHIPS AND COLLABORATIONS

9.1.                  Chapter Overview

9.2.                  Partnership Models

9.3.                  Subcutaneous Formulation Technologies: Partnerships and Collaborations

9.3.1.                Analysis by Year of Partnership

9.3.2.                Analysis by Type of Partnership

9.3.3.                Most Active Players: Analysis by Number of Partnerships

9.3.4.                Regional Analysis

9.3.5.                Intercontinental and Intracontinental Agreements

 

  1. SUBCUTANEOUS DRUG DELIVERY SYSTEMS: CURRENT MARKET LANDSCAPE

10.1.                 Chapter Overview

10.2.                 Different Types of Subcutaneous Drug Delivery Systems

10.3.                 Subcutaneous Drug Delivery Systems: Overall Market Landscape

10.3.1.              Large Volume Wearable Injectors

10.3.1.1.           Overview

10.3.1.2.           Current Market Landscape of Devices for Non-insulin Biologics

10.3.1.2.1.        Analysis by Stage of Development

10.3.1.2.2.        Analysis by Type of Device

10.3.1.2.3.        Analysis by Type of Dose Administered

10.3.1.2.4.        Analysis by Volume / Storage Capacity

10.3.1.2.5.        Analysis by Usability

10.3.1.2.6.        Analysis by Mode of Injection

10.3.1.2.7.        Analysis by Mechanism of Action

10.3.1.2.8.        Most Active Players: Analysis by Number of Devices

10.3.1.2.9.        Product Competitiveness Analysis

 

10.3.1.3.           Current Market Landscape of Devices for Insulin

10.3.1.3.1.        Analysis by Stage of Development

10.3.1.3.2.        Analysis by Type of  Device

10.3.1.3.3.        Analysis by Volume / Storage Capacity

10.3.1.3.4.        Analysis by Usability

10.3.1.3.5.        Analysis by Availability of Integrated CGM / BGM System

10.3.1.3.6.        Most Active Players: Analysis by Number of Devices

10.3.1.3.7         Product Competitiveness Analysis

 

10.3.2.              Autoinjectors

10.3.2.1.           Overview

10.3.2.2.           Current Market Landscape

10.3.2.2.1.        Analysis by Usability

10.3.2.2.2.        Analysis by Type of Primary Container

10.3.2.2.3.        Analysis by Volume / Storage Capacity

10.3.2.2.4.        Analysis by Type of Dose

10.3.2.2.5.        Analysis by Actuation Mechanism

10.3.2.2.6.        Most Active Players: Analysis by Number of Devices

10.3.2.2.7.        Product Competitiveness Analysis

10.3.2.3.           Drug Device Combination Products

 

10.3.3.              Pen Injectors

10.3.3.1.           Overview

10.3.3.2.           Current Market Landscape

10.3.3.2.1.        Analysis by Usability

10.3.3.2.2.        Analysis by Volume / Storage Capacity

10.3.3.2.3.        Analysis by Type of Dose

10.3.3.2.4.        Most Active Players: Analysis by Number of Devices

10.3.3.3.           Drug Device Combination Products

 

10.3.4.              Needle-Free Injection Systems

10.3.4.1.           Overview

10.3.4.2.           Current Market Landscape

10.3.4.2.1.        Analysis by Stage of Development

10.3.4.2.2.        Analysis by Volume / Storage Capacity

10.3.4.2.3.        Analysis by Usability

10.3.4.2.4.        Analysis by Actuation Mechanism

10.3.4.2.5.        Most Active Players: Analysis by Number of Devices

10.3.4.2.6.        Product Competitiveness Analysis

 

10.3.5.              Drug Reconstitution Delivery Systems

10.3.5.1.           Overview

10.3.5.2.           Current Market Landscape

10.3.5.2.1.        Analysis by Usability

10.3.5.2.2.        Analysis by Type of  Device

10.3.5.2.3.        Analysis by Type of Drug Container

10.3.5.2.4.        Most Active Players: Analysis by Number of Devices

 

10.3.6.              Prefilled Syringes

10.3.6.1.           Overview

10.3.6.2.           Current Market Landscape

10.3.6.2.1.        Analysis by Barrel Fabrication Material

10.3.6.2.2.        Analysis by Number of Barrel Chambers

10.3.6.2.3.        Analysis by Type of Needle System

10.3.6.2.4.        Analysis by Volume / Storage Capacity

10.3.6.3.5.        Most Active Players: Analysis by Number of Devices

10.3.6.3.           Product Competitiveness Analysis

10.3.6.4.           Drug Device Combination Products

 

10.3.7.              Implants

10.3.7.1.           Overview

10.3.7.2.           Current Market Landscape

10.3.7.2.1.        Analysis by Stage of Development

10.3.7.2.2.        Analysis by Target Therapeutic Area

10.3.7.2.3.        Analysis by Implant Material

10.3.7.2.4.        Analysis by Treatment Duration

10.3.7.2.5.        Most Active Players: Analysis by Number of Devices

 

  1. SWOT ANALYSIS

11.1.                 Chapter Overview

11.2.                 Comparison of SWOT Factors

11.2.1.              Strengths

11.2.2.              Weaknesses

11.2.3.              Opportunities

11.2.4.              Threats

 

  1. MARKET FORECAST AND OPPORTUNITY ANALYSIS

12.1.                 Chapter Overview

12.2.                 Subcutaneous Biologics Market

12.2.1.              Forecast Methodology and Key Assumptions

12.2.2.              Overall Subcutaneous Biologics Market, 2020-2030

12.2.2.1.           Subcutaneous Biologics Market, 2020-2030:Distribution by Phase of Development

12.2.2.2.           Subcutaneous Biologics Market, 2020-2030:Distribution by Type of Pharmacological Molecule

12.2.2.3.           Subcutaneous Biologics Market, 2020-2030:Distribution by Target Therapeutic                                     Area

12.2.2.4.           Subcutaneous Biologics Market, 2020-2030:Distribution by Key Geographical                                     Regions

 

12.3.                 Subcutaneous Drug Delivery Systems Market

12.3.1.              Device Type 1: Large Volume Wearable Injectors

12.3.1.1.           Forecast Methodology and Key Assumptions

12.3.1.2.           Global Large Volume Wearable Injectors Market for Non-Insulin Drugs, 2020-2030

12.3.1.2.1.        Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device, 2020-2030

12.3.1.2.2.        Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability, 2020-2030

12.3.1.2.3.        Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Target Therapeutic Area, 2020-2030

12.3.1.2.4.        Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Key Geographical Regions, 2020-2030

 

12.3.1.3.           Global Large Volume Wearable Injectors Market for Insulin , 2020-2030

12.3.1.3.1.        Global Large Volume Wearable Injectors Market for Insulin: Distribution by Type of Device, 2020-2030

12.3.1.3.2.        Global Large Volume Wearable Injectors Market for Insulin: Distribution by Usability, 2020-2030

12.3.1.3.3.        Global Large Volume Wearable Injectors Market for Insulin: Distribution by Key Geographical Regions, 2020-2030

 

12.3.2.              Device Type 2: Autoinjectors

12.3.2.1.           Forecast Methodology and Key Assumptions

12.3.2.2.           Global Autoinjectors Market, 2020-2030

12.3.2.2.1.        Global Autoinjectors Market: Distribution by Usability, 2020-2030

12.3.2.2.2.        Global Autoinjectors Market: Distribution by Type of Pharmacological Molecule, 2020-2030

12.3.2.2.3.        Global Autoinjectors Market: Distribution by Key Geographical Regions, 2020-2030

 

12.3.3.              Device Type 3: Prefilled Syringes

12.3.3.1.           Forecast Methodology and Key Assumptions

12.3.3.2.           Global Prefilled Syringes Market, 2020-2030

12.3.3.2.1.        Global Prefilled Syringes Market: Distribution by Type of Syringe Barrel Material, 2020-2030

12.3.3.2.2.        Global Prefilled Syringes Market: Distribution by Type of Chamber System, 2020-2030

12.3.3.2.3.        Global Prefilled Syringes Market: Distribution by Type of Pharmacological Molecule, 2020-2030

12.3.3.2.4.        Global Prefilled Syringes Market: Distribution by Target Therapeutic Area, 2020-2030

12.3.3.2.5.        Global Prefilled Syringes Market: Distribution by Key Geographical Regions, 2020-2030

 

12.3.4.              Device Type 4: Needle-Free Injection Systems

12.3.4.1.           Forecast Methodology and Key Assumptions

12.3.4.2.           Global Needle-Free Injection Systems Market, 2020-2030

12.3.4.2.1.        Global Needle-Free Injection Systems Market: Distribution by Usability, 2020-2030

12.3.4.2.2.        Global Needle-Free Injection Systems Market: Distribution by Actuation Mechanism, 2020-2030

12.3.4.2.3.        Global Needle-Free Injection Systems Market: Distribution by Target Therapeutic Area, 2020-2030

12.3.4.2.4.        Global Needle-Free Injection Systems Market: Distribution by Key Geographical Regions, 2020-2030

 

12.3.5.              Device Type 5: Novel Drug Reconstitution Systems

12.3.5.1.           Forecast Methodology and Key Assumptions

12.3.5.2.           Global Novel Drug Reconstitution Systems Market, 2020-2030

 

12.4.                 Subcutaneous Formulation Technologies Market

12.4.1.              Subcutaneous Formulation Technologies Market: Distribution by Upfront and Milestone Payments, 2020-2030

 

  1. CONCLUDING REMARKS

 

  1. EXECUTIVE INSIGHTS

14.1.                 Chapter Overview

 

14.2.                 Lindy Biosciences

14.2.1.              Company Snapshot

14.2.2.              Interview Transcript: Deborah Bitterfield, Chief Executive Officer and Founder

 

14.3.                 Oval Medical Technologies

14.3.1.              Company Snapshot

14.3.2.              Interview Transcript: Matthew Young, Chief Technology Officer and Founder

 

14.4.                 Xeris Pharmaceuticals

14.4.1.              Company Snapshot

14.4.2.              Interview Transcript: Steve Prestrelski, Chief Scientific Officer and Founder; Hong Qi, Vice President, Product Development; and Scott Coleman, Sr. Scientist Formulation)

 

14.5.                 DALI Medical Devices

14.5.1.              Company Snapshot

14.5.2.              Interview Transcript: David Daily, Chief Executive Officer and Co-Founder

 

14.6.                 Excelse Bio

14.6.1.              Company Snapshot

14.6.2.              Interview Transcript: Michael Reilly, Chief Executive Officer and Co-Founder

 

14.7.                 i-novion

14.7.1.              Company Snapshot

14.7.2.              Interview Transcript: Poonam R Velagaleti, Co-Founder

 

14.8.                 Enable Injections

14.8.1.              Company Snapshot

14.8.2.              Interview Transcript: Michael Hooven, Chief Executive Officer

 

14.9.                 Immunovaccine Technologies

14.9.1.              Company Snapshot

14.9.2.              Interview Transcript: Frederic Ors, Chief Executive Officer

 

14.10.               Portal Instruments

14.10.1.            Company Snapshot

14.10.2.            Interview Transcript: Patrick Anquetil, Chief Executive Officer

 

14.11.               Elcam Medical

14.11.1.            Company Snapshot

14.11.2.            Interview Transcript: Menachem Zucker, Vice President and Chief Scientist

 

14.12.               West Pharmaceutical Services

14.12.1.            Company Snapshot

14.12.2.            Interview Transcript: Tiffany H Burke, Director, Global Communications and Graham Reynolds, Vice President and General Manager, Global Biologics

 

14.13.               MedinCell

14.13.1.            Company Snapshot

14.13.2.            Interview Transcript: David Heuzé, Communication Leader

 

  1. APPENDIX 1: TABULATED DATA

 

  1. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATION

 

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com

 

 

There is a growing body of evidence supporting the vast applicability and superiority of treatment outcomes of stem cell therapies, compared to conventional treatment options. In fact, the unmet needs within this domain have spurred the establishment of m


Submitted 104 day(s) ago by Harry sins

 

There is a growing body of evidence supporting the vast applicability and superiority of treatment outcomes of stem cell therapies, compared to conventional treatment options. In fact, the unmet needs within this domain have spurred the establishment of many start-ups in recent years. Further, recent studies suggest that mesenchymal stem cells mesenchymal stem cells can be effectively used to improve patients' resistance to the SARS-CoV-2 virus induced pneumonia leading to speedy recovery.

 

To order this 500+ page report, which features 185+ figures and 220+ tables, please visit this link

 

The USD 8.5 billion (by 2030) financial opportunity within the stem cell therapies market has been analyzed across the following segments:

  • Source of stem cell
  • Allogeneic
  • Autologous

 

  • Origin of stem cell
  • Adult
  • Embryonic

 

  • Type of stem cell
  • Hematopoietic
  • Mesenchymal
  • Progenitor
  • Others

 

  • Lineage of stem cell
  • Adipose Tissue
  • Bone Marrow
  • Cord Blood
  • Others

 

  • Route of Administration
  • Intraarticular
  • Intracoronary
  • Intramuscular
  • Intramyocardial
  • Intrathecal
  • Intravenous
  • Surgical Implantations
  • Others

 

  • Therapeutic Area
  • Autoimmune / Inflammatory Disorder
  • Cardiovascular Disorders
  • Metabolic Disorder
  • Musculoskeletal Disorders
  • Oncological Disorders
  • Neurological Disorders
  • Ophthalmic Disorders
  • Others

 

  • End Users
  • Ambulatory Surgery Centers
  • Hospitals
  • Specialty Clinics

 

  • Key Geographies
  • North America
  • Europe
  • Asia-Pacific and Rest of the World

 

The Global Stem Cells Market: Focus on Clinical Therapies, 2020–2030 (Based on Source (Allogeneic, Autologous); Origin (Adult, Embryonic); Type (Hematopoietic, Mesenchymal, Progenitor); Lineage (Amniotic Fluid, Adipose Tissue, Bone Marrow, Cardiosphere, Chondrocytes, Corneal Tissue, Cord Blood, Dental Pulp, Neural Tissue Placenta, Peripheral Blood, Stromal Cells); and Potency (Multipotent, Pluripotent)), report features the following companies, which we identified to be key players in this domain:

  • Anterogen
  • Athersys
  • CHABiotech
  • Cytopeutics
  • Hope Biosciences
  • Japan Regenerative Medicine
  • Lineage Cell Therapeutics
  • Orchard Therapeutics
  • Osiris Therapeutics
  • Pluristem Therapeutics
  • Promithera Biosciences
  • Regenexx
  • Stempeutics Research
  • SCM Life Sciences
  • TICEBA

 

Table of Contents

 

  1. Preface

    2. Executive Summary

  2. Introduction

  3. Market Landscape

  4. Company Profiles

  5. Key Therapeutic Areas

  6. Assessment of Relative Competition and Growth Opportunities

  7. Academic Grants Analysis

  8. Clinical Trail Analysis

  9. Stem Cell Manufacturing Market Landscape and KPIs for Evaluating Contract

Services Partners

  1. Stem Cell Therapy Developers and CMOs: Opportunity Assessment

  2. Key Commercialization Strategies

 

  1. Market Forecast

  2. Conclusion

  3. Executive Insights

 

  1. Appendix 1: Tabulated Data

 

  1. Appendix 2: List of Companies and Organizations

 

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/stem-cells-market/296.html/

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com

 

More than 120 industry players are engaged in evaluating the potential of over 280 stem cell therapy products for the treatment of a variety of disease indications


Submitted 104 day(s) ago by Harry sins

 

There is a growing body of evidence supporting the vast applicability and superiority of treatment outcomes of stem cell therapies, compared to conventional treatment options. In fact, the unmet needs within this domain have spurred the establishment of many start-ups in recent years. Further, recent studies suggest that mesenchymal stem cells mesenchymal stem cells can be effectively used to improve patients' resistance to the SARS-CoV-2 virus induced pneumonia leading to speedy recovery.

 

To order this 500+ page report, which features 185+ figures and 220+ tables, please visit this link

 

The USD 8.5 billion (by 2030) financial opportunity within the stem cell therapies market has been analyzed across the following segments:

  • Source of stem cell
  • Allogeneic
  • Autologous

 

  • Origin of stem cell
  • Adult
  • Embryonic

 

  • Type of stem cell
  • Hematopoietic
  • Mesenchymal
  • Progenitor
  • Others

 

  • Lineage of stem cell
  • Adipose Tissue
  • Bone Marrow
  • Cord Blood
  • Others

 

  • Route of Administration
  • Intraarticular
  • Intracoronary
  • Intramuscular
  • Intramyocardial
  • Intrathecal
  • Intravenous
  • Surgical Implantations
  • Others

 

  • Therapeutic Area
  • Autoimmune / Inflammatory Disorder
  • Cardiovascular Disorders
  • Metabolic Disorder
  • Musculoskeletal Disorders
  • Oncological Disorders
  • Neurological Disorders
  • Ophthalmic Disorders
  • Others

 

  • End Users
  • Ambulatory Surgery Centers
  • Hospitals
  • Specialty Clinics

 

  • Key Geographies
  • North America
  • Europe
  • Asia-Pacific and Rest of the World

 

The Global Stem Cells Market: Focus on Clinical Therapies, 2020–2030 (Based on Source (Allogeneic, Autologous); Origin (Adult, Embryonic); Type (Hematopoietic, Mesenchymal, Progenitor); Lineage (Amniotic Fluid, Adipose Tissue, Bone Marrow, Cardiosphere, Chondrocytes, Corneal Tissue, Cord Blood, Dental Pulp, Neural Tissue Placenta, Peripheral Blood, Stromal Cells); and Potency (Multipotent, Pluripotent)), report features the following companies, which we identified to be key players in this domain:

  • Anterogen
  • Athersys
  • CHABiotech
  • Cytopeutics
  • Hope Biosciences
  • Japan Regenerative Medicine
  • Lineage Cell Therapeutics
  • Orchard Therapeutics
  • Osiris Therapeutics
  • Pluristem Therapeutics
  • Promithera Biosciences
  • Regenexx
  • Stempeutics Research
  • SCM Life Sciences
  • TICEBA

 

Table of Contents

 

  1. Preface

    2. Executive Summary

  2. Introduction

  3. Market Landscape

  4. Company Profiles

  5. Key Therapeutic Areas

  6. Assessment of Relative Competition and Growth Opportunities

  7. Academic Grants Analysis

  8. Clinical Trail Analysis

  9. Stem Cell Manufacturing Market Landscape and KPIs for Evaluating Contract

Services Partners

  1. Stem Cell Therapy Developers and CMOs: Opportunity Assessment

  2. Key Commercialization Strategies

 

  1. Market Forecast

  2. Conclusion

  3. Executive Insights

 

  1. Appendix 1: Tabulated Data

 

  1. Appendix 2: List of Companies and Organizations

 

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/stem-cells-market/296.html/

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com

 

With multiple approved products, the field of stem cell therapies has gained substantial momentum over the last decade; several innovator companies are currently progressing their proprietary therapy candidates with cautious optimism. In fact, recent stud


Submitted 104 day(s) ago by Harry sins

 

 

Roots Analysis has done a detailed study on “Global Stem Cells Market: Focus on Clinical Therapies, 2020–2030 (Based on Source (Allogeneic, Autologous); Origin (Adult, Embryonic); Type (Hematopoietic, Mesenchymal, Progenitor); Lineage (Amniotic Fluid, Adipose Tissue, Bone Marrow, Cardiosphere, Chondrocytes, Corneal Tissue, Cord Blood, Dental Pulp, Neural Tissue Placenta, Peripheral Blood, Stromal Cells); and Potency (Multipotent, Pluripotent))” covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

 

To order this 500+ page report, which features 185+ figures and 220+ tables, please visit this link

 

Key Market Insights

  • Eminent representatives from different biopharmaceutical companies confirm the growing interest in stem cell therapy research, highlighting the prevalent and anticipated trends in ongoing R&D activities.
  • More than 120 industry players are engaged in evaluating the potential of over 280 stem cell therapy products for the treatment of a variety of disease indications.
  • The pipeline features a variety of marketed / clinical therapies being evaluated across different stages targeting various types of stem cells; these products are designed for administration via diverse routes of administration.
  • Stem cell therapies have demonstrated the applicability across over 25 unique therapeutic areas; cardiovascular, neurological, musculoskeletal and autoimmune / inflammatory disorders are presently the primary focus.
  • Several organizations have extended financial support to aid research efforts in this domain; the current focus is on the evaluation of different stem cell types across multiple clinical conditions.
  • In the last few years, over 540 clinical trials, evaluating various types of stem cell therapies in more than 52,000 patients, have been initiated; most of these trials are presently being conducted in centers across the US.
  • As several therapy candidates progress towards regulatory approval, developers are exploring diverse commercialization strategies to be implemented across different stages of a product’s launch cycle.
  • Owing to the rising demand for stem cell therapies, and challenges associated with manufacturing and scale up, industry players have demonstrated preferences to engage the services of contract service providers.
  • More than 80 industry / non-industry players, based in different regions across the globe, claim to provide contract development and manufacturing services to cater to the specific unmet needs of therapy developers.
  • Future growth of the market is likely to be driven by the success of different types of stem cell therapies, which are allogeneic and autologous in nature, as stakeholders continue to remain optimistic about proprietary products.
  • The foreseen future market opportunity, based on the revenue generation potential of such therapies, is anticipated to be distributed across different therapeutic areas, end-users and key geographical regions.
  • Products based on bone marrow derived adult stem cells are likely to continue to dominate the market in the mid-long term; adoption of therapies administered via novel routes of administration is likely to gradually rise.

 

For more information, please visit https://www.rootsanalysis.com/reports/view_document/stem-cells-market/296.html/

 

Table of Contents

 

  1. PREFACE

1.1.      Scope of the Report

1.2.      Research Methodology

1.3.      Chapter Outlines

 

  1. EXECUTIVE SUMMARY

 

  1. INTRODUCTION

3.1.      Chapter Overview

3.2.      Overview of Stem Cell Therapies

3.2.1.    Historical Evolution of Stem Cell Research

 

3.2.2.    Classification of Stem Cells

3.2.2.1. Based on Source of Stem Cell

3.2.2.2. Based on Origin of Stem Cell

3.2.2.3. Based on Potency of Stem Cell

 

3.2.3.    Administration of Stem Cell Therapies

3.2.4.    Applications of Stem Cell Therapies

3.2.5.    Challenges Associated with Development of Stem Cell Therapies

 

3.3.      Regulatory Guidelines for Stem Cell Therapies

3.3.1.    Current Scenario

3.3.2.    Regulatory Guidelines in North America

3.3.3.    Regulatory Guidelines in Europe

3.3.4.    Regulatory Guidelines in Japan

 

3.4.      Prevalent Trends Related to Stem Cell Therapies

3.4.1.    Emerging Focus Areas

3.4.2.    Key Historical Trends

3.4.3.    Geographical Activity

 

3.5.      Growth Drivers and Roadblocks

  1. MARKET LANDSCAPE

4.1.      Chapter Overview

4.2.      Stem Cell Therapies: Marketed and Development Pipeline

4.2.1.    Analysis by Phase of Development

4.2.2.    Analysis by Source of Stem Cell

4.2.3.    Analysis by Origin of Stem Cell

4.2.4.    Analysis by Type of Stem Cell

4.2.5.    Analysis by Lineage of Stem Cell

4.2.6.    Analysis by Potency of Stem Cell

4.2.7.    Analysis by Target Indication

4.2.8.    Analysis by Therapeutic Area

4.2.9.    Analysis by Route of Administration

 

4.3.      Stem Cell Therapies: Additional Information

4.3.1.    Information on Dosage and Commercial Rights

4.3.2.    Information on Designations Awarded

 

4.4.      Stem Cell Therapies: List of Technology Platforms

 

4.5.      Stem Cell Therapies: List of Therapy Developers

4.5.1.    Analysis by Year of Establishment

4.5.2.    Analysis by Company Size

4.5.3.    Analysis by Location of Headquarters

4.5.4.    Analysis by Company Size and Location of Headquarters

4.5.5.    Leading Drug Developers: Analysis by Number of Stem Cell Therapies

4.5.6.    Leading Drug Developers: 4D Bubble Analysis based on Strength of Pipeline, Target Indication          and Company Size

 

4.6.      Heptagon Representation: Analysis by Phase of Development and Key Therapeutic Area

4.7.      Grid Representation: Analysis by Phase of Development, Source of Stem Cell and Therapeutic      Area

4.8.      Tree Map Representation: Analysis by Therapeutic Area and Size of the Company

4.9.      World Map Representation: Analysis of Regional Activity

 

  1. COMPANY PROFILES

5.1.      Chapter Overview

5.2.      Anterogen

5.2.1.    Company Overview

5.2.2.    Product Portfolio: Clinical-Stage Stem Cell Therapies

5.2.3.    Recent Developments and Future Outlook

 

5.3.      Athersys

5.3.1.    Company Overview

5.3.2.    Product Portfolio: Clinical-Stage Stem Cell Therapies

5.3.3.    Recent Developments and Future Outlook

 

5.4.      CHA Biotech

5.4.1.    Company Overview

5.4.2.    Product Portfolio: Clinical-Stage Stem Cell Therapies

5.4.3.    Recent Developments and Future Outlook

 

5.5.      Cytopeutics

5.5.1.    Company Overview

5.5.2.    Product Portfolio: Clinical-Stage Stem Cell Therapies

5.5.3.    Recent Developments and Future Outlook

 

5.6.      Hope Biosciences

5.6.1.    Company Overview

5.6.2.    Product Portfolio: Clinical-Stage Stem Cell Therapies

5.6.3.    Recent Developments and Future Outlook

 

5.7.      Mesoblast

5.7.1.    Company Overview

5.7.2.    Product Portfolio: Clinical-Stage Stem Cell Therapies

5.7.3.    Recent Developments and Future Outlook

5.8.      Pluristem Therapeutics

5.8.1.    Company Overview

5.8.2.    Product Portfolio: Clinical-Stage Stem Cell Therapies

5.8.3.    Recent Developments and Future Outlook

 

5.9.      Takeda Pharmaceutical

5.9.1.    Company Overview

5.9.2.    Product Portfolio: Clinical-Stage Stem Cell Therapies

5.9.3.    Recent Developments and Future Outlook

 

5.10.     TICEBA

5.10.1.  Company Overview

5.10.2.  Product Portfolio: Clinical-Stage Stem Cell Therapies

5.10.3.  Recent Developments and Future Outlook

 

  1. KEY THERAPEUTIC AREAS

6.1.      Chapter Overview

6.2.      Autoimmune / Inflammatory Disorders

6.2.1.    Crohn’s Disease

6.2.1.1. Disease Description

6.2.1.2. Epidemiology

6.2.1.3. Current Treatment Options

6.2.1.4. Side Effects of Current Treatment Options

6.2.1.5. Stem Cell Therapies for Crohn’s Disease

 

6.2.2.    Ulcerative Colitis

6.2.2.1. Disease Description

6.2.2.2. Epidemiology

6.2.2.3. Current Treatment Options

6.2.2.4. Side Effects of Current Treatment Options

6.2.2.5. Stem Cell Therapies for Ulcerative Colitis

 

6.3.      Cardiovascular Disorders

6.3.1.    Critical Limb Ischemia

6.3.1.1. Disease Description

6.3.1.2. Epidemiology

6.3.1.3. Current Treatment Options

6.3.1.3.1. Pharmacological Interventions

6.3.1.3.2. Endovascular Treatments

6.3.1.3.3. Surgical Interventions

6.3.1.4. Stem Cell Therapies for Critical Limb Ischemia

 

6.3.2.    Heart Failure

6.3.2.1. Disease Description

6.3.2.2. Epidemiology

6.3.2.3. Current Treatment Options

6.3.2.3.1. Pharmacological Interventions

6.3.2.3.2. Therapeutic Devices

6.3.2.3.3. Surgical Interventions

6.3.2.4. Stem Cell Therapies for Heart Failure

 

6.3.3.    Myocardial Infarction

6.3.3.1. Disease Description

6.3.3.2. Epidemiology

6.3.3.3. Current Treatment Options

6.3.3.3.1. Pharmacological Interventions

6.3.3.3.2. Surgical Interventions

6.3.3.4. Stem Cell Therapies for Myocardial Infarction

 

6.4.      Dermatological Disorders

6.4.1.    Acne Vulgaris

6.4.1.1. Disease Description

6.4.1.2. Epidemiology

6.4.1.3. Current Treatment Options

6.4.1.4. Side Effects of Current Treatment Options

6.4.1.5. Stem Cell Therapies for Acne Vulgaris

 

6.5.      Metabolic Disorders

6.5.1.    Diabetes

6.5.1.1. Disease Description

6.5.1.2. Associated Health Risks / Complications

6.5.1.3. Epidemiology

6.5.1.4. Disease Diagnosis

6.5.1.5. Current Treatment Options

6.5.1.5.1. Insulin Therapies

6.5.1.5.2. Non-Insulin Therapies

6.5.1.6. Side Effects of Current Treatment Options

6.5.1.7. Stem Cell Therapies for Diabetes

 

6.5.2.    Non-alcoholic Steatohepatitis (NASH)

6.5.2.1. Disease Description

6.5.2.2. Epidemiology

6.5.2.3. Current Treatment Options

6.5.2.4. Stem Cell Therapies for NASH

 

6.6.      Oncological Disorders

6.6.1.    Bladder Cancer

6.6.1.1. Disease Description

6.6.1.2. Epidemiology

6.6.1.3. Current Treatment Options

6.6.1.4. Stem Cell Therapies for Bladder Cancer

 

6.6.2.    Breast Cancer

6.6.2.1. Disease Description

6.6.2.2. Epidemiology

6.6.2.3. Current Treatment Options

6.6.2.4. Stem Cell Therapies for Breast Cancer

 

6.6.3.    Colorectal Cancer

6.6.3.1. Disease Description

6.6.3.2. Epidemiology

6.6.3.3. Current Treatment Options

6.6.3.4. Side Effects of Current Treatment Options

6.6.3.5. Stem Cell Therapies for Colorectal Cancer

 

6.6.4.    Kidney Cancer

6.6.4.1. Disease Description

6.6.4.2. Epidemiology

6.6.4.3. Current Treatment Options

6.6.4.4. Stem Cell Therapies for Kidney Cancer

 

6.6.5.    Liver Cancer

6.6.5.1. Introduction

6.6.5.2. Epidemiology

6.6.5.3. Current Treatment Options

6.6.5.4. Stem Cell Therapies for Liver Cancer

 

6.6.6.    Lung Cancer

6.6.6.1. Disease Description

6.6.6.2. Epidemiology

6.6.6.3. Current Treatment Options

6.6.6.4. Side Effects of Current Treatment Options

6.6.6.5. Stem Cell Therapies for Lung Cancer

 

6.6.7.    Ovarian Cancer

6.6.7.1. Disease Description

6.6.7.2. Epidemiology

6.6.7.3. Current Treatment Options

6.6.7.4. Stem Cell Therapies for Ovarian Cancer

 

6.6.8.    Pancreatic Cancer

6.6.8.1. Disease Description

6.6.8.2. Epidemiology

6.6.8.3. Current Treatment Options

6.6.8.4. Stem Cell Based Therapies for Pancreatic Cancer

 

6.7.      Neurological Disorders

6.7.1.    Alzheimer’s Disease

6.7.1.1. Disease Description

6.7.1.2. Epidemiology

6.7.1.3. Symptoms of the Disease

6.7.1.4. Causes of Alzheimer’s Disease

6.7.1.5. Stages of Alzheimer’s Disease

6.7.1.6. Current Treatment Options

6.7.1.7. Stem Cell Therapies for Alzheimer’s Disease

 

6.7.2.    Parkinson’s Disease

6.7.2.1. Disease Description

6.7.2.2. Epidemiology

6.7.2.3. Current Treatment Options

6.7.2.3.1. Pharmacological Management of Parkinson’s Disease

6.7.2.3.2. Non-Pharmacological Management of Parkinson’s Disease

6.7.2.3.3. Management of Parkinson’s Disease Using Dietary Supplements

6.7.2.4. Stem Cell Therapies for Parkinson’s Disease

 

  1. ASSESSMENT OF RELATIVE COMPETITION AND GROWTH             OPPORTUNITIES

7.1.      Chapter Overview

7.2.      Assumptions and Methodology

7.3.      Analysis of Relative Competition and Growth Opportunities

7.3.1.    Established Therapeutic Areas in Emerging Regions

7.3.2.    Established Therapeutic Areas in Established Regions   

7.3.3.    Emerging Therapeutic Areas in Emerging Regions         

7.3.4.    Emerging Therapeutic Areas in Established Regions                              

           

  1. ACADEMIC GRANTS ANALYSIS

8.1.      Chapter Overview

8.2.      Scope and Methodology

8.3.      Stem Cell Therapies: Analysis of Grants Awarded by the National Institutes of Health (NIH)

8.3.1.    Analysis by Year of Award

8.3.2.    Analysis by Amount Awarded

8.3.3.    Analysis by Administering Institute Center

8.3.4.    Analysis by Funding Institute Center

8.3.5.    Analysis by Support Period

8.3.6.    Analysis by Funding Institute Center and Support Period

8.3.7.    Most Popular NIH Spending Categorizations

8.3.8.    Analysis by Funding Mechanism

8.3.9.    Emerging Focus Areas

8.3.10.  Analysis by Source of Stem Cell

8.3.11.  Analysis by Origin of Stem Cell

8.3.12.  Analysis by Type of Stem Cell

8.3.13.  Analysis by Lineage of Stem Cell

8.3.14.  Analysis by Potency of Stem Cell

8.3.15.  Analysis by Therapeutic Area

8.3.16.  Analysis by Type of Grant Application

8.3.17.  Popular NIH Departments

8.3.18.  Analysis by Study Section

8.3.19.  Analysis by Types of Recipient Organizations

8.3.20.  Popular Recipient Organizations

8.3.21.  Analysis by Grant Mechanism

8.3.22.  Prominent Program Officers

8.3.23.  Regional Distribution of Recipient Organizations

 

8.4.      Grant Attractiveness Analysis

 

  1. CLINICAL TRIAL ANALYSIS

9.1.      Chapter Overview

9.2.      Scope and Methodology

9.3.      Stem Cell Therapies: Clinical Trial Analysis

9.3.1.    Analysis by Trial Registration Year

9.3.2.    Analysis by Trial Phase

9.3.3.    Analysis by Number of Patients Enrolled by Trial Registration Year

9.3.4.    Analysis by Study Design

9.3.5.    Analysis by Trial Recruitment Status

9.3.6.    Analysis by Sponsor / Collaborator

9.3.7.    Leading Industry Sponsors: Based on Number of Registered Trials

9.3.8.    Analysis by Trial Focus

9.3.9.    Analysis by Type of Stem Cell

9.3.10.  Analysis by Therapeutic Area

9.3.11.  Analysis by Type of Stem Cell and Therapeutic Area

9.3.12. Geographical Analysis by Number of Clinical Trials

9.3.13.  Geographical Analysis by Trial Recruitment Status

9.3.14. Geographical Analysis by Enrolled Patient Population

 

  1. STEM CELL MANUFACTURING MARKET LANDSCAPE AND KPIs FOR EVALUATING CONTRACT SERVICES PARTNERS

10.1.     Chapter Overview

10.2.     Stem Cell Therapy Manufacturing

10.2.1.  Need for Stem Cell Therapy Contract Manufacturing

10.2.2.  Advantages of Outsourcing Stem Cell Therapy Manufacturing

10.2.3.  Guidelines for Selecting a Contract Manufacturing Organization (CMO) Partner

 

10.2.4.  Stem Cell Therapy CMOs: List of Industry Players

10.2.4.1. Analysis by Year of Establishment

10.2.4.2. Analysis by Company Size

10.2.4.3. Analysis by Scale of Stem Cell Manufacturing

10.2.4.4. Analysis by Location of Headquarters

10.2.4.5. Analysis by Location of Manufacturing Facilities

10.2.4.6. Analysis by Types of Services Offered

10.2.4.7. Analysis by Source and Origin of Stem Cell

 

10.2.5.  Stem Cell Therapy CMOs: List of Non-Industry Players

10.2.5.1. Analysis by Year of Establishment

10.2.5.2. Analysis by Scale of Stem Cell Manufacturing

10.2.5.3. Analysis by Location of Headquarters

10.2.5.4. Analysis by Location of Manufacturing Facilities

10.2.5.5. Analysis by Types of Services Offered

10.2.5.6. Analysis by Source and Origin Stem Cell

 

10.3.     Stem Cell Therapy Manufacturing: KPI Analysis

10.3.1.  KPI Definitions

10.3.1.1. Financial Indicators

10.3.1.1.1. Big Pharma Perspective

10.3.1.1.2. Contract Manufacturers’ Perspective

10.3.1.2. Process and Capability Indicators

10.3.1.2.1. Big Pharma Perspective

10.3.1.2.2. Contract Manufacturers’ Perspective

10.3.1.3. Market Reputation Indicators

10.3.1.3.1. Big Pharma Perspective

10.3.1.3.2. Contract Manufacturers’ Perspective

10.4.     Concluding Remarks

 

  1. STEM CELL THERAPY DEVELOPERS AND CMOs: OPPORTUNITY ASSESSMENT

11.1.     Chapter Overview

11.2.     Therapy Developers and CMOs in North America

11.2.1.  Gap Analysis by Scale of Stem Cell Manufacturing

11.2.2.  Gap Analysis by Source of Stem Cell

11.2.3.  Gap Analysis by Origin of Stem Cell      

 

11.3.     Therapy Developers and CMOs in Europe

11.3.1.  Gap Analysis by Scale of Stem Cell Manufacturing

11.3.2.  Gap Analysis by Source of Stem Cell

11.3.3.  Gap Analysis by Origin of Stem Cell

 

11.4.     Therapy Developers and CMOs in Asia-Pacific and Rest of the World

11.4.1.  Gap Analysis by Scale of Stem Cell Manufacturing

11.4.2.  Gap Analysis by Source of Stem Cell

11.4.3.  Gap Analysis by Origin of Stem Cell

 

11.5.     Concluding Remarks

 

  1. KEY COMMERCIALIZATION STRATEGIES

12.1.     Chapter Overview

12.2.     Successful Drug Launch Strategy: ROOTS Framework

12.3.     Successful Drug Launch Strategy: Product Differentiation

12.4.     Commonly Adopted Commercialization Strategies based on Stage of Product Development

 

12.5.     Key Approved Stem Cell Therapies: Profiles

12.5.1.  CARTISTEM®

12.5.2.  HiQCell®

12.5.3.  Prochymal®

12.5.4.  Strimvelis®

 

12.6.     Key Commercialization Strategies Adopted by Stem Cell Therapy Developers

12.6.1.  Strategies Adopted before Therapy Approval

12.6.1.1. Participation in Global Events

12.6.1.2. Collaboration with Stakeholders and Pharmaceutical Firms

12.6.1.3. Seeking Approval for Multiple Target Indications

12.6.1.4. Seeking Special Therapy Designations and Other Credentials

12.6.1.5. Leveraging Uniqueness to Establish Competitive Edge

12.6.1.6. Anticipation of Likely Market Dynamics and Trends

12.6.1.7. Outsourcing Manufacturing Operations

 

12.6.2.  Strategies Adopted Post Therapy Approval

12.6.2.1. Geographical Expansion

12.6.2.2. Participation in Global Events

12.6.2.3. Patient Assistance Programs

12.6.2.4. Miscellaneous Programs

 

12.7.     Opportunities and Challenges with Unapproved Therapies

12.8.     Concluding Remarks

 

  1. MARKET FORECAST

13.1.     Chapter Overview

13.2.     Scope and Limitations

13.3.     Forecast Methodology and Key Assumptions

 

13.4.     Overall Stem Cell Therapies Market, 2020-2030

13.4.1.  Stem Cell Therapies Market: Distribution by Source of Stem Cell

13.4.1.1. Stem Cell Therapies Market for Allogeneic Therapies, 2020-2030

13.4.1.2. Stem Cell Therapies Market for Autologous Therapies, 2020-2030

 

13.4.2.  Stem Cell Therapies Market: Distribution by Origin of Stem Cell

13.4.2.1. Stem Cell Therapies Market for Adult Stem Cells, 2020-2030

13.4.2.2. Stem Cell Therapies Market for Embryonic Stem Cells, 2020-2030

 

13.4.3.  Stem Cell Therapies Market: Distribution by Type of Stem Cell

13.4.3.1. Stem Cell Therapies Market for Hematopoietic Stem Cells, 2020-2030

13.4.3.2. Stem Cell Therapies Market for Mesenchymal Stem Cells, 2020-2030

13.4.3.3. Stem Cell Therapies Market for Progenitor Cells, 2020-2030

13.4.3.4. Stem Cell Therapies Market for Others, 2020-2030

 

13.4.4.  Stem Cell Therapies Market: Distribution by Lineage of Stem Cell

13.4.4.1. Stem Cell Therapies Market for Adipose Tissue Derived Stem Cells, 2020-2030

13.4.4.2. Stem Cell Therapies Market for Bone Marrow Derived Stem Cells, 2020-2030

13.4.4.3. Stem Cell Therapies Market for Cord Blood Derived Stem Cells, 2020-2030

13.4.4.4. Stem Cell Therapies Market for Others, 2020-2030

 

13.4.5.  Stem Cell Therapies Market: Distribution by Route of Administration

13.4.5.1. Stem Cell Therapies Market for Intraarticular Therapies, 2020-2030

13.4.5.2. Stem Cell Therapies Market for Intracoronary Therapies, 2020-2030

13.4.5.3. Stem Cell Therapies Market for Intramuscular Therapies, 2020-2030

13.4.5.4. Stem Cell Therapies Market for Intramyocardial Therapies, 2020-2030

13.4.5.5. Stem Cell Therapies Market for Intrathecal Therapies, 2020-2030

13.4.5.6. Stem Cell Therapies Market for Intravenous Therapies, 2020-2030

13.4.5.7. Stem Cell Therapies Market for Surgical Implants, 2020-2030

13.4.5.7. Stem Cell Therapies Market for Others, 2020-2030

 

13.4.6.  Stem Cell Therapies Market: Distribution by Therapeutic Area

13.4.6.1. Stem Cell Therapies Market for Autoimmune / Inflammatory Disorders, 2020-2030

13.4.6.2. Stem Cell Therapies Market for Cardiovascular Disorders, 2020-2030

13.4.6.3. Stem Cell Therapies Market for Metabolic Disorders, 2020-2030

13.4.6.4. Stem Cell Therapies Market for Musculoskeletal Disorders, 2020-2030

13.4.6.5. Stem Cell Therapies Market for Neurological Disorders, 2020-2030

13.4.6.6. Stem Cell Therapies Market for Oncological Disorders, 2020-2030

13.4.6.7. Stem Cell Therapies Market for Ophthalmic Disorders, 2020-2030

13.4.6.8. Stem Cell Therapies Market for Others, 2020-2030

 

13.4.7.  Stem Cell Therapies Market: Distribution by End-Users

13.4.7.1. Stem Cell Therapies Market for Ambulatory Surgery Centers, 2020-2030

13.4.7.2. Stem Cell Therapies Market for Hospitals, 2020-2030

13.4.7.3. Stem Cell Therapies Market for Specialty Clinics, 2020-2030

 

13.4.8.  Stem Cell Therapies Market: Distribution by Key Geographical Regions

13.4.8.1. Stem Cell Therapies Market in North America, 2020-2030

13.4.8.2. Stem Cell Therapies Market in Europe, 2020-2030

13.4.8.3. Stem Cell Therapies Market in Asia-Pacific and Rest of the World, 2020-2030

 

13.5.     Concluding Remarks

 

  1. CONCLUSION

 

  1. EXECUTIVE INSIGHTS

15.1.     Chapter Overview

15.2.     Seraxis

15.2.1.  Company Snapshot

15.2.2.  Interview Transcript: William L Rust, Founder and Chief Executive Officer

 

15.3.     Xcelthera

15.3.1.  Company Snapshot

15.3.2.  Interview Transcript: Xuejun Huang Parsons, Chief Executive Officer

 

15.4.     Kadimastem

15.4.1.  Company Snapshot

15.4.2.  Interview Transcript: Michel Revel, Co-Founder / Chief Scientist and Galit Mazooz-Perlmuter,         Director, Business Development

 

15.5.     Heartseed

15.5.1.  Company Snapshot

15.5.2.  Interview Transcript: Kikuo Yasui, Director and Chief Operating Officer

 

15.6.     University of Rostock

15.6.1.  Organization Snapshot

15.6.2.  Interview Transcript: Gustav Steinhoff, Director and Chairman, Department of Cardiac Surgery

 

15.7.     Bio Elpida

15.7.1.  Company Snapshot

15.7.2.  Interview Transcript: Gilles Devillers, President

 

15.8.     Roslin Cell Therapies

15.8.1.  Company Snapshot

15.8.2.  Interview Transcript: Fiona Bellot, Business Development Manager

 

15.9.     University of Minnesota

15.9.1.  Organization Snapshot

15.9.2.  Interview Transcript: David Mckenna, Professor and American Red Cross Chair in Transfusion       Medicine

 

15.10.   Waisman Biomanufacturing

15.10.1.Company Snapshot

15.10.2.Interview Transcript: Brian Dattilo, Manager of Business Development

 

15.11.   YposKesi

15.11.1.Company Snapshot

15.11.2.Interview Transcript: Mathilde Girard, Department Leader, Cell Therapy Innovation and Development

 

  1. APPENDIX 1: TABULATED DATA

 

  1. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com

 

Presently, there are two approved drug and over 150 product candidates, which are being evaluated for the treatment of a variety of disease indications, based on the RNAi principle, claims Roots Analysis


Submitted 104 day(s) ago by Harry sins

 

 

Significant advancements in the developmental pipeline across various oncological disorders, infectious diseases and genetic disorders have amplified the interest of various pharmaceutical establishments and have inspired research groups across the world, to focus their efforts on the development of RNAi therapeutics. Further, there are multiple pipeline candidates in mid to late-stage (phase II and above) trials and are anticipated to enter the market over the next 5-10 years.

 

To order this 350+ page report, which features 130+ figures and 190+ tables, please visit this link

 

The USD 9.2 billion (by 2030) financial opportunity within the RNAi therapeutics market has been analyzed across the following segments:

  • Key therapeutic areas
  • Oncological disorders
  • Infectious diseases
  • Genetic disorders
  • Ophthalmic disorders
  • Hepatic disorders
  • Respiratory disorders

 

  • Type of RNAi molecule
  • siRNA
  • miRNA
  • shRNA
  • sshRNA
  • DNA

 

  • Route of administration
  • Subcutaneous
  • Intravenous
  • Intradermal
  • Intratumoral
  • Intravitreal
  • Oral
  • Intramuscular

 

  • Key geographical regions
  • North America
  • Europe
  • Asia Pacific and the Rest of the World

 

  • Leading Players

 

The RNAi Therapeutics Market (2nd Edition), 2019 - 2030: Focus on siRNA, miRNA, shRNA and DNA report features the following companies, which we identified to be key players in this domain:

  • Quark Pharmaceuticals
  • Alnylam Pharmaceuticals
  • Dicerna Pharmaceuticals
  • Souzhou Ribo Life Sciences
  • Olix Pharmaceuticals
  • Sirnaomics
  • Ariz Precision Medicine
  • Arrowhead Pharmaceuticals
  • Gradalis
  • Benitec Biopharma

 

Table of Contents

 

  1. PREFACE

 

  1. EXECUTIVE SUMMARY

 

  1. INTRODUCTION

 

  1. COMPETITIVE LANDSCAPE

 

  1. COMPANY COMPETITIVENESS ANALYSIS

 

  1. LATE STAGE RNAi THERAPEUTICS

 

  1. TECHNOLOGY PLATFORMS AND DELIVERY SYSTEMS

 

  1. KEY THERAPEUTIC INDICATIONS

 

  1. CLINICAL TRIAL ANALYSIS

 

  1. PATENT ANALYSIS

 

  1. RECENT PARTNERSHIPS

 

  1. FUNDING AND INVESTMENT ANALYSIS

 

  1. PROMOTIONAL ANALYSIS

 

  1. MARKET SIZING AND OPPORTUNITY ANALYSIS

 

  1. RNAi IN DIAGNOSTICS

 

  1. SERVICE PROVIDERS FOR RNAi THERAPEUTICS

 

  1. SWOT ANALYSIS

 

  1. CONCLUSION

 

  1. INTERVIEW TRANSCRIPT(S)

 

  1. APPENDIX 1: TABULATED DATA

 

  1. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/rnai-therapeutics-market-2nd-edition-2019-2030/278.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com 

 

 

Submit your article?

Submit your articles for more traffic to your website!

Submit
© 2021 posts123.com. Imprint, All rights reserved.